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Abstract
The 2-oxoacid dehydrogenase complexes; pyravate dehydrogenase (PDC), 2- 
oxoglutarate dehydrogenase (OGDC) and branch-chain 2-oxoacid dehydrogenase 
(B CO ADC), are mitochondrial multienzyme complexes which comprise of multiple 
copies of three different enzymes; E l, E2 and E3, that catalyse the oxidative 
decarboxylation of 2-oxoacids to their respective acyl Co A derivatives. The E2 enzyme 
forms the structural core, to which several copies of both E l and E3 are non-covalently 
bound. Despite being three of the largest known proteins, relatively little is known 
regarding the interactions between the constituent components. This is due primarily to 
the flexibility within the complex which makes the generation of large quantities of 
material difficult.
In this thesis, we have demonstrated the abihty to overexpress various subgenes of the 
complexes in E. coli. The first is a sub-gene of the E2-PDC enzyme from various 
sources and also the corresponding sub-gene of protein X, temied the di-domain. 
These di-domains, are comprised of the peripheral subunit binding domain and adjacent 
lipoyl domain. We have shown that the di-domains have retained their ability to fold 
correctly, by studying their lipoylation state. Their function to bind the E3 enzyme has 
been demonstrated by surface piasmon resonance. By binding purified E3 enzymes to 
the surface of a dextran-coated chip and passing crude extracts containing the 
overexpressed di-domains over the E3, we have determined that the strongest binding 
affinities were between human E3 and the protein X di-domain, further substantiating 
the hypothesis that protein X has evolved to bind E3. The binding affinities between 
E2-PDC and E3 are sufficiently high to suggest that in the absence of competition from 
E l, E3 may be able to foim a stable complex with E2.
The sequences surrounding the lipoylation site, a conserved DKA motif within the 
lipoyl domain, have been investigated using a monoclonal Ab specific for the lipoylated 
form of the domain, to determine residues critical for recognition by the lipoylating
&I
enzymes. To date, there has been some ambiguity with regard to the requirements of the
.1
lipoylating enzymes to enable lipoylation to occur. We have shown, with the use of 
lipoyl domain point mutants that the levels of lipoylation can be altered by mutating 
residues close to the critical lipoyl lysine.
The structure of OGDC has evolved with significant structural differences to PDC and 
BCG ADC. In particular, the E l component has the ability to interact directly with E3 as 
well as the E2 core. The N-termlnal region of E l is thought to be important in these 
interactions. Subsequently we have overexpressed, in E. coli, three N-terminal 
fragments for use as competitive inhibitors of OGDC reconstitution. Despite failing to 
bind E3, these fragments display inhibition following MgClj dissociation, suggesting 
interference with E l binding to the E2 core.
Future work is planned to further investigate the divergent structure and protein-protein 
interactions of OGDC, along with interactions within the other two complexes. The 
overexpression and subsequent purification of each individual component should allow 
progress in this area. ^
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INTRODUCTION
Introduction
The 2-Oxoacid Dehydrogenase Complexes
1.1 Multienzyme complexes
Pv
Protein-protein interactions within a multienzyme complex can also enhance overall 
activity. Many enzymes are only active in an oligomeric form because residues from 
more than one monomer are required to form the active site. This is the case for the 
dihydrolipoamide dehydrogenase (E3) enzyme of the 2-oxoacid dehydrogenase 
complexes. A further advantage of a multienzyme complex is the speed at which 
regulatory conti’ol can be established. Many complexes have permanent or transient 
assoeiations with regulatory enzymes such as kinases and phosphatases which enable 
rapid modulation of complex activity.
In the scope of this work, a family of multienzyme complexes called the 2-oxoacid 
dehydrogenases has been studied, which display many of the above mentioned
:
In order to maximise catalytic efficiency in metabolic pathways, enzymatic components i
are often coupled or complexed together. One means of clustering different enzyme 
functions is to assemble the polypeptide chains into complexes held together by non-
, *
covalent bonds. As well as enhancing complex activity, this also has the advantages of i
allowing substrate channelling and giving protection to reaction intermediates, which 
may be unstable.
The close proximity of each component enzyme and the substrate channelling act to 
increase local intermediate concentration, thus decreasing the effects of diffusion.
Efficiency is further enhanced by the closeness of the active sites. Transfer of substrates 
between them is quicker and often carried out by flexible prosthetic groups, acting as J|
"swinging arms" (Reed 1974).
Introduction
properties and serve as paradigms for the analysis of structure-function relationships in 
complex multimeric assemblies.
1.2. The 2»oxoacid dehydrogenase complexes
1.2.1. General
(BCOADC), each occupying a key position in inteimediary metabolism.
■■3
I Loosely associated with the inner mitochondrial membrane is located a family of 
multienzyme complexes known as the 2-oxoacid dehydrogenase complexes. There are f
three principal members; pyruvate dehydrogenase (PDC), 2-oxoglutaiate 
dehydrogenase (OGDC) and the branched chain amino acid 2-oxoacid dehydrogenase
The complexes consist of multiple copies of three distinct enzymes; E l, E2 and E3, 
(Table 1.1) which catalyse the lipoic acid-mediated oxidative decarboxylation of 2- 
oxoacids to their respective acyl CoA derivatives (reviewed in Perham, 1991). PDC 
converts pyruvate to acetyl CoA, CO2  and NADH, an irreversible step in carbohydrate
metabolism. The acetyl CoA is channelled either into the TCA cycle or used in the 
synthesis of compounds such as fatty acids, steroids and cholesterol. OGDC catalyses 
the oxidative decarboxylation of 2-oxoglutarate to succinyl CoA and is important in 
controlling flux through the TCA cycle. BCOADC is responsible for the committed 
steps in the degradation of the branched chain 2-oxoacids derived from valine, leucine 
and isoleucine, namely 2-oxo-valeric acid, 2-oxo-isocaproic acid and 2-oxo-3-methyl- 
valeric acid respectively, to produce the appropriate acyl CoA . Figure 1.1 illustrates the 
key metabolic steps controlled by these multienzyme complexes within the 
mitochondrial compartment.
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Branched Chain 
Amino Acids
Branched Chain 
a-Keto Acids
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OGDC|
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Figure 1.1 Metabolic Locations of the Mitochondrial 2-Oxoacid Dehydrogenase 
Complexes.
1.2.2. Quaternary structure of the 2-oxoacid dehydrogenase complexes
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The E l and E2 enzymes aie complex-specific; however, in mammals the E3 component 
(dihydrolipoamide dehydrogenase) appears to be common to all three complexes (Table 
1.1). The overall reaction catalysed by these three enzymes is outlined in Figure 1.2.
I-The E l enzyme catalyses i) the irreversible decarboxylation of the 2-oxoacid to a ThDP- 
linked intermediate (Frey et a l, 1989) and ii) the subsequent reductive acylation of the 
lipoyl moiety of E2 (Figure 1.2, reactions 1 & 2). The lipoyl group is reductively 
acylated, generating an 8 S-acyldihydrolipoamide intermediate. Acyl transfer can occur 
to produce isomers, but this does not normally occur during in vivo catalysis (Yang 
& Frey, 1986). E2 subsequently transfers the acyl CoA, leaving the lipoic acid in its 
reduced state (reaction 3).133 then reoxidises the dihydi'olipoyl group using its FAD co­
factor (reaction 4) to generate NADH (reaction 5) as the final electron acceptor.
■iï
Each complex is organised around a core of E2 polypeptides, to which multiple copies 
of E l and E3 are bound by non-covalent bonds. Two polyhedral forms of E2 cores 
have been observed using electron microscopy; the cube and the pentagonal 
dodecahedron (Oliver & Reed, 1982). The former design is common to Gram negative
ibacteria such as E. coll (Reed, 1974) and Azotobacter vinelandii (Hanemaijer et a l,
1989) and the OGDC and BCOADC of eukaryotic organisms. They exhibit a core with 
24 identical E2 subunits arranged with octahedral (432) symmetry (Oliver & Reed, I1982). These subunits are grouped in threes about the eight vertices of the cube. The 
latter design consists of 60 E2 subunits arranged with icosahedral (532) symmetry, 
again in groups of three about the 20 vertices of the pentagonal dodecahedron. This 
structure is found in PDC from the Gram positive bacteria Bacillus stearothermophilus 
(Henderson & Perham, 1980), Bacillus subtilis (Lowe et al, 1983) the yeast 
Saccharomyces cerevisae (Keha et a l, 1982; Stoops et a l, 1992) and mammals (Reed,
1974).
Introduction
^sCom plex
Enzyme
PDC OGDC BCOADC
El
Elp
EC 1.2.4.1
Pyruvate
Dehydrogenase
Elo
EC 1.2.4.2
2-Oxoglutarate
Dehydrogenase
E lb
EC 1.2.4.4 
Branched-chain 
2-Oxoacid 
Dehydrogenase
E2
E2p
EC 2.3.1.12
Dihydrolipoamide
Acetyltransferase
E2o
EC 2.3.1.16
Dihydrolipoamide
Succinyltransferase
E2b
Dihydrolipoamide
Acyltransferase
E3
E3
EC 1.8.1.4
Dihydrolipoamide Dehydrogenase
Table 1.1.
Enzyme Components of the 2-Oxoacid Dehydrogenase Mnltienzyme Complexes.
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NAD^
-SHHS-
[FAD] NADH+OH E3[Lipsa:[RC=TPP]CO,
-S-S-
[FAD]
E l E2
RC-SCoA
[TPP]RCCO2
CoASH
Figure 1.2 Reaction Scheme for the Oxidative Decarboxylation of the 2-Oxoacids 
by their Respective 2-Oxoacid Dehydrogenase Complex,
The numbers 1 to 5 represent the 5 reactions as detailed in the text. Abbreviations;
El, E2 & E3 are the three enzymatic components of the multienzyme complexes, 
ThDP, thiamine diphosphate; LipS2  & Lip(SH2 ); oxidised & reduced forms of the 
lipoyl moiety attached to E2; CoASH; Coenzyme A FAD, flavin adenine
dinucleotide; NAD**" & NADH, oxidised & reduced forms of nicotinamide 
adenine dinucleotide.
(Adapted from Reed & Ymman, 1987).
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The 2-oxoacid dehydrogenase multienzyme complexes aie among the largest enzymes 
known, with molecular* masses of 4x10^-1x10^ Da. Eai'ly electron microscopy studies 
(Ohver & Reed, 1982) suggested the complexes to be between 30 and 40nm in 
diameter, but recent work using ci*yoelectron microscopy suggests a value of at least 
50nm (Wagenknecht et a/., 1991). The difference is thought to be caused by the 
dehydration associated with the negative staining process.
STEM imaging (scanning election transmission electron microscopy) of bovine 
BCOADC has confirmed the cube (octahedral) model (Hackert et ah, 1989) and also 
shown the lipoyl domains of the E. coli core to be vei*y mobile and cover an area with a 
radius of 17-18nm. This has also been shown by NMR (Green et a l, 1995). These 
lipoyl domains protrude to overlap with the E l and E3 subunits (Hale et al, 1992).
X-ray crystallography studies (Fuller et al, 1979) suggest that homodimers (in E. coli) 
of E l, associate along the 12 edges of the octahedral core, whilst six homodimers of E3 
associate along the faces. In icosahedral complexes, El a2p2 tetramers and E3 dimers
are thought to bind near the 30 edges and 12 faces respectively (BaiTera et a l ,  1972), 
but the exact ratios vai*y from one organism to another (Reed, 1974; Henderson & 
Perham, 1980).
The E l, E2 and E3 components are all required for catalysis, but not in a 1:1:1 
stoichiometi*y. De Kok and Westphal (1985) reported the optimum binding 
stoichiometry of E, coli E1/E2 and E3/E2 to be 2:1 and 2.5:1 respectively, in PDC. 
Yang et a l (1985) showed purification of PDC to yield the ratio 1:1:0.5 (E1:E2:E3). 
The vai'iation was initially thought to reflect binding competition between E l and E3 for 
their respective binding sites. This has now been confirmed by Lessard et a l (1996).
In addition to the E l and E3 enzymes, a further component known as protein X (E3- 
binding protein) has been identified in mammalian and yeast PDC (De Marcucci &
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Lindsay, 1985; De Marcucci et a l, 1985; Jilka et a l, 1986; Behal et a l ,  1989), which 
tightly associated with the E2 core as well as exhibiting stmctural and functional 
homology to this component.
A final pair of enzymes associated with the E2 core is a kinase and a phosphatase (Reed 
& Yeaman, 1987), the former being tightly bound whereas the latter interacts only 
loosely. These enzymes are involved in the overall regulation of the complexes. |■'7
Phosphorylation causes complete inactivation, preventing breakdown of essential amino 
acids. Recent evidence now suggests that there are in fact four separate kinases, 
showing tissue specific expression (Popov et a l ,  1993; Popov et a l ,  1994; Popov et 
a l, 1995; Rowles et al, 1996; Popov et al, 1997).
1.3. The E2 Component
The E2 component of the 2-oxoacid dehydrogenase complexes plays a central role in
::5the structure, assembly and catalytic activity of the complex. As mentioned above, it
vlforms the symmetrical core about which the complex is assembled; it also provides the |
attachment site for the lipoic acid moiety, servicing the various active sites in addition to 
catalysing the formation of an acyl CoA product.
Initial structural characterisation was performed by Bleile et a l  (1979) using limited
tryptic digestion of the E2p protein from E. coll They revealed a unique multidomain 
structure capable of independent folding and joined by flexible polypeptide linker 
segments (Figure 1.3). Under controlled conditions, the E2p protein yielded a structural 
domain consisting of the subunit binding and catalytic domains and a further extended 
region canying the lipoic acid moieties. Limited chymotryptic cleavage of the E2p core 
of & stearothermophilus (Packman et a l, 1988; Borges et al, 1990) causes the release 
of its lipoyl domain leaving peptide chains of 45kDa. Further digestion with trypsin 
promotes the release of the E l and E3 components previously bound to the peripheral 
subunit binding domain.
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(a) Lipoyldomain \ /
Lipoyl
domain S / Lipoyldomain
(b)
(c)
(d)
Lipoyl
domain
Lipoyl
domain
Lipoyl
domain
Lipoyl
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1/E3?
binding
Catalytic
domain
Catalytic
domain
Figure 1.3. Schematic Representation of the Multidomain Structure 
of E2 and P rotêt X
(a) E, coli PDC
A. vinelandii PDC
(b) Mammalian PDC S.faecalis PDC
(c) Mammalian BCOADC 
Gram +ve bacteria
(d) Protein X of mammals and yeast
Each domain is separated by linker regions (zig-zag lines). Subunit binding 
specificity is indicated as E l and/or E3.
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Additional limited proteolysis studies on the E2p and E2o from E. coli and other 
sources (Bleile et a l, 1981; Hale & Perham, 1979; Packman & Perham, 1986, 1987; 
Komuniecki et al., 1992) have further substantiated similar multidomain structures and 
have also revealed that the number of lipoyl domains varies from one to three depending 
on both complex type and species. Each E2p of E. coli. was shown to contain three 
lipoyl domains (Hale & Perham, 1979), following growth in the presence of 
sulphate. Subsequent elucidation of the E. coli aceF gene sequence encoding the E2p 
polypeptide, showed 3 homologous domains arranged in tandem, each containing a 
conserved lysine residue which was capable of lipoylation (Stephens et a l, 1983).
These lipoyl domains, approx. 80 amino acids in length, are located in the N-terminal 
region of the E2 chain. They are joined by flexible linker regions of 25-30 amino acids, 
rich in proline and alanine residues. Miles et al. (1988) demonstrated that the mobility 
provided by the linkers is essential for complex activity by providing the lipoyl domain 
with freedom to interact with all the active sites.
Studies suggest that each lipoyl domain has the ability to fold independently and 
support overall catalysis (Graham et a l, 1986). Bates et a l (1977) proposed a 
mechanism of catalysis called "active site coupling", whereby acyl groups ai*e 
transferred between the lipoic acid groups on different E2 polypeptide chains within an 
E2 core and that more than one lipoyl domain could interact with any E l active site.
Ananged at the C-terminal end of the lipoyl domain(s) is the peripheral subunit binding 
domain of approximately 50 amino acids, which has the ability to bind E3 and/or El 
(source-dependent). In E. coli and B. subtilis PDC for example, both E l and E3 
components compete for the binding region, although, in the case of Gram negative 
organisms at least part of the site of E l interaction is situated within the C-terminal core 
(see figure 1.3).
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A 29kDa C-terminal domain (catalytic domain) is joined to the binding domain by a 
flexible linker peptide. It acts as the active site for the acetlytransferase reaction and is 
also involved in core assembly.
1.3.1. Lipoyl Domains
Lipoic acid is attached to a specific lysine residue via an amide linkage witliin each 
lipoyl domain. This residue provides the "swinging arm", allowing movement between 
the active sites of the complex. The attachment of the lipoic acid moiety to the mature 
domain seems to be essential for the reductive acétylation by the E l enzyme as it has 
been demonstrated that free lipoic acid, lipoamide and also a lipoylated synthetic 
decapeptide aie poor substrates (Graham et al, 1989).
There is a poorly defined molecular recognition process occurring between the lipoyl 
domain and its cognate E l. The lipoyl domains from E. coli E2p and E2o can only act 
as substrates for E lp and E lo  respectively (Graham et a l,  1989). Tliis specificity 
provides a potent means of substrate channelling.
As previously mentioned, the number of lipoyl domains varies between species and 
even complex within the same species. The number does not correlate directly with the 
core symmetry (cubic versus dodecahedral). E. coli and A. vinelandii PDC have three 
domains per E2p chain, mammalian PDC and S. faecalis PDC have two and B. 
stearothermophilus (Figure 1.4) and yeast have only one. All OGDCs and BCG ADCs 
cany one lipoyl domain per E2.
Guest et a l  (1985) showed that E. coli PDC is fully catalytically active and capable of 
complex assembly when two of their three lipoyl domains are deleted. However, 
activity is lost when all three are removed or when the lipoylated lysine residue of a 
'one lip E2p' is mutated to glutamine (Ali & Guest, 1990). Additional studies by Allen
12
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Figure 1.4 Three-dimensional structure of the lipoyl domain from  
B. stearothermophilus PD C .
The position of the lipoyl-lysine residue is shown, forming part of the exposed 
loop. The structure was taken from Wallis (1996) and was prepared using the 
programme MOLSCRIPT (Kraulis, 1991).
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(1989) showed that each of the E, coli lipoyl domains is capable of independent 
functioning. Experiments by Machado (1993) demonstrated that the E3 binding domain 
of the thi'ee-lipoyl domain constructs show increased mobility compared to those with 
1 ,2  or 4 to 9 domains, suggesting the reason for the presence of three. This fails, 
however, to explain why other species function fully with one or no superfluous 
domains.
Until recently, little was known about the enzyme(s) responsible for the attachment of 
lipoic acid. The study of lipoate attachment has been enhanced by the creation of E. coli 
strains capable of overexpressing subgenes containing the lipoyl domain from B. 
stearothermophilus (Dardel gf a/., 1990). Three forais were present upon purification; 
lipoylated (16%), unlipoylated (80%) and octanoylated (4%) (Fujiwara, 1992). As 
octanoic acid is a potential lipoic acid precursor (Figure 1.5), it remains unclear whether 
the octanoylated domain is a genuine reaction interaiediate or whether it accumulates 
because of the limiting levels of lipoic acid in the culture medium.
Two lipoyl ligase enzymes IplA and IplB were described in E. coli by Brookfield et al. 
(1991) and initially by Reed (1958). They have the ability to activate lipoyl-deficient 
PDC complexes with the additional requirement of ATP and Mg^'^, using L-lipoate and 
lipoyl adenylate as substrates. LplB could also use octanoate as a further substrate, 
suggesting it could be responsible for the octanoylation of holo-lipoyl domain. More 
recently, two further enzymes have been characterised from E. coli (LipA and LipB), 
which are thought to play a role in lipoic acid synthesis and metabolism (Reed & 
Cronan, 1993). LipA is thought to add the first sulphur to octanoate. This is supported 
by its similar amino acid sequence to biotin synthase which catalyses the incorporation 
of sulphur into a biotin group (Hayden et a i, 1992). LipB seems to be involved in the 
process of actual lipoylation. It is possible to increase the degree of lipoylation by the E. 
coli enzymes by adding exogenous lipoate to culture media (see chapter 3). This further
14
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Figure 1.5 Comparison of tiie Structures of A) Lipoate and B) Octanoic Acid.
A) The lipoate moiety is shown attached to the specific lysine residue via an amide linkage
B) Octanoic acid is one of the precursor molecules of lipoic acid, before the addition of two 
sulphurs.
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suggests that endogenous levels of lipoic acid act as the rate-limiting factor in
16
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lipoylation.
Little is known about the mechanism of lipoylation in mammals. It has been shown to 
occur within the mitochondrion (Griffin & Cliuang, 1990; Fujiwara et a l, 1990).
Mammalian lipoyl hpase has been partially purified from bovine liver mitochondria 
(Fujiwara et al, 1992) and found to be unable to use free lipoic acid with ATP i.e. it is 
unable to activate lipoic acid to lipoyl adenylate. This infers that two separate enzyme- 
catalysed reactions may be required for lipoic acid attachment in mammals.
k
Both % - and ^^N-NMR spectroscopy were used to determine the secondary structures 
of B. stearothermophilus and A. vinelandii lipoyl domains (Dardel et a l, 1991; Berg et 
a l, 1994). The former technique was able to show that the conformations of lipoylated 
and unlipoylated domains were identical.
I
The complete three dimensional structures of B. stearothermophilus (Dardel et a l,
1993) and E. coli (Green et a l ,  1995) lipoyl domains have been elucidated, showing 
two 4-stranded p-sheets forming a flattened p-bairel around a hydrophobic core. These 
two sheets are related by a quasi 2-fold symmetry. The N and C termini are close 
together in space at the opposite end of the domain to the lipoyl-lysine. The polypeptide 
chain displays one tight type-I p-turn, which is where the lipoyl-lysine residue (Lys-42) 
is accessibly situated. The sequence suiTounding Lys 42 is important in the recognition 
of E l, but other sequences must also be involved. It has been demonstrated that 
mutation of the adjacent residues does not prevent lipoylation, but does cause a 
reduction in the rate of reductive acétylation by E l (Wallis & Perham, 1994).
. ::
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1.3.2. Flexible Linker Sequences
For complex activity, the lipoyl domain must move between the active sites of each 
component enzyme (El, E2 and E3) during catalysis. This active site coupling is 
facilitated in part by the lipoyl-lysine "swinging arm" (Reed, 1974) and also by flexible 
interdomain linker segments. The arm is 1.4nm, so has a maximum span of 2.8nm. 
Fluorescence studies of E. coli PDC showed the active sites of El and E3 to be at least 
5nm apart (Shepherd & Hammes, 1976). Thus exti'a flexibility is required for active site 
coupling. Evidence for this comes from studies using genetically reconstituted PDC 
which had segments of linker deleted. Large deletions, shortening the 30 amino acid 
linkers by 50% or more, caused a drop of as much as 50% in complex activity (Miles 
et ah, 1987, 1988). Flexibility is reduced when the linker is removed.
functions in the self-assembly of the E2 core and catalyses the formation of acyl CoA. 
The primary and secondary structures of the E. coli domain show some similarities to 
those of chloramphenicol acetly transferase (CAT) (Guest et al., 1987). CAT catalyses 
the acétylation (and thus inactivation) of chloramphenicol in antibiotic-resistant bacteria 
(Shaw, 1983). One interesting similarity is the positioning of the sequence -HXXXDG- 
in the active site of both enzymes (Guest, 1989). This suggests that the catalytic
17
Variation between linker sequences seems to fall into three categories. The most |
common is alanine-proline rich segments, found in E. coli. The second group is
proline-rich and the final group is rich in charged and hydrophilic residues. The f
,rmajority of the Ala-Pro peptide bonds are in the trans configuration, preventing the ÿ
lipoyl domains collapsing into the core. The significances of these differences in linker s
design is not fully understood at present.
1.3.3. Catalytic Domain
The C-terminal catalytic domain, consisting of between 200 and 250 amino acids.
I
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domains are structurally related and that acetyl transfer is mediated by a related |
histidine-mediated mechanism (Kleanthous, 1985; Guest, 1987, 1989). The His acts as 
a general base and the Asn stabilises the transition state by hydrogen-bonding to it.
Evidence in support of this comes from site-directed mutagenesis of the corresponding 
His in E2p of E. coli (Russell & Guest, 1990; Maedayorita et al., 1994) and bovine 
E2b (Meng & Chuang, 1994). This resulted in loss of catalytic activity. However, the
1.3.4. Peripheral subunit binding domain
similar mutation in S. cerevisiae (Niu et al., 1990) had no effect on enzyme activity. $
Several other residues of the CAT active site have been assigned catalytic roles 
(Lewendon, 1988) including Ser^^S and Aspl^^. Mutation of the corresponding 
residue (Ser^^^) of E. coli PDC reduces catalytic activity (Russell & Guest, 1991).
I
X-ray crystallography studies of the A. vinelandii core domain of E2p has given a high 
resolution structural insight into the similarities with the trimeric structure of CAT 
(Mattevi et al., 1992, 1993) (Figure 1.6). Furthermore, each E2p core domain was seen 
to be folded into a six-strand p-sheet surrounded by five a-helices and a small two- 
stranded p-sheet, demonstrating similarity to CAT (Mattevi et al., 1993; Leslie et al.,
1990). Any differences in conformation were accounted for by the different substrates 
(chloramphenicol for CAT and lipoamide for E2p). |
I
Located between the N-terminal lipoyl domains and the C-terminal catalytic domain lies
the subunit binding domain. Depending on the source, this domain is the site for either I
E3 or E l binding, or indeed both. The 3-D structures of the binding domain from E.
coli OGDC (Robien et al., 1992) (Figure 1.7) and B. stearothermophilus BDC (Kaiia
et al, 1993) have been determined by means of 2D NMR spectroscopy. Both exhibit
two parallel a-helices, separated in the case of E. coli by a short extended strand and ^
helical turn from a disordered loop structure and in B. stearothermophilus by a 3io
helix from a highly structured loop. Kalia et al. (1993) also showed that the structure of
18
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Subunit 
core
Subunit 
core
Subunit 
core
Chloramphenicol Acetyltransferase (CAT)
NSubunitSubunit core core
NSubunit
E2p
Figure 1.6. Schematic Representation of the Organisation of the Catalytic 
Domain of CAT and E2p.
The two cores display several similarities including their ability to form 
trimers. The shaded boxes represent common secondary structure regions. The 
arrows represent regions of a-helix.
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Figure 1.7. The E3-binding domain from the E2 core of the E. 
coli OGDC complex.
The schematic diagram shows the binding domain with the positions of 
conserved residues. The structure was taken from Robien et at. (1992).
2 0
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the binding domain when complexed to E3 is similar to uncomplexed domain, implying 
a ‘lock and key’ mechanism of recognition, rather than ‘induced fit’. In B. 
stearothermophilus, only the first helix interacts with E3. It has been suggested that 
helix 2 is involved in binding E l (Mande et ah, 1996).
It has not been determined exactly which residues are involved in the binding of El 
and/or E3. The mode of binding may involve electrostatic interactions such as H-bonds 
and salt bridges between residues on the a-helices of the binding domain and the El 
and E3 components. This was fiielled further by Russell and Guest (1991) who
■ÎVshowed that under high ionic conditions, E l and E3 are easily dissociated. The most 
recent work on the binding between the peripheral subunit binding domain and E3 was 
carried out by Mande et a l (1996). They showed that an electrostatic zipper was 
responsible for the main interactions (Figure 1.8) In B. stearothermophilus, this is 
formed between Argl35 and Argl39 of the binding domain and Asp344 and Glu431 of 
one of the E3 monomers. Sequence alignment studies highlighted the conserved tri­
peptide Glyl55-Ai'gl56-Vall57. As well as its role in binding, it appears important for 
the stability of the binding domain. The Gly residue has a stmctural role, the Arg 
residue maintains the loop geometry in close proximity to the E3 while the Val residue 
contributes to the hydrophobic core of the domain.
It has been observed in E. coli that one E3 dimer can bind only to one binding domain 
(Hipps et al., 1994; Maeng et al., 1994). This could be either due to a change in 
conformation on binding to E2 or steric hindrance (Mande et a l, 1996) Studies of the 
binding of E lp  to E2p in B. stearothermophilus have also shown that only one El 
heterotetramer (a2p2) can bind to each domain. Furthennore, E l and E3 cannot bind to
the same binding domain simultaneously (Mori et a l, 1994; Lessard & Perham, 1995) 
and E l binds with a stronger affinity than E3 (Lessard & Perham, 1995). It could be 
proposed that, because E l and E3 occupy different sites around the E2 core, they bind
I
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6IUB431
A ,A spB 344
BD Arg139
Figure 1.8. Electrostatic zipper formed between the E3 and 
peripheral binding domain of E2 of B. stearothermophilus.
The side chains of Asp344 and Glu431 of one monomer of E3 adopt a different 
conformation to that of uncomplexed E3 to allow binding to the peripheral subunit 
binding domain via salt bridges. (Adapted from Mande et a l, 1996).
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to different binding sites within E2 and binding of one of these enzymes a causes 
steric hindrance effect, preventing binding by the other enzyme.
1.4. The Dihydrolipoamide Dehydrogenase (E3) Component
1.4.1. General
Dihydrolipoamide dehydrogenase is a flavoprotein belonging to the family of 
flavoprotein disulphide oxidoreductases that catalyses the reversible oxidation of the 
protein bound moiety of the E2 component of the 2-oxoacid dehydrogenase complexes.
Other such flavoproteins include glutathione reductase, NADH peroxidase and mercuric 
reductase. With the exception of the latter, they all catalyse electron transfer between 
disulphide compounds and nicotinamide dinucleotides (Roche & Patel, 1989).
E3 has been isolated, sequenced and characterised from a variety of sources including 
E. coli (StQph&ns et aL, 1983b), B. stearothermophilus et al., 1990), humans
(Carothers et al., 1989), B. subtilis (Hemila et al., 1990) and Halobacterium halobium 
(Danson et al., 1986). Their primary structures have been determined by nucleotide 
sequence analysis of the coding genes and found to be highly conserved (human liver 
E3 and porcine heart E3 have 96% sequence homology; Otulakowski & Robinson, 
1987). Based on this information, the enzyme has a subunit size of approximately 
50kDa.
Functional E3 is a homodimer with a non-covalently bound FAD co-enzyme associated
' k-with each subunit. X-ray crystallography studies have provided information regarding
the overall structure of E3. Such studies on A. vinelandii (Mattevi et at., 1991) show f
the presence of four domains per subunit; an FAD-binding domain, an NAD-binding
domain, a central domain and an interface domain (in this order from the N-terminus to
C-terminus). The two catalytic sites of the dimer contain sulphide bridges and are found
23
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at the interface between the two subunits. Residues from both subunits form the active 
sites. There is a lai'ge aiea of contact upon dimérisation, with as much as 16% of 
previously accessible surfaces becoming buried.
1.4.2. Enzymatic reaction of E3
The reaction catalysed by E3 (reviewed in Williams, 1992) is tenned a ping-ping bi-bi 
mechanism, divided into two half reactions;
(i) Protein-[Lip(SH)2 ] +E3-[FAD] <-> Protein-[LipS2 ] + E3 [FADH2 ]
Reduction of the oxidised enzyme to the 2-electron reduced form (EH2 ), with the 
electrons being shared between the flavin and reactive disulphide.
(ii) E3- [FADH2] + NAD+ <-> E3- [FAD] + NADH + H+
Transfer of electrons from the 2-election reduced foim to the NAD"*" cofactor via the 
flavin to regenerate the oxidised enzyme (Figure 1.9).
Only the reduced (EH2 ) form can bind NAD"^. The catalytic mechanism directly
involves a histidine side chain donated by the opposite subunit to the reactive 
disulphide. This essential His has been identified by site-directed mutagenesis (Kim & 
Patel, 1992). Deletion and mutagenesis of residues in A. vinelandii E3 (Schulze et a l,
1991) has also demonstrated a conserved Tyr. Positional analysis suggests that a 
hydrogen bond is formed between this Tyr and the His of the second subunit.
One E3 dimer binds to only one peripheral subunit binding domain (Hipps et al., 1994; 
Maeng et al., 1994; Mandeef a l, 1996). This is thought to be due to a change in 
conformation or steric hindrance. Schulze et a/. (1991) have shown that dimérisation is 
necessary for E2p binding, as both monomers provide residues forming the binding- 
site.
a
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Figure 1.9. Schematic Representation of the Mechanism of 
Dihydrolipoamide Dehydrogenase (E3)
Abbreviations: F, FAD, B, active site His.; S-S, Redox active disulphide;
Lip(SH)2 , dihydrolipoamide; , charge transfer 
(Adapted from Vettakkommakankav & Patel, 1996).
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1.5. The E l  Com ponent
1.5.1. G enera l
The E l component is a ThDP-dependent enzyme which catalyses the oxidative 
decarboxylation reaction with the concomitant transfer of the acyl group to the E2- 
bound hpoic acid. There are two forms of PDC El; in octahedal PDC and OGDC 
complexes it is a homodimer (012) (Reed, 1974) and in octahedral BCOADC complexes 
and icosahedral complexes it is found as a heterotetramer (a2P2)- Iri PDC, the a  
subunit is 41kDa and the P subunit 36kDa. In the latter form, the a  subunit is thought 
to bind thiamine diphosphate (ThDP) (Stepp et a l, 1985) and the p subunit is involved 
in the reductive acétylation of the dithiolane ring of the lipoyl group (Yeaman, 1989; 
Patel & Roche, 1990). E la  is thought to bind to E2 indirectly via binding to E ip  
(Rahmatullah e/a/., 1989).
Lessard & Perham, (1994) have overexpressed the E la  and E lp  genes from B. 
stearotheimophilus in E. coli and shown that E lp  could bind to E2, without the 
presence of E la . The converse was not true, in that E la  could not bind to E2, unless 
E lp  was also present in the form of an Elp-E2p subcomplex.
The binding of E l to E2 in mammalian sources relies on the peripheral binding domain 
(Wynn et a l,  1992). This was demonstrated by using truncated E2. Only the constructs 
devoid of the peripheral subunit binding domain were unable to bind El.
This is in contrast to E l binding in octahedral complexes, such as E. coli and A. 
vinelandii. It is still able to bind to the E2 core despite the removal of the peripheral 
subunit binding domain, showing the involvement of part of the inner catalytic domain 
(Packman et al., 1988). Studies by Schulze et al. (1991) using site-directed 
mutagenesis of residues within the catalytic domain of A. vinelandii have confirmed the 
involvement of the inner domain in E l binding. This group also showed that the
26
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peripheral subunit binding domain and the core domain must be from the same species 
(Schulze et al., 1992).
Sequence analysis of E. coli E lp and E lo  has shown a lack of homology, in contrast to 
E2p with E2o (Stephens et a l, 1983b; Guest et a l,  1989). In fact, there seem to be 
sequences within the OGDC El enzyme which show similarities to those within E3 
binding domains. There is also similaiity to the putative E3 binding region of protein X. 
from this evidence, it has been suggested that the E l component of OGDC has evolved 
to bind E3, in a similar way to protein X having apparently evolved as a separate gene 
product from E2-PDC, assuming a principal role in E3 binding in the process.
1.5.2. Enzymatic reaction of E l
The decarboxylation of pyruvate by E l has been fairly well defined (Figure 1.10), but 
the final part of the catalytic reaction is still not fully deteimined. Two possible 
pathways for the reductive transfer of the acetyl group have been suggested (Gruys et 
a l, 1989; Frey et a l, 1989) (Figure 1.11).
In E l from icosahedral complexes, it is the a  subunit which binds the ThDP. Primaiy 
sequence analysis has shown it contains a highly conserved sequence of approx. 30 
amino acids, beginning -GDG~ and ending with -NN-, which is common to other 
enzymes wliich also use ThDP as a cofactor, such as transketolases and pyruvate 
decarboxylases (Hawkins et a i, 1989). Several studies involving mutagenesis of 
various residues of both the a  and p subunits have suggested that up to six tryptophan 
residues are involved in cofactor binding (AM et a l, 1995; Khailova et a l ,  1989). 
Furthermore, it has been demonstrated that the presence of a Ca^+ ion is important for 
ThDP-binding (Lindquistefa/., 1992).
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1.5.3. C ontrol of E l  via K inase and Phosphatase Activity
E l catalyses the overall rate-limiting step in the sequence of reactions catalysed by the 
2-oxoacid dehydrogenase complexes. Its activity is conti'olled by the phosphorylation 
and déphosphorylation of three specific serine residues in the a  subunit (reviewed in 
Reed & Yeaman, 1987; Patel & Roche, 1990). The Mg^'^'-dependent kinase 
responsible for the phosphorylation and subsequent inactivation is tightly bound to the 
E2 core.
To date, four such kinases have been cloned. The first, BDK (branched chain a -  
ketoacid dehydrogenase kinase) was cloned by Popov et al. (1992). It phosphorylates 
and inactivates the BCOADC complex. This conserves leucine, isoleucine and valine, 
when required for protein synthesis by all tissues. The phosphorylation of Ser293 ^nd 
Ser303 of E l a  causes the inhibition of the ThDP-dependent step catalysed by El 
leading to inhibition of overall complex activity. BCOADC phosphatase is the enzyme 
responsible for the dephosphorylation and therefore activation of the complex.
The second kinase to be cloned (Popov et a i,  1993) is PDK (pyruvate dehydrogenase 
kinase). The phosphorylation of PDC causes a decrease in glucose utilisation and 
conserves the metabolic intermediates, alanine, lactate and pyruvate needed for the 
homeostasis of blood glucose levels. Phosphorylation can occur at 3 sites (Ser233^ 
Ser240 and Ser^'^^) of the E la  subunit (Yeaman et at., 1978), the first of these being 
the main site of inactivation. Inhibition is enhanced by the concomitant phosphorylation 
of the other 2 sites. Inactivation is rapid, possibly due to the tight binding of the kinase 
to PDC. The inactivating effect of the kinase is reversed by PDC phosphatase.
The third kinase to be cloned (Popov et a i, 1994) also inactivates PDC upon 
phosphorylation, showing the existence of PDK isoforms in higher eukaryotes. The
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amino acid sequences deduced form the full-length cDNAs encoding BDK, PDKl and 
PDK2, show 30% homology between BDK and the PDKs, while the PDKs are 70% |
homologous.
PDK3 and PDK4 have different allosteric and regulatory properties which are tailored 
to the distinctive energy demands of individual tissues. PDK3 and PDK4 are found at 
its highest levels in heart and skeletal muscle.
The most recent PDK kinase to be cloned is the isoform PDK4, discovered by Rowles 
et a i, 1997. Harris et al. (1997) demonstrated starvation and also diabetes leads to an 
increase in the amount of the PDK4 isofbrm. In the rat model, it normally accounts for .H'
less than 30% of total PDK activity, but this was increased to above 50% in the starved 3
state to 75% in the diabetic animals. As PDK4 activity is 7 times greater than the other 
isoforms, this isoenzyme shift resulted in greater phosphorylation and hence reduced |
PDC activities. Furthermore, due to PDK4 being less sensitive to pyruvate inhibition 
than PDKl and PDK2 (Bowker-Kinley et al., 1997), the PDC activity remains 
increased. Refeeding of the animals starved for 48h, reversed the increase in PDC Iactivity. Insulin treatment of the animals leads to a decrease in PDK4 activity, although
the mechanism has yet to be determined. i
Mapping of the kinases reveals 5 highly conserved regions (Popov et a i, 1992),
■"-'3
implicated as important for catalytic function. They may either directly form the active
A'site or contribute structurally.
BDK expression in various tissues and its association with BCOADC under different 
physiological conditions is an important factor in regulating complex activity. The f
activity of BCOADC in the liver is greater that in any other tissue and it is here that 
BDK levels are lowest (Popov et al., 1995). The tissue distribution of the PDKs has 
been determined by Northern blot analysis (Popov et al, 1994). PDKl mRN,A is found
31
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mainly in the heart. PDK2 mRNA is expressed in the heart and skeletal muscle but also 
to some degree in testes, liver, brain and kidney. PDK1/PDK2 ratios may alter 
according to physiological and pathological states.
1.6, P ro tein  X
A fourth component has been identified associated with the PDCs of mammals and 
yeast (De Marcucci et a l, 1985). Initially it was assumed to be a proteolytic fragment of 
E2 or E3 as a band of approximately 50kDa was observed to migrate with the E2 
component of bovine heart and kidney PDC. However, subsequent immunological, 
structural and genetic studies showed it to be an independent species (De Marcucei & 
Lindsay, 1985; De Marcucci et a l, 1986; Jilka et al, 1986).
Sequence analysis of the protein X gene from yeast, S. cerevisiae (Behai et a l, 1989) K
and bovine heart (Neagle et ah, 1989) have shown it to possess a multidomain 
stmcture, similar to E2, comprising a single lipoyl domain and a peripheral subunit 
binding domain. The similarity does not extend to the C-terminal domain as it lacks the |
“HXXXDG" motif. The protein X lipoyl domain is capable of undergoing acétylation, 
deacetylation and reoxidation in the absence of E2 (Roche et a l, 1989b).
The most recent work involving protein X, suggests a role in the binding of E3 to the 
PDC complex (Neagle et a l, 1991). Indeed it now has the alternative name, E3 binding 
protein (E3BP). Native bovine kidney PDC was subjected to proteolysis with arg C.
Selective degradation of protein X was shown to occur, by employing SDS-PAGE 
analysis. Two fragments were generated; a 35kDa fragment and an immunoreactive 
15kDa species, the latter corresponding to the lipoyl peptide. Despite this degradation, 
there was a minimal effect of the overall PDC enzymatic activity. However, there was a 
decrease in the affinity of E3 for the E2 core and an enhanced sensitivity to high ionic 
strength. This suggested that either protein X is not essential for PDC activity or that the
32
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35kDa truncated C-terminus peptide, still attached to the E2 core, is responsible for 
keeping the PDC function by positioning the E3 in the optimal location on the E2 core 
surface to facihtate its role in electron transfer. McCartney et al. (1997) showed that 
when protein X is removed, the PDC activity is reduced to between 10 and 15% of 
normal levels, but this can be enhanced by the presence of excess exogenous E3.
.Î
1.7. Regulation of the 2-Oxoacid Dehydrogenase Complexes
The location of the complexes within the energy-generating pathways of most aerobic 
tissues and cells means the requirement for close regulatory control. This is especially 
so for PDC, being located at a significant committed step in the metabolic pathway 
channelling intermediates into the TCA cycle. For example, during lipogenesis, |
increased PDC activity is required to supply acetyl CoA for fatty acid biosynthesis. On
::3,the other hand, in the presence of other substrates such as ketone bodies or fatty acids,
suppression of complex activity is needed to allow carbohydrate ‘sparing’ for the brain, y
. " 3
which is glucose-dependent. Thus the role of PDC could be looked upon as one of - 33
glucose homeostasis.
In other words, regulation must be both bioenergetically and biosynthetically sensitive. 
Three forms of control have been determined; end-product inhibition by NADH and 
acetyl CoA (Garland et a l, 1964; Kanzaki et a l, 1969), altered gene expression and 
through phosphorylation and déphosphorylation by the previously mentioned kinase 
and phosphatase. The latter mechanism is specific to PDC and is regulated by a number 
of effectors (Figure 1.12).
It has been demonstrated that hormones such as insulin are able to influence the activity 
of the complexes. In adipose tissues for example, PDC activity is increased several­
fold. The mechanism of signalling between the insulin receptor and PDC is as yet 
unresolved, but several have been proposed, including the activation of secondary
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Figure 1.12. The regulation of mammalian PDC through the 
phosphorylation-déphosphorylation cycle.
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messengers (Wieland et a i,  1989) and the production of small mediator molecules on 
the outside of the plasma membrane which interact with other cell surface receptors 
(Larner er a/., 1989) Gottschalk et al. (1992) have demonsti’ated that a 110 amino acid 
portion of the C-terminus of the insulin receptor may be involved in mediating PDC 
activity. It seems to possess determinants required for effective coupling to the PDC 
signalling system. Palmer et al. (1983) have shown that BCOADC activity in 
diaphragm muscle is inhibited following elevated levels of glucagon or adrenaline.
1.8. Physiological diseases associated with the 2-oxoacid 
dehydrogenase complexes
A large number of related disorders have been attributed to deficiencies in the activities 
of the 2-oxoacid dehydrogenase complexes. Primary biliary cirrhosis (PBC) is a 
chronic autoimmune disease, characterised by progressive inflammatory destruction of 
intrahepatic bile ducts, leading to fibrosis and ultimately liver failure (Kaplan et al., 
1987; Sherlock & Dooley, 1993). A serological marker for diagnosis is the presence of 
antimitochondrial autoantibodies directed against the E2 components of PDC, OGDC 
and BCOADC (collectively termed the M2 antigens). Other antigenic components 
include protein X and the E la  and E lp  subunits of PDC (Yeaman et al., 1988; Fussey 
et al., 1988; Surh et al., 1989). The vast majority (95%) of PBC sufferers have 
antibodies against the inner lipoyl domain of PDC-E2. Within the lipoyl domain, the 
site of attachment of the lipoic acid moiety is the most immunoreactive segment. Fussey 
et al. (1990) demonstrated that the lipoic acid itself has a role in the antibody 
recognition. Subsequent work (Joplin et al., 1997) has suggested that the lipoic acid of 
protein X is involved in the aetiology of disease. The major autoantigen involved in 
PBC is located on the plasma membrane of bile duct epithelial cells. It can therefore be 
postulated that a defect in the targeting of PDC-E2 epitopes, or incorrect antigen 
processing, resulting in their wrongful location on the cell surface, could lead to the 
generation of an autoimmune response and disease promotion.
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The largest group of PDC-related disorders aie those resulting from a defect in the El 
genes. This is possibly due to the fact that one of the genes coding for E l, is located on 
the short aim of the X chromosome. The precise nature and degree of abnormality is 
dependent not only on the actual mutation, but also on the X-inactivation pattern in 
females. Most of the mutations occurring in exons I-IX aie missence mutations, which 
allow some residual function. The insertion and deletion mutations in exons IX-XI 
result in an altered reading frame and the synthesis of truncated or elongated proteins, 
leading to inactive El.
An example of an inborn error of metabolism caused by a defect in complex activity is 
the autosomal recessive ‘Maple Syrup Urine Disease’ (MSUD). This is characterised by 
a large number of phenotypes ranging from mental retardation and death to milder 
conditions with late onset. It results in the accumulation of branched-chain amino acids 
and derived products in the urine. The disease is caused specifically by a genetic defect 
in the E l and/or E2 enzymes of BCOADC. The mutations are heterozygous and include 
deletion, insertion, missense and splicing abnormalities (Indo & Matsuda, 1996).
Studies have shown a possible link between OGDC deficiencies and Alzheimer’s 
disease. Glutamate, which acts as a potent neurotoxin (Beal et al., 1992) accumulates 
when 2-oxoglutarate oxidation is impaired. Sheu et al. (1994) demonstrated that 
patients with familial Alzheimer’s had defective OGDC activity, possibly due to 
mutations in the E2 gene.
Deficiencies in the recently discovered protein X have been attributed to primary 
congenital lactic acidosis. In 1990, Robinson et al. described three patients with 
decreased PDC activity. The first patient had no E2 and decreased levels of protein X . 
The second had no protein X and the third showed a lower molecular- mass form of 
protein X. In 1993, Marsac et al. also described three patients (two of whom were 
siblings) with defective protein X. This was followed by Geoffroy et al. (1996), then
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De Meiiieir et a l . and Ling et a l  (1998). The fact that some of the patients had no 
immunologically detectable protein X, yet retained partial PDC activity, further 
substantiates the E3-binding role of protein X, whilst confirming that E2-PDC displays 
low levels of E3 binding
To date very few E3-linked deficiencies have been documented. This is likely to be due 
to the severity of such diseases. A decreased E3 activity causes a reduction in each of 
the three complexes’ activities, resulting in the accumulation of lactic, 2-oxo and branch 
chain amino acids (Liu et a l, 1993). Patel et al. (1997) were able, with the use of 
tr ansgenic mice, to disrapt the E3 gene (Did) by inserting a neomycin phosphatase gene 
into exon 10. The heterozygous animals showed a 50% reduction in the activity of the 
complex and a 50% reduction in the E3 mRNA, while displaying a normal phenotype. 
The homozygous animals, however, were embryonic lethal mutants. This highlights the 
importance of mitochondrial oxidative pathways during the implantation stage of 
development.
1.9. Mitochondrial Targeting
4
It is known that the individual polypeptides making up the multienzyme complexes are 
nuclear encoded, as the translation products of the mitochondrial genome have been 
identified (Glover & Lindsay, 1992). The nascent precursor forms take only 2 to 5 
minutes to cross the membrane, making detection and characterisation difficult.
However, by uncoupling the electrochemical gradient necessary for translocation it has 
been possible to study the precursors via their accumulation in the cytoplasmic 
compaitment.
There are three stages involved in the transfer of a newly synthesised mitochondrial 
polypeptide from the cytoplasm into the mitochondrion;
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(a) The maintenance of a translocational competent state i.e. unfolded polypeptide, 
involving chaperones and the presequence.
(b) The targeting to the mitochondrion, involving binding proteins.
(c) The translocation across the mitochondrial membrane.
J'7;' ■
The heat shock family of proteins, also termed chaperones, are important in keeping the 
precursor forms in an unfolded or translocation competent state and preventing self-
'l'4aggregation. One such protein is the cytosolic Hsp70. It is also responsible for the uni- 
directional translocation of polypeptides through the mitochondrial membrane and for 
the correct folding once within the matrix (Stuart et al., 1994). The presequences have 
been shown to be highly amphipathic and it is this characteristic which may promote 
binding by Hsp70 (Endo et al., 1996). As well as Hsp70 is PBF (presequence binding
factor) which may also bind the presequence after translation of the mRNA to
,'"r
polypeptide. PBF was shown by Murakami & Mori, (1990) to stimulate the import of 
precursor forms, but not the mature form of rat ornithine carbamoyItransferase.
I
Once the precursor arrives at the mitochondrial membrane, it is directed to a 
‘translocation contact site’. There are several receptors, called mitochondrial outer 
membrane proteins (MOMs) to which the precursor binds initially. They tend to be '
membrane bound with the receptor part on the cytosolic side, recognising either the 
signal peptide sequence or a bound cytosolic factor. On binding, the chaperone protein 
is removed, possibly involving another chaperone called Hsp40.
It has been suggested and demonstrated that not aU the information required for 
targeting is confined to the presequence. There may be further information in the mature 
protein itself. This was shown to be the case in yeast, where mutants were able to 
transport mature mitochondrial proteins correctly as well as leaving synthetic fusion
-4proteins in the cytosol (Schatz & Dobberstein, 1996). There is still a lot of ambiguity as 7
to the full model of the translocation process itself. Many proteins are involved forming
1
7
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a pore thi'ough which the polypeptide travels and others aiding the transfer across the 
membrane. Both a membrane potential and ATP supply are required.
Following the initial binding to the surface receptor, the polypeptide enters the outer 
membrane pore, then moves in to the innermembrane through a second pore. 
Mitochondrial proteins, including mt Hsp70, located in the matrix, bind the incoming 
polypeptide and aid its entiy (Stuart et a l, 1994).
Processing of the polypeptide occurs immediately following translocation, the 
presequence is removed by MPP (mitochondrial processing peptidase) and the mature 
form adopted upon folding. MPP requires zinc and cleaves by recognising a particular 
3D motif, rather than primary sequence.
Next, the mature polypeptide is either re-tai'geted or folded according to its final 
destination. Many polypeptides whose tai'get is the intermembrane space or the inner 
membrane have a ‘bipartite signal’, which means that one sequence tai'gets it to the 
mitochondrion then another is exposed to target it to its final destination.
The pre-sequence itself tends to be between 19 and 40 amino acids in length, although 
longer sequences have been identified. They contain high levels of serine, threonine and 
basic amino acids. In an a-helical conformation, they are amphipathic i.e. hydrophilic 
on one side and hydrophobic on the other (Heijne et a l, 1989). There appears to be no 
sequence homology but there must be defined signals within these sequences.
39
Introduction
1.10 Aims of this thesis.
Within this thesis there are several aims, which all tend towai'ds obtaining a greater 
understanding into the interactions occurring within the 2-oxoacid dehydrogenase 
complexes.
The first was to devise a method to allow the amplification and subsequent 
overexpression of sub genes (the di-domain) of the E2 enzyme and the corresponding 
sequences of protein X. Following on from this is an investigation of the actual 
lipoylation of the E2 and protein X di-domains, including the use of site directed 
mutagen^ Sto determine specific residues essential for lipoylation. In addition, a 
preliminary study has been undertaken to investigate the effect that the large 
mitochondrial presequence has on the ability of the sub genes to fold and undergo 
lipoylation.
The N-terminal region of the E l component of OGDC has been studied with the aim of 
studying its involvement in interacting with the E2 and E3 components.
Finally a study has been carried out, using the BIAcore instmmentation to obtain 
binding and affinity constants for interaction between the PDC di-domain and E3 and 
also between the protein X di-domain and E3. This was caixied out to deteimine 
whether protein X has evolved with a greater ability to bind E3 than E2-PDC. Full- 
length protein X and full-length E2 has also been subected to the same analysis.
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2.1.1 B ac te ria .
Five strains of E.coli were employed:
Escherichia coli DHSa : (Stratagene). For general propagation of plasmid vectors. ;
Escherichia coli X L l Blue : (Stratagene). For propagation of plasmid vectors.
Escherichia coli XL-10 Gold: (Stratagene). For the propagation of pET vectors.
Escherichia coli DE3 (BL21): (Novagen). For the expression of the pET vectors 
carrying the T7 promoter.
Escherichia coli DE3 pLysS: (Novagen). For the expression of the pET vectors 
carrying the T7 promoter.
2.1.2 B acterial M edia.
Cultures were grown in either LB (lOg bacto-tryptone, lOg NaCl and 5g yeast per litre) 
or DYT (16g bacto-tryptone, 5g NaCl and lOg yeast per litre). Media was autoclaved 
prior to use. Where necessary, media and plates were supplemented with ampicillin at 
50p,g/ml and/or chloramphenicol at 34|ig/ml.
I
2.1.3 Chem icals. iFisons, Loughborough supplied the Polyethylene glycol 6000 and Triton X-100.
IPyronin dye was obtained from George T. Gurr, London. Mikrobiologie supplied the 
growth media for bacterial cultures. Reagents for SDS-PAGE and native gel ielectrophoresis were obtained from BDH Chemicals Ltd., Poole. All other chemicals
were at least of analytical grade. Unless stated, water was glass-distilled. '
2.1.4 E nzym es.
DNA restriction enzymes and DTT were supplied by Boehringer Mannheim Ltd. Taq
VDNA polymerase, calf intestinal alkaline phosphatase, proteinase K and DNA ligase
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were supplied by Promega Ltd., Southampton. Cloned Pfu DNA Polymerase was 
supplied by Stratagene.
2.1.5 Molecular Size & Weight Markers.
For agarose gel electrophoresis, 50bp, lOObp and Ikb ladders were used (GIBCO 
BRL) and also Hindin/EcoRJ digested Lambda phage (Pharmacia). For SDS-PAGE 
analysis of proteins, broad-range molecular weight markers were used (NEB Biolabs).
2.1.6 O ligonucleotides.
Primers for PCR were designed in the laboratory and synthesised by GIBCO BRL, 
Paisley or Genosys Biotechnologies (Europe) Ltd., Cambridgeshire.
2.1.7 Photographic Materials.
Hyperfilm was obtained from Amersham, Bucks. The X-Omat-100 processor was 
supplied by Kodak.
2.1.8 Plasmid Vectors.
pHUM IT (Kind donation by Dr. E. Gershwin). This vector contained the entire 
human PDC E2 gene.
pTSE2al (Kind donation by Dr. D. Danner). This vector contained the bovine 
BCOADC E2 gene.
pGS623 (Kind donation by Prof. J. Guest).This vector contained the E. coli PDC E2 
gene.
p E T lla  and p E T lld  (Novagen). These vectors were used for the overexpression of 
heterologous proteins in E. coli. (Figure 2.1)
pGEX-2T (Pharmacia). This was used for the overexpression of GST-Fusion 
proteins in E. coli, (Figure 2.2)
pGLIP-2T (Kind donation by J. Quinn). This vector contained the lipoyl domain of 
human E2-PDC.
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CCCCT10ÇÇCCCTCTAAACCCCTCTT6ACC6CTTTTTTC
Figure 2.1 Map of expression vector p E T lla . The pETlla-d vectors carry an 
N-terminal T7 Tag sequence and Bam HI cloning site. The circular map shows the 
unique sites. The cloning region of the coding strand transcribed by T7 RNA 
polymerase is shown below. The expression region is reversed on the circular map as 
the sequence is numbered by the pBR322 convention. The pE T lld  vector has the 
following exceptions to the above map; it is a 5674bp plasmid and an Nco I site is 
substituted for the Nde I site with a net Ibp deletion at position 359 of pE T llc . As a 
result, Nco I cuts pETl Id at position 355.
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Throm bin pGEX-2T
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Figure 2 .2  Map of the glutathione S-transferase fusion vector^ pG EX- 
2T, showing the reading frames and main features of the multiple 
cloning site. The vector has a tac promoter, for chemically inducible expression. A 
thrombin recognition site is located immediately upstream of the cloning site, allowing 
cleavage of the desired protein from GST.
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2.2. METHODS
2 . 2 . 1  Determination of protein concentration.
i
Proteins concentrations were determined by the method of Lowry et al. (1951),
s'modified by Markwell et a l (1976). For low concentrations, the Micro BCA assay was 
employed (Biorad). Protein standards were constructed using bovine serum albumin or 
IgG and absorbancies read at 595nm.
2 . 2 . 2  Dialysis of protein samples.
Dialysis was carried out at 4^C in Visking Tubing which had previously been boiled for 
10 min in ImM EDTA (pH 8.0) and lOmM sodium bicarbonate, then rinsed with
:S ;distilled water and stored in 100% (v/v) ethanol. r
2 . 2 . 3  Concentration of protein samples.
Protein samples were concentrated in Visking Tubing by covering with polyethylene 
glycol-6000 (PEG-6000) at room temperature until the volume inside the tubing had
been sufficiently reduced.
■
2 , 2 . 4  Polymerase Chain Reaction (PCR) of the E2 or protein X
di-dom ain.
The oligonucleotides (see below) were obtained from Life Technologies, Paisley. The 
underlined sequences in the 5' primers indicate the Nde I restriction site. The underlined 
sequences in the 3' primers indicate the Bam HI restriction site.
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PCR reactions were carried out in a 50jJ,l volume containing 50ng template DNA, 
0.25mM dATP, dGTP, dCTP & dTTP (Promega), 5|ig each primer, 1.5mM MgCl2,
Ix Taq Polymerase buffer, 1 unit Taq Polymerase (Promega). Each reaction was 
overlaid with 50pl paraffin to prevent evaporation. Amplification was carried out on a 
PTC-100 thermocycler (GRI) for 30 cycles (30 sec at 92°C, 30 sec at 53^C, 1.5 min at 
72®C) preceded with an initial dénaturation step of 3 min at 94^C and concluding with a 
5 min extension time at 72°C. Prior to further analysis, the PCR products were stored 
at 40c .
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a) Human PDC S' Primer:
AGG CTC CTCATATGT CAT ATC CCC CTC ACA TG 
Human PDC 3' Primer:
CTT GGC ACG GAT CCA GTG ATA TCC TTC CTG GTG
b) Bovine BCOADC S' Primer:
GCT GCT CATATGGGA CAG GTT GTT GAG TTC AAG 
Bovine BCOADC 3' Primer:
CAA TAT AGC GGA TCC AGT CCT TTC CAA ATA GTT
c) E. coli PDC S' Primer:
GTG ACT GAA CAT ATG GTG AAA GGC GAC AA 
E. coli PDC 3' Primer:
GAT AGC TTC GGA TCC AGT AGC CTG AAC GTC TTC
d) Human protein X S' Primer:
ACG CAG TGG CAT ATG GGT GAT CCC ATT AAG ATA CTA 
Human protein X 3' Primer:
TCC AGA TGT GGA TCC AGT GGG CGA AGG TGC TGT
i/
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2 .2 .5  Polym erase Chain Reaction (PCR) of the OGDC E l  N-
term inus
The four oligonucleotides designed following careful study of previously published
2 .2 .6  Agarose gel electrophoresis of the am plified DNA encoding
the di-dom ain.
lOjLil of PCR product was electiophoresed on a 2% (w/v) agarose gel, with 2pl of 
bromophenol blue/xylene cyanol loading buffer (Promega). The gel was run in Ix TAE 
buffer at 75V until the dye front was within 1 cm of the end of the gel. A lOObp ladder 
was used as a molecular mass marker (Life Technologies, Paisley). The gel was stained 
with ethidium bromide (lOmg/ml) (Sigma) for Ih, destained for Ih in distilled water
50
sequences, were obtained from Life Technologies, Paisley. The underlined sequences
in all the primers indicate the Bam HI restiiction site.
Upstream primer: CAGATTCGGGGATCCTCTGCACCTGTTGCTGCTG j
OGDC-60 CACAGCAGCGGATCCAGTTCGGCTCAGGGAAGG
OGDC-110 CAGATCAGCGGATCCAGTCCCCAGGGGTCCAG
OGDC-160 GATCTCCCGGATCCAGTTGCTGATTCCTGTCC
OGDC-60 was used to amplify the first 60 amino acids, OGDC-110 the first 110 and
OGDC-160 the first 160.
PCR reactions were carried out in SOpl volumes containing 50ng human foetal heart 
cDNA, 0.25mM dATP, dGTP, dCTP & dTTP (Promega), 5|Lig each primer, Ix Pfu 
DNA polymerase buffer, 2 units Pfu DNA Polymerase (Stratagene). Each reaction was 
overlaid with 50pl paraffin to prevent evaporation. Amplification was carried out on a 
PTC-100 thermocycler (GRI) for 35 cycles (45sec at 95^C, 30sec at 65°C, 10 min at
7 2 ^ 0  preceded with an initial dénaturation step of 45 sec at 95 ^ C and concluding with -7
" I.
a 15 min extension time at 720C. Prior to further analysis, the PCR products were 
stored at 4°C.
Materials and Methods
and the banding pattern visuahsed under transillumination with an ultraviolet (UV) light 
source,
2 . 2 . 7  DNA isolation from agarose gels.
The PCR product was run on a 2% low melting point TAE-agaiose gel and the DNA 
recovered using the Promega Wizard^^^ PCR Preps kit or Qiagen prep kit and provided 
protocol. The DNA was eluted into 50jal distilled water.
2 . 2 . 8  Restriction digests.
Both Nde I and Bam HI were supplied by Boehringer. Nco I was supplied by 
Stratagene, and NEBuffer 2 was supplied by New England Biolabs.
2 . 2 . 8 . 1  p E T lla  digestion with Nde I and Bam HI.
Digests were carried out in a 40fxl volume, containing the following components; 15p.l 
pE T lla  vector, 15 units Nde I, 15 units Bam HI, 4pl Buffer B and 18|il distilled 
water. The mixture was incubated in a water bath at 37®C for 2h. After tlie first hour, 
lp,l alkaline phosphatase was added to prevent self-ligation. The 40p.l digestion mix 
was run on a 1.5% TAE-agarose gel. DNA was recovered using the Promega 
WizardTM p cR  Preps kit and the provided protocol. The DNA was eluted into 50p,l 
distilled water.
2 . 2 . 8 .2 Di-domain PCR product digestion with Nde I and Bam HI.
Digests were carried out in a volume of 40)11, containing the following components; 
20p,l di-domain product, 15 units Nde I, 15 units Bam HI, 4jil Buffer B and 13(il 
distilled water. The mixture was incubated in a water bath at 37^C for 2h and the 
resultant products run on a 2% low melting point (LMP) agarose gel. DNA was 
recovered using the Promega WizardTM pcR  Preps kit, and the provided protocol.
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2 . 2 . 8 . 3  OGDC N-terminal fragment PCR product digestion with 
Bam HI.
Digests were caii'ied out in 40jil volumes, containing the following components;
20pl PCR product, 15 units Bam HI, 4|il Buffer B and 12|li1 distilled water. The 
mixture was incubated in a water bath at 37^C for 2h and purified DNA recovered 
using the Qiagen Preps kit and the provided protocol.
2 . 2 . 9  L igations.
2 . 2 . 9 . 1  Ligation of E2 di-domain with p E T lla  vector.
The ligation of the vector with the E2 di-domain was carried out for lOh; 5h at 16®C 
followed by 5h at 10%. Various ratios of insert to linearised vector were tried, with the 
optimal ratio being approx. 1:1. Each reaction was carried out in a lOpl volume, 
containing DNA, T4 ligase buffer, 2 units T4 ligase and distilled water.
2 . 2 . 9 . 2  Ligation of OGDC E l N-terminal fragments with
pGEX-2T vector.
The same protocol was employed as detailed above.
2 . 2 . 1 0  Preparation and Transformation of E. coli.
DH5a or XL 1-Blue cells were grown overnight in 5ml LB, then 1ml per 
transformation were made supercompetent, using the following method (2.2.12), prior 
to being transformed with the lOp.1 ligation mixes. For each transformation, 1ml of
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2 . 2 . 8 . 4  pGEX-2T digestion with Bam HI.
Digests were carried out in 40pl volumes, containing the following components; 15pl i '
pGEX-2T, 15 units Bam HI, 4pl Buffer B and 7pi distilled water. The digestion was 
incubated at 37%  for 3h, then for a further 30 min with the addition of Ipl alkahne 
phosphatase. The DNA was purified using a Qiagen Preps kit and the provided 
protocol.
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overnight culture was pelleted in a microcentrifuge for 1 min The cells were 
resuspended in 500pl ice-cold, sterile 0.1 M CaCl2 and left on ice for 10 min. They 
were then pelleted for 1 min, resuspended in 300pl O.IM CaCl2 and incubated on ice 
for 30 min. At this point the lOpl ligation mixes were added and each sample left on ice 
for at least 30 min. Heat shock was carried out in a water bath at 42^C for exactly 90 
sec, then 1ml LB was added to each sample. After Ih of shaking incubation at 37®C, 
the cells were pelleted in a microcentrifuge, resuspended in lOOpl LB and spread on 
agar plates containing ampicillin. The plates were incubated overnight at 37% .
The plates were made by dissolving 15g of agai* in a litre of LB broth. Following 
autoclaving, the broth was allowed to cool to below 50%  before adding antibiotic (final 
concentration 50pg/ml) and pouring under sterile conditions.
2 . 2 . 1 1  Isolation of plasmid DNA.
A single colony was used to inoculate 5ml LB and grown overnight at 37%  in the 
presence of ampicillin. The plasmid DNA was then isolated using the Promega 
W iza rd ^ M  Minipreps kit and the provided protocol.
2 . 2 . 1 2  Preparation of supercompetent DE3 or DE3pLysS E, coli 
cel l s .
A single colony was used to inoculate a 5ml culture of LB, wliich was supplemented 
with ampicillin (plus chloramphenicol if using DE3pLysS). After overnight growth at 
37% , a 1ml sample was then used to inoculate 50ml of LB, again containing ampicillin 
and the culture grown until an A^QQ of 0.3 was reached. The sample was stored on ice
for 15 min, then centrifuged at 5000 x g for 10 min at 4^C. The resultant pellet was 
resuspended in 10ml of O.IM ice-cold MgCQ and centrifuged again at 5000rpm for 10 
min at 4^C. The resultant pellet was resuspended in lOmls ice-cold O.IM CaCl2 and 
left on ice for 30 min before a final centrifugation at 5000 x g for 10 min at 4^C. The
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resultant pellet was resuspended in 2ml O.IM ice-cold CaCl2 and aliquoted into 200pl 
samples, with 200pl 50% (v/v) glycerol. Storage was at -80% .
2 . 2 . 1 3  Overexpression of heterologous protein.
A single colony was used to inoculate a 5ml culture of LB, which was supplemented 
with the appropriate antibiotic. After overnight growth at 37% , a 1ml sample was then 
used to inoculate 50ml of LB, again containing ampicillin, and the culture incubated in a 
37%  orbital shaker at 225i*pm until an AgoO of 0.5 was reached. At this point, the cells
were induced with 0.4mM IPTG. Samples (1ml) were removed at 0, 1, 2 and 3h 
following induction, and their A600 determined. The cells were then pelleted in a
microcentrifuge and resuspended in Laemmli sample buffer (lOpl per absorbance unit), 
containing lOmM DTT. Samples (20pl) were loaded onto a 15% SDS-polyacrylamide 
gel, following 5 min boiling in a water bath.
2 . 2 . 1 4  Large-scale overexpression of heterologous protein.
A single colony was used to inoculate a 5ml culture of LB, which was supplemented 
with the appropriate antibiotic. After overnight growth at 37% , the 5ml sample was 
then used to inoculate 330ml of LB, again containing ampicillin with or without 
chloramphenicol, and the culture grown at 225rpm until an AôQQ of 0.8 was reached. A
total of 11 of LB was used for each sample. At this point, the cells were induced with 
0.4mM IPTG. The flasks were shake-incubated for a further 3h at 37*^C, then the 
contents spun for 15 min at 5000 x g. The pellet was resuspended in a minimal volume 
of Resuspension buffer (20mM potassium phosphate (pH 7), 0.02% (w/v) sodium 
azide) then subjected to dismption in a French Pressure cell (2x 950MPa). The sample 
was then centrifuged for 45 min at 5,000 x g.
2 . 2 . 1 5  Large-scale preparation of Bacterial PDC and E3.
21 of ampicillin (50pg/ml) and 0.2% (w/v) glucose-supplemented LB were inoculated 
with overnight cultures of plasmid JRG 2872. The flasks were shake-incubated at 37®C
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until the A^OO reached 0.5, when the cultures were induced with 60|xM IPTG. The 
cells were haiwested by spinning at 5000 x g for 40 min, following an 8h incubation. 
The pellet was resuspended in Buffer A (KH^PO^, 2mM EDTA (disodium salt), ImM 
benzamidine). This was repeated a twice more, with the final resuspension volume 
being 15ml. The cells were broken by two passages through the French press at 
95MPa. The extract was then clarified by a 30 min spin at 40,000 x g. PDC was 
sedimented by spinning for a further 4h. The resultant supernatant contains the E3. The 
PDC pellet was resuspended in Buffer A. To purify the E3, the supernatant was heated 
to 65%  for 10 min then spun in a microcentrifuge at 14,000 x g.
2 . 2 . 1 6  SDS-polyacrylamide gel electrophoresis.
Samples (20|il) were electrophoresed on 20cm x 20cm slab gels, using a model V-16 
polyacrylamide gel apparatus (Life Technologies). The glass plates were cleaned with 
100% (v/v) ethanol, prior to pouring. 30ml resolving gel solution was made up (15ml 
resolving gel buffer, 15ml 29:1 acrylamide:bisacrylamide solution, 360p,l 10% (w/v) 
ammonium persulphate, 36fxl TEMED). The gel was overlaid with 100% isopropanol 
until set. Excess fluid was poured off and a stacking gel solution layered on top (8.2ml 
stacking gel buffer, 1.8ml 29:1 acrylamide:bisacrylamide, 120pl 10% (w/v) ammonium 
persulphate, 12jil TEMED) Once set, the comb was removed and the wells washed out 
with distilled water. Prior to loading, the samples were boiled for 5min at 95°C in 
Laemmli sample buffer. The gel was run in Ix electrode buffer containing 0.02M Tris, 
0.05M glycine and 3mM SDS. Electrophoresis was carried out until the dye front was 
within 2cm of the end of the gel. Staining was performed using a Coomassie Brilliant 
Blue R stain (0.1% (w/v) Coomassie blue, 10% (v/v) acetic acid, 50% (v/v) methanol) 
for Ih. The banding pattern was visualised on a transilluminator, following overnight 
destaining in 10% (v/v) acetic acid, 25% (v/v) isopropanol.
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2 .2 .1 6 .1  B uffers used in the SDS-PAGE electrophoresis system.
Resolving Gel (pH 8.8)
Stacking Gel (pH 6.8)
Electrode Buffer (pH 8.3)
Laemmli Sample Buffer
15% (w/v) Aciylamide
0.3% (w/v) Bis-acrylamide
0.75M Tris
0.2% (w/v) SDS
0.1% (v/v) TEMED
1% (w/v) Ammonium persulphate
6.5% (w/v) Aciylamide
0.2% (w/v) Bis-acrylamide
0.17M Tris
0.2% (w/v) SDS
0.1% (v/v) TEMED
1% (w/v) Ammonium persulphate
0.02M Tris
0.05M Glycine
3mM SDS
62.5mM Tris
2% (w/v) SDS
10% (w/v) Sucrose
2 . 2 . 1 7  Native Gel Electrophoresis.
Samples (20pl) were electrophoresed on a 20cm x 20cm slab gel as before. The casting 
technique was identical to that for SDS-PAGE. The 10% gel was run for 2-3h at a 
constant current of 65mA in electiode buffer. Electrophoresis was performed until the 
dye front was within 2cm of the end of the gel. Staining was carried out using a 
Coomassie Brilliant Blue R stain (0.1% (w/v) Coomassie blue, 10% (v/v) acetic acid, 
50% (v/v) methanol) for Ih. The banding pattern was visualised on a transilluminator, 
following overnight destaining in 10% (v/v) acetic acid, 25% (v/v) isopropanol.
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2 . 2 . 1 7 , 1  Buffers used in the Native Gel electrophoresis system.
Resolving Gel (pH 8.8)
Stacking Gel (pH 6.8)
Electrode Buffer (pH 8.3) 
Loading Buffer
10% (w/v) Acrylamide
0.3% (w/v) Bis-acrylamide
0.75M Tris
0.1% (v/v) TEMED
1% (w/v) Ammonium persulphate
6.5% (w/v) Acrylamide
0.2% (w/v) Bis-acrylamide
0.17M Tris
0.1% (v/v)TEMED
1% (w/v) Ammonium persulphate
0.02M Tris
0.05M Glycine
62.5mM Tris
10% (w/v) Sucrose
0.5% (w/v) Xylene cyanol
2 . 2 . 1 8  ECL^M Western Blotting
In order to confiim the presence of the di-domain in the cmde E. coli extract, Western 
blotting, in the form of enhanced chemiluminescence (ECL) was employed.
Crude extract samples were subjected to SDS-PAGE, then transferred overnight onto a 
nitrocellulose membrane (Amersham), at a constant cuivent of 40mA. Non-specific sites 
were then blocked for 6h at room temperature, using blocking buffer (see below). The 
blot was then incubated in primary antibody solution (see below) overnight, at 4®C. 
The following day the blot was washed 4 times for 30 min in wash buffer (see below), 
then incubated for 2h with the secondary antibody which was conjugated to horseradish 
peroxidase. Following a further 3 x 30 min. washes, the blot was incubated in high salt 
buffer for 30 min, then exposed to X-ray film (Hyperfilm^M eCL^M^ Kodak).
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2 . 2 . 1 8 . 1  Buffers used in the ECL Western Blotting system.
Transfer Buffer (lOx) (11) 30.3g Tris base
144g Glycine 
2g SDS
Blocking Solution
Primary Antibody Solution
Wash Solution
Secondary Antibody Solution
20mM Tris (pH 7.2)
15mM NaCl 
5% (w/v) Non-fat milk 
5% (v/v) Donkey serum 
0.2% (v/v) Tween 20
20mM Tris (pH 7.2)
1% (w/v) Non-fat milk 
1% (v/v) Donkey serum 
0.1% (v/v) Tween 20 
1:1000 dilution of primary antibody 
20mM Tris (pH 7.2)
15mM NaCl
1% (w/v) Non-fat milk 7
1% (v/v) Donkey serum 1
5.5
20mM Tris (pH 7.2) 1
150mM NaCl
1% (w/v) Non-fat milk
1% (v/v) Donkey serum
1:5000 dilution of secondary antibody
A ')  f
A
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Glutathione Elution Buffer
lOmM reduced glutathione in 50mM Tris-HCl (pH 8.0).
Materials and Methods
High Salt Wash Solution 20mM Tris (pH 7.2)
150iuM NaCl
2 , 2 . 1 9  GST Fusion Protein Purification.
The lipoyi domain point mutants (donated by Janet Quinn) had been generated as GST- 
fusion proteins. Purification was canied out in accordance with the protocol supplied 
with the Pharmacia system. A column with a bed volume of 2ml was used. Following 
overexpression in E. coli DESpLysS, the fusion proteins were passed down a 
Glutathione Sepharose 4B column and eluted in 1ml fractions with elution buffer (see 
below). Samples (20p,l) of each fraction were run on a 15% SDS-PAGE gel to confirm 
the purification.
2 . 2 . 1 9 . 1  Buffers used in the GST fusion protein purification.
PBS (Phosphate Buffered Saline) 140mM NaCl
2.7mM KCl 
lOmM Na2 HP0 4  
1.8mM KH2 PO4  (pH 7.3)
2.2.20 Surface Plasmon Resonance.
Measurements were canied out on a BIAcore 2000 machine (Phaimacia Biosensor AB, 
Upsalla, Sweden). A temperature of 25^C was maintained thi'oughout as was a flow 
rate of 30fil/min. E3 was immobilised onto the CM5 sensor chip, which was activated 
using an equimolai' solution of O.IM NHS (N-hydroxysuccinimide) and O.IM EDC 
(N-ethyl-N’-[3-(dimethylamino) propyl] carboiimide hydrochloride). Blocking of free 
sites was achieved using IM ethanolamine. E3 was bound to the chip by passing a 
SOpg/ml solution in lOmM NaOAc (pH 4.5) over the chip surface. Equilibration of the
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flow cell was achieved with HBS buffer (lOmM HEPES, (pH 7.4), 15mM 3.4mM 
EDTA, NaCl, 0.005% surfactant P20). Regeneration was achieved with IM NaCl. The 
amount of E3 immobilised was between 1000 and 2000 resonance units (RUs).
For the collection of kinetic data, 60pl of the E. coli cell extracts containing the 
overexpressed di-domains were passed over the chip (association phase) at 
concentrations between 250nM and 50joM. The flow was continued for a further Imin 
with the equilibrium buffer (dissociation phase). lOjiil of IM NaCl was passed over the 
chip for regeneration.
2 . 2 . 2 1  Isolation of PDC and OGDC from bovine heart 
m itochondria.
The isolation of the complexes from bovine heart tissue was carried out at 4^C using 
the method of Stanley & Perham (1980), with several modifications as detailed here. To 
600g of fresh heart tissue, the following was added; 500ml of 3% (v/v) Triton X-100 
buffer (50mM MOPS, 2.7mM EDTA, 3% (v/v) Triton-X 100, O.lmM DTT, ImM 
PMSF, ImM benzamidine, 0.2% (v/v) anti-foam, adjusted to pH 7 with 6M NaOH), 
before blending for 5 min, after which time the volume was made up to 21 with more 
buffer. The homogenate was then clarified at 10,000 x g for 20min, the pellets 
discarded and the supernatant adjusted to pH 6.45 with 10% (v/v) acetic acid. The 
complexes were precipitated by adding 0.12 vol. of 35% (w/v) PEG, stirred for 30min 
and pelleted at 18,000 x g for 15min. The pellets were resuspended by homogenisation 
in 400ml 1% (v/v) Triton X 100 buffer, this time with the addition of 1.5)iM leupeptin,
and the pH adjusted to 6.8, before clarification at 25,000 x g for 40 min.
The supernatant was filtered through muslin and 0.013vol. of IM MgCfy and 0.05vol.
ill
IM sodium phosphate buffer (pH 6.3) were added with 0.5M NaOH to maintain the 
pH at 6.8. Acetic acid was added to lower the pH to 6.45 then a second 0.12 vol. of 
35% (w/v) PEG was added and the supernatant stirred for 30min at 4 % . The 
complexes were pelleted at 25,000 x g for lOmin, resuspended by homogenisation in
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I160ml of 1% Triton-X 100 buffer (pH 6.8) and fresh solutions of ImM PMSF, 
benzamidine, leupeptin plus 0.5% (v/v) rat serum added and left overnight at 4% .
Re-homogenisation was followed by a clarifying spin at 25,000 x g for Ih and the 
supernatant adjusted to pH 6.45 before the addition of 0.04-0.06 vol. of 35% (w/v)
PEG for 30min with stirring. This differential cut enables the separation of OGDC 
(pelleted at 25,000 x g for lOmin) from PDC which remains in the supernatant and is 
pelleted by an ultracentrifugation step of 200,000 x g for 2.5h. A
The pelleted complexes were subsequently resuspended in 1% (v/v) Triton-X 100 
buffer (pH 6.8) and further purified using a 100cm x 3cm Sepharose CL-2B gel 
filtration column, equilibrated overnight at 4 %  with 50mM sodium phosphate buffer 
(pH7.0) containing 2.7mM EDTA and 1% (v/v) Triton X 100. Approx. lOOmg of 
protein were routinely resolved. The individually purified complexes were then pelleted 
at 200,000 X g for 2.5 h and resuspended in 1% (v/v) Triton X 100 buffer.
2 .2 .2 2  Preparation of E3 from human OGDC.
The human OGDC was kindly provided by Professor Steve Yeaman, University of
INewcastle, in 50% glycerol at 9.25 mg/ml. The sample was cooled to 4^C for 20 min,
then heated to 65^C for lOmin in the presence of IM NaCl and 20mM potassium #
phosphate buffer (pH 7.6). Cell debris was removed by centrifuging the sample at
14,000 X g for 15 min. The supernatant was transferred to dialysis tubing and dialysed 
for 2h against a 25mM Tris/Bis-Tris Propane buffer (pH 7.6). Following a lOmin 
centrifugation step at 14,000 x g, 1ml was loaded on to a Poros 20Pi column and the 
following programme run;
■■I!
To equilibrate the column, 25mM Tris buffer (pH 9) was blended with 25mM Tris
buffer (pH 6) to give a working buffer at pH 7.5 and 10 column vols passed through
the column. After injecting the sample onto the column an NaCl gradient was started, %
ranging from 400mM to SOOmM. Fractions (1ml) were collected for analysis by SDS-
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PAGE. A final wash step was added, whereby 10 column volumes of 2M NaCl was 
passed through the column.
2 .2 .2 3  Enzyme Assays.
I2 .2 .2 3 .1  2-O xoadd Dehydrogenase Complexes
The activities of PDC and OGDC were determined spectrophotometrically at 340nm as 
the rate of formation of NADH, at 30% . Approx. 2-5|ag of complex was added to 
670pl of solution A (50mM potassium phosphate buffer (pH 7.6) containing 3mM 
NAD" ,^ 2mM MgCfy and 0.2mM TPP), 14pl solution B (0.13M cysteine HCl, 0.13mM 
Li2CoASH) and 14pl solution C (lOOmM pyruvic acid (for PDC assay) or 2- 
oxoglutaiate (for OGDC assay)). The reaction was initiated by the addition of enzyme 
to the above solutions and carried out at 30% . Activity was expressed as nkatals (the #
amount of enzyme required to produce 1 nmole of NADH per sec).
2 .2 .2 3 .2  Dihydrolipoamide Dehydrogenase (E3)
The activity of the E3 enzyme was determined spectrophotometrically at 340nm as the 
rate of formation of NADH, at 30°C, from the conversion of dihydrolipoamide to 
lipoamide. Dihydrolipoamide was prepared from the oxidised form of DL-6,8-thioctic 
acid amide using the method of Kochi & Kikuchi (1976), whereby 60mg of DL- 
lipoamide was dissolved in 1.2ml of 50% (v/v) ethanol in IM potassium phosphate 
buffer (pH 8) to which 2.4ml 5% (w/v) NaBH4 (in lOmM NaOH) was added, for
lOmin followed by neutralisation with 1.2ml of 3M HCl. The dihydiolipoamide was 
then extracted into the upper solvent layer by the addition of 3 x 3ml vols of toluene. 
Evaporation of the toluene under nitrogen gas left the dihydiolipoamide which was 
stored at -20%  until use at which time 20.7mg was dissolved in 1ml of 70% (v/v) 
ethanol.
Materials and Methods
For the assay itself, approximately 2-5pg of E3 were added to 670pl of solution A 
(50mM potassium phosphate buffer, pH 7.6, containing 3mM NAD" ,^ 2mM MgCfy and 
0.2mM TPP) and 10-20jil fresh dihydrolipoamide (preincubated at 30%  in a quaitz 
cuvette) and the activity expressed as nkatals (the amount of enzyme required to 
produce 1 nmole of NADH per sec at 30% ).
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CHAPTER 3.
AMPLIFICATION AND EXPRESSION OF THE LÏPOYL 
AND ADJACENT PERIPHERAL ENZYME BINDING  
DOMAINS OF THE E2 COMPONENTS OF HUMAN PDC, 
HUMAN PROTEIN X, BOVINE BCOADC AND E. COLI 
PD C .
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3 .1  Introduction
A solid knowledge and precise understanding of protein function can be enhanced 
greatly by obtaining detailed structural information. X-ray crystallography and NMR 
spectroscopy ai'e two of the major techniques currently employed to gain such insights. 
The requirement to produce well-ordered crystals for high-resolution structural analysis 
is an important limiting factor in X-ray ciystallographic studies, though easier when the 
protein of interest displays a relatively rigid structure. In the case of the 2-oxoacid 
dehydrogenase complexes, the flexibility of N-terminal domains is considered to 
prevent the formation of highly ordered crystals.
The E2 component of each complex consists of three types of independently folded 
protein domains (lipoyi domain, peripheral subunit binding domain and catalytic 
domain) joined by flexible polypeptide linker regions (Figure 3.1). The flexibility of the 
structure is necessary for multienzyme function, but appears to greatly reduce the ability 
to form intact crystals. For this reason, previous studies have attempted to overexpress 
and characterise the individual domains of the E2 component and also a truncated E2 
core, lacking the N-terminal region, from several sources.
The lipoyi domain(s) and subgenes of the domains have been successfully 
overexpressed and shown to function independently (Miles & Guest, 1987; Ali & 
Guest, 1990; Daidel et a l ,  1990). 3-D structures have been obtained using NMR 
spectroscopy, of the lipoyi domains from PDC of B. stearothemiophilus (Daidel et al, 
1993) and E. coli (Green et a l, 1995). The catalytic domain from PDC of A, vinelandii 
has been overexpressed, leading to the three dimensional structure elucidation of the 
octahedral inner core complex (Mattevi et a i ,  1992). However, attempts at the 
overexpression of the peripheral subunit binding domain alone, from any source, have 
proved unsuccessful. This has been overcome for the bacterial subunit binding domain 
by co-expression with the adjacent lipoyi domain (Hipps et al., 1992; M.D. Allen, PhD 
thesis, 1995). This di-domain of B. stearothermophilus, comprising the lipoyi domain
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Figure 3.1. Schematic representation of the multidomain structure of E2 and protein 
X.
(a) Mammalian PDC
(b) Mammalian BCOADC
(c) E, coli PDC
(d) Protein X
The an'ows define the boundries of the di-domain.
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Outer lipoyi domain Inner lipoyi domain Peripheral subunit 
binding domain
Catalytic
domain
/N
1-98 128-229 266-311 331-560
Schematic representation of human E2-PDC demonstiating the approximate amino acid 
positions of each domain. The inner lipoyi domain DKA lipoic acid binding motif 
encompasses residues 172 to 174,
The numbering system is similai* to that used by Gershwin et a l,  1990 and Quinn et aL, 
1993.
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and binding domain, joined by the flexible linker region was overexpressed in E. coli. 
The independently folded binding domain was then obtained following limited 
proteolytic digestion and purification (Hipps et a i, 1994).
To facilitate studies involving the subunit binding domain and inner lipoyi domain (the 
di-domain), large quantities of the domains are needed. None of the previous studies 
have involved the use of domains from mammalian sources. This chapter describes the 
molecular biological techniques employed to make the expression vectors allowing the 
overexpression of the di-domains from several sources; human PDC-E2, protein X, 
bovine BCOADC and E. coli PDC-E2. Successful overexpression will greatly facilitate 
crystallography studies and also permit investigation of domain interactions with the El 
and E3 enzymes, by surface plasmon resonance, leading to a greater understanding of 
the moleculai' recognition phenomena and active-site coupling within these complex 
multimeric assemblies.
3 .2  Materials
The di-domain was PCR amplified from one of three plasmid sources:
Plasmid pHUMIT was the source of the human E2-PDC (kind donation by Dr. E. 
Gershwin). Plasmid pTSE2al was the source of the bovine BCOADC (kind donation 
by Dr. D.J. Danner). Plasmid pGS623 was the source of the E. coli PDC (kind 
donation by Prof. J. Guest). Human fetal liver cDNA was the template for the protein 
X di-domain.
The sequences of these sources are shown in Figures 3.2a to d.
The resultant product was amplified following ligation into the expression vector 
pE T lla  (Novagen) and insertion into E. coli DH5a. Recombinant plasmid was 
subsequently used to transform the E. coli strains DE3 (BL21), or DE3plysS. This 
resulted in the production of large quantities of polypeptide in all cases.
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1-MSPHCSTTYLRTLGRTTMFWKTTEGRDGKMAVQEFSEFGLLLQLLGSPGR
RYYSLPPHQKVPLPSLSPTMQAGTIARWEKKEGDKINEGDLIAEVETDKATVGF
ESLEECYMAKILVAEGTRDVPIGAncrrVGKPEDIEAFKNYTLDSSAAPTPQAAP
APTPAATASPPTPSAOAPGSSYPPHMOVLLPALSPTMTMGTVORWEKKVGEKL
SEGDLLAEIETDKATIGFEVQEEGYLAKILVPEGTRDVPLGTPLCnVEKEADISA
FADYRPTEVTDLKPQVPPPTPPPVAAVPPTPQPLAPTPSTPCPATPAGPKGRVFV
DPLAKKLAVEKGIDLTOVKGTGPDGRITKKDIDSFVPSKVAPAPAAVVPPTGPG
MAPVPTGVFTDIPISNIRRVIAQRLMQSKQTIPHYYLLSCKYGEVLLVRKELNKI
LEGRSKISVNDFnKASALACLKVPEANSSWMDTVIRQNHVVDVSVAVSTPAGL
ITPrVFNAHIKGVETIANDVVSLATKAREGKLQPHEFQGGTFTISNLGMFGIK
NFSAIINPPQACILAIGASEDKLVPADNEKGFDVASMMSVTLSCDHRVVDGAVG
AQWLAEFRKYLEKPITMLL-613
Figure 3.2a. The protein sequence of the E2 component of human PDC.
The underlined sequences indicate the sequences to which the di-domain primers were 
made. The conserved DKA motif, to which the lipoic acid co-factor is attached, is 
highlighted in bold. The E2 gene is encoded by 613 amino acids, including a 
mitochondrial targeting sequence located at the N-terminus. The di-domain itself 
encompasses Ser-128 to Val-311.
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-61MAAVRMLRTWSRNAGKLICVRYFQTCGNVHVLKPNYVCFFGYPSFKYSHP
HHFT.KTTAALRGOVVOFKLSDIGEGIREVTVKEWYVKEGDTVSOFDSICE
VQSDKASVTITSRYDGVIKKLYYNLDDIAYVGKPLVDIETEALKDSEEDVVETP
AVSHDEHTHQEIKGRKTLATPAVRRLAMENNIKLSEVVGSGKDGRILKEDILN
YT^EKOTGAILPPSPKVEIMPPPPKPKDMTVPILVSKPPVFTGKDKTEPIKGFOKA
MVKTMSAALKIPHFGYCDEIDLTELVKLREELKPIAFARGIKLSFMPFFLKAASL
GLLQFPILNASVDENCQNITYKASHNIGIAMDTEQGLIVPNVKNVQICSIFDIATE
LNRLQKLGSVGQLSTTDLTGGTFTLSNIGSIGGTFAKPVIMPPEVAIGALGSIKA
IPRFNQKGEVYKAQIMNVSWSADHRVIDGATMSRFSNLWKSYLENPAFMLLD
LK-482.
Figure 3.2b. The protein sequence of bovine BCOADC E2 component.
The underlined sequences indicate the sequences to which the di-domain primers were 
made. The conserved DKA motif, to which the lipoic acid co-factor is attached, is 
highlighted in bold. The E2 gene is encoded by 482 amino acids, including a 
mitochondrial targeting sequence located at the N-terminus. The di-domain itself 
encompasses Ala-58 to Leu-217.
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LMAIEIKVPDIGADEVEITEILVKVGDKVEAEQSLrrVEGDDKASMEVPSPQAGI
VKEIKVSVGDKTQTGALIMEFDSADGAADAAPAQAEEKKEAAPAAAPAAAAAK
DVNVPDIGSDEVEVTEILVKVGDKVEAEQSLrrVEGDKASMEVPAPFAGTVKEIL
VNVGDKVSTGSLÏMVFEYAGEAGAAPAAKQEAAPAAAPAPAAGVKEVNVPDIG
GDEVEVTEVMVLVGDKVAAEOSLITVEGDKASMEVPAPFAGVVK£LKVNVGD
KVKTGSLIMIFEVEGAAPAAAPAKQEAAAPAPAAKAEAPAAAPAAKAEGKSEP
AEND A YVHATPLTRRT AREFGVNT AKVKGTGRLGRILREDVOAYVKEAIKRAE
AAPAATGGGIPGMLPWPKVDFSKFGEIEEVELGRIQKISGANLSRNWVMIPHV
THFDKTDITELEAFRKQQNEEAAKRKLDVKrrPVVFIMKAVAAALEQMPRFNSS
LSEDGQRLTLKKYINIGVAVDTPNGLVVPVFKVNKKGIIELSRELMTISKKARD
GKLTAGEMQGGCFTISSIGGLGTTHFAPIVNAPEVAILGVSKSAMEPVWNGKE
FVPRLMLPISLSFDHRVIDGADGARFmiNNTSDIRRLVM-627
Figure 3.2c. The protein sequence of the aceF gene, encoding the E2 
component of the E. coli PDC.
The underlined sequences indicate the sequences to which the di-domain primers were 
made. The conserved DKA motif, to which the lipoic acid co-factor is attached, is 
highlighted in bold. The E2 gene is encoded by 627 amino acids. The di-domain itself 
encompasses Val-221 to Ile-369.
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-53MAASWRLGCDPRLLRYLVGFPGCRSVGLVKGALGWSVSRG 
ANWRWFHSTQWLRGDEUGLMPSLSPTMEEGNIVKWLKKEGEAVSAGDAL 
CEEETDKAVVTLDASDDGILAKIVVEEGSKNIRLGSLIGLIVEEGEDWKHVEIPK
DVGPPPPVSKPSEPRPSPEPQISIPVKKEHIPGTLRFRLSPAARNELEKHSLDASQ
Figure 3.2d. The protein sequence of protein X from a human feta! liver 
source.
The underlined sections indicate the sequences to which the di-domain primers were 
m ade^^ The conserved DKA motif, to which the lipoic acid co-factor is attached, is 
highlighted in bold. The protein X gene is encoded by 448 amino acids. The di-domain 
itself encompasses Gly-1 to Gly-199.
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GTATGPRGTFTKEDALKLVOLKOTGKTTESRPTPAPTATPTAPSPLOATSGPSYP 
RPVIPPVSTPGQPNAVGTFTEIPASNIRRVIAKRLTESKSTVPHAYATADCDLGA 
VLKVRQDLVKDDIKVSVNDFnKAAAVTLKQMPDVNVSWDGEGPKQLPFIDISV 
AVATDKGLLTPnKDAAAKGIQEIADSVKALSKKARDGKLLPEEYQGGSFSISNL 
GMFGIDEFTAVINPPQACrLAVGRFRPVLKLTEDEEGNAKLQQRQLrrVTMSSDS 
RVVDDELATRFLKSFKANLENPIRLA-448
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3 .3  Aims of this chapter
(i) Generation of PCR-amplified di-domains.
(ii) Engineering of E. coli strains capable of overexpressing the di-domains.
(iii) Confirmation of the conect folding of the di-domains.
(iv) Investigation into the effect of exogenous lipoic acid on the lipoylation of the di­
domains.
(v) Investigation into the effect of the presence of the mitochondrial presequence on the 
folding and lipoylation of the BCOADC di-domain.
3 .4  R esults
3.4.1 Construction of di-domain DNA
The PCR reactions were carried out using the oligonucleotides described in Figure 3.3 
and the products analysed on 2% agarose gels (Figure 3.4). PCR mutagenesis was 
employed such that each upstream primer was designed so as to create an Nde I 
restriction site on the resultant PCR product. The site also incorporates an ATG start 
codon. Each downstream primer was designed to create a Bam HI restriction site in the 
PCR product. These allowed incorporation into the multiple cloning site of the pETl la 
expression vector (Novagen).
3.4.2 Construction of p E T lla  expression vector
The expression vector pE T lla  (Novagen) was digested with the Nde-I and Bam HI, as 
detailed in section 2.2.9.1 and treated with calf intestine alkaline phosphatase. The PCR 
fragments containing the di-domains were then ligated into the pET vector. Ligation 
was carried out as detailed in Materials and Methods section 2.10. E. coli DH5a cells 
were transformed with the resultant plasmid and grown on plates containing LB 
medium supplemented with ampicillin (Materials and Methods section 2.12). Colonies
:
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Human PDC
5'Primer: AGG CTC CTC ATATGT CAT ATC CCC CTC ACA TG
3' Primer: CTT GGC ACGGATÇÇA GTG ATA TCC TTC CTG GTG
Bovine BCOADC
5’ Primer: GCT GCT CAT ATG GGA GAG GTT GTT GAG TTC AAG
3' Primer: CAA TAT AGC GGA TCC AGT CCT TTC CAA ATA GTT
E, coli PD C
5’ Primer: GTG ACT GAA CAT ATG GTG AAA GGC GAC AA
3’ Primer: GAT AGC TTC GGA TCC AGT AGC CTG AAC GTG TTC
Human protein X
5' Primer: ACG GAG TGG CAT ATG GGT GAT CCC ATT AAG ATA CTA
3' Primer: TCC AGA TGT GGA TCC AGT GGG CGA AGG TGC TGT
Figure 3.3. Primer sequences to allow the amplification of the di-domain  
from the E2 and protein X sources.
The underlined portion of the 5' primer indicated the site of the Nde I restriction digest 
site and the underlined portion of the 3' primer indicates the site of the Bam HI 
restriction digest site.
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(a) (b)
(C)
DD350bp
50bp
(d)
DD
DD350bp
50bp
DD
M M M M
Figure 3.4. PCR amplifîcation of the di-domain (DD) from various 
sou rces .
(a) Bovine BCOADC-E2 (b) E. coli PDC-E2 (c) Human protein X (d) Human PDC-E2 
Samples were run on 2% agarose gels, then visualised using UV illumination following 
ethidium bromide staining. M, molecular mass marker (50bp ladder).
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were picked and grown overnight in 5ml aliquots of ampicillin-supplemented LB. 
Minipreps were carried out (Promega) to obtain plasmid DNA for the subsequent 
transformation of the expression strains E. coli DE3 or DE3 pLysS.
3.4.3 Overexpression of vector in E, coli DE3 (BL21)
Overexpression of each of the four sources of di-domain was observed following the 
transfomiation of E. coli DE3 (BL21) cells (Materials and Methods section 2.15) using 
IPTG induction (Materials and Methods section 2.16). Visualisation of the protein was 
canied out by resolution on a 15% SDS-polyaciylamide gel (Materials and Methods 
section 2.2.16) and staining with Coomassie Brilliant Blue. A substantial 
overexpression was observed within an hour of induction in all cases (Figure 3.5a-d).
3.4.4 Confirmation of correct folding of the di-domain
The lipoylation of the heterologously-expressed domains can only occur after conect 
folding of theh respective lipoyi domains. Access to a monoclonal antibody (PDl) 
which exclusively recognises the holodomain form of the human inner E2 lipoyi 
domain was generously provided by Prof. F. Stevenson, University of Southampton. 
(Figure 3.6b). Initially the specificity of the antibody for the holodomain was tested 
using purified human unlipoylated and lipoylated domain (kind donation from Dr. J . 
Palmer, University of Newcastle). Samples of each domain were initially resolved on a 
15% SDS-polyaciylamide gel and stained with Coomassie Brilliant Blue (Figure 3.6a) 
to confirm their purity, prior to being used for immunoblotting. It is clear from figure 
3.6b that monoclonal PDl displays strong reactivity solely with the lipolyated form of 
the domain. Figures 3.7 and 3.8 demonstrate that, in addition to E2-PDC, a high level 
of reactivity is observed with the di-domains of BCOADC and protein X. This 
indicates that both of these di-domains are also recognised by the E. coli lipoyi ligase. 
No cross reactivity was observed with E. coli E2-PDC.
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Figure 3.5 (a) Overexpression of the di-domain of human PDC in E. coli 
DE3.
Following IPTG-induction, total E. coli extracts were run on a 15% SDS-PAGE gel 
(see Materials and Methods). Lane 1, sample taken prior to induction and lane 2, 
sample taken 3h after induction. Lane M, molecular mass marker. The arrow indicates 
the overexpressed protein.
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Figure 3.5 (b) Overexpression of the bovine BCOADC di-domain in E . 
coli D E 3.
E. coli extracts were prepared from cultures and samples were collected prior to and 1 
and 3h following IPTG-induction, then run on a 15% SDS-PAGE gel. Lanes 1 and 5, 
molecular mass marker. The pre-induced sample is in lane 2, the Ih post-induction 
sample in lane 3 and the 3h post-induction sample in lane 4. The arrow indicates the di­
domain.
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Figure 3.5 (c) Overexpression of E. coli PDC di-domain in E. coli DE3. 
E. coli extracts were prepared from cultures and samples collected prior to and then 1 
and 3h following IPTG-induction (Lanes 1, 2 and 3 respectively). Lane M, molecular 
mass marker. Samples were resolved on a 15% SDS-PAGE gel. The arrow indicates 
the di-domain.
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Figure 3.5 (d) Overexpression of human protein X di-domain in E. coli 
D E3pL ysS .
E. coli extracts were prepared from cultures and samples collected prior to and 3h 
following IPTG-induction, then run on a 15% SDS-PAGE gel. Lanes 1 and 2 show a 
non-expressing clone, prior to and 3h after induction. Lanes 3 and 4 show the 
overexpression of the di-domain after 3h. Lane M, molecular mass marker.
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Figure 3.6 (a). SDS-PAGE analysis of purified apo- and h olo-lipoyl 
domain from human PDC.
Samples were run on a 15% SDS gel and stained with Coomassie Blue. Lane 1, the 
unlipoylated protein (3pg) and Lane 2, the lipoylated protein (1.5fig). M, molecular 
mass marker.
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Figure 3.6(b). Immunoblot of apo- and holo-forms of the lipoyl 
dom ain.
Samples of purified unlipoylated (Ipg) and lipoylated (l|Xg) human lipoyl domain 
were resolved on a 15% SDS-polyacrylamide gel prior to Western blotting with a 
monoclonal antibody, specific for the holodomain.
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Figure 3.7. Immunoblot of the di-domains of E2-PDC and E2-BCOADC  
induced in the presence or absence of exogenous lipoic acid.
Lanes 1 and 4 contain pre-induced di-domain. Lanes 2 and 5 contain samples of E2- 
PDC and E2-BCOADC respectively, collected 3h following IPTG induction. Lanes 3 
and 6 contain samples collected 3h after induction, in the presence of lipoic acid 
(lOpg/ml).
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Figure 3.8. Immunoblot analysis of the di-domain of protein X , 
showing enhancement of lipoylation in the presence of exogenous lipoic 
acid .
Lane 1 contains the pre-induced sample. Lane 2 contains the 3h post-induction sample, 
grown without lipoic acid, and Lane 3, the 3h post-induction sample grown with lipoic 
acid.
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3.4.5 Enhancement of Lipoylation using exogenous Lipoic Acid
The immunoblots also demonstrate the ability to enhance the amount of domain that has
been lipoylated by the addition of lipoic acid (lOpg/ml) to the cultures at the time of
IIPTG-induction. The immunoblots were also analysed on native gels (Figure 3.9) but 
the signal was not as strong or specific, so SDS gels were employed in subsequent 
studies.
IIn the case of the protein X di-domain, a mobility shift can clearly be observed on 
enhanced lipoylation, as monitored by SDS-PAGE and staining with Coomassie Blue 
(Figure 3.10). In the absence of lipoic acid, two bands of approx. equal intensity were 
seen to be overexpressed (apo- and holo-domain). When lipoic acid is added to the 
culture, there is a marked shift to the lower band (the holo-domain). The lipoylated 
domain runs faster presumably as a result of a change in conformation caused by the |
presence of the lipoic acid co-factor.
3.5 C onclusions
A prerequisite for in-depth analysis of interactions between the constitutive components 
of the 2-oxoacid dehydrogenase complexes is the ability to produce large quantities of 
native protein. In this chapter, a method has been devised to allow the production of 
large amounts of the requisite lipoyl domain linked to the adjacent peripheral subunit 
binding domain (termed the di-domain). It has been possible to overexpress 
successfully the di-domain from 4 sources; human E2-PDC, bovine E2-PDC, E. coli 
E2-PDC and human protein X using the expression vector pET lla. Indeed, high levels 
of protein were detected within Ih of induction with IPTG. The overexpression was 
attempted over a series of temperatures, (data not shown) and 37°C deemed optimal, in 
all cases.
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It has also been demonstrated that the heterologously-expressed mammalian di-domains 
retain then ability to fold correctly and act as substrates for the E. coli lipoylation 
system as evidenced by their cross reactivity with monoclonal antibody PD l. 
Previously studies with this antibody have been performed with native polyacrylamide 
gels (Quinn, 1997), so it was necessary to determine its ability to cross-react 
specifically with the holodomain under denaturing conditions. It has been shown here 
that the denaturing conditions did not affect the specificity or inhibit the cross-reactivity 
of the antibody, despite the fact that many monoclonals are only active against native 
protein, since they are raised against non-contiguous epitopes. In the absence of 
exogenous lipoate, it is apparent that incorporation of the lipoic acid prosthetic group 
into the apodomains of E2-PDC and BCOADC and protein X is incomplete. Best 
estimates are that approx. 50% lipoylation occurs in the absence of added cofactor as 
there is a 1.5-2.5-fold enhancement in cross reactivity with PDl when induction is 
performed in the presence of lipoate (lOpg/ml). Due to the high levels of expression of 
the di-domains (approx. 20% of the whole cell extract appears to be the di-domain 
protein) the lipoylating apparatus of the E. coli is not capable of attaining 100% 
lipoylation without exogenous assistance. The rate of production of endogenous lipoic 
acid is not capable of meeting the rate of production of the di-domain.
In retrospect, a different expression vector may have been chosen to cany out these 
studies. Following the overexpression of the di-domain, a method to purify it is 
required for many types of biochemical and biophysical analyses. It would seem more 
advantageous to produce the di-domains as GST-fusion proteins or His tagged 
proteins, which would greatly simplify their purification. Indeed, various members of 
the laboratory are presently undertaking this work.
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Figure 3.9. Immunoblot on a native gel of the di-domain of E2-PD C , 
showing the enhancement of lipoylation as a result of exogenous lipoic  
acid.
Lane 1 contains the pre-induced sample. Lane 2 contains the 3h post-induction sample, 
grown without lipoic acid, and lane 3, the 3h post-induction sample grown with lipoic 
acid.
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Figure 3.10. SDS-PAGE analysis of human protein X di-domain  
overexpression in E. coli  DE3pLysS, in the absence and presence o f  
exogenous lipoic acid.
Lanes 1 to 4 represent pre-induced, then 1, 2, and 3h post-induction samples grown 
without exogenous lipoic acid. Lanes 5 to 8 represent the same culture grown in the 
presence of exogenous lipoic acid (10|lg/ml). Two proteins seem to be overexpressed, 
representing the unlipoylated (UL) and lipoylated (L) forms. An obvious shift to the 
lipoylated form is seen when lipoic acid is added. Lane M, molecular mass marker.
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The generation of E. coli with the abihty to express the di-domains to such high levels
provides a method of producing sufficient protein to further investigate protein-protein a
interactions within these important multienzyme complexes. It will allow the study of %
the kinetics of the various domain interactions with the aim of generating affinity and
binding constants, which until now has been hampered by the low levels of material
available. An investigation into this area is detailed in chapter 6 of this thesis.
3.6 The effect of the presence of the presequence on the ability of the |
BCOADC di-domain to undergo lipoylation.
As an adjunct to this chapter, it was decided to investigate the effect that the presence of -I
the mitochondrial presequence has on the ability of the BCOADC di-domain to fold and
undergo lipoylation. As previously mentioned, the components of the 2-oxoacid
dehydrogenase complex are nuclear encoded and therefore require to be transported to
and then across the mitochondrial membrane. The precursor polypeptide has a long
presequence attached at the N-terminus, which is involved in the targeting to the
organelle.
3 .6 .1  Construction of BCOADC sub gene:
Presequence-di-dom ain.
IIn order to do this, a primer was designed to the N-terminus of the precursor 
polypeptide and used along with the existing primer designed to sequence downstream 
of the di-domain to amplify the intermediate sequence from the vector pTSE2al. This |iIcontains the entire bovine BCOADC E2 gene. The primers were both designed with 
restriction sites (Nde I on the upstream primer and Bam HI on the downstream primer)
■I'to facilitate ligation to the pE T lla expression vector. Following propagation in E. coli
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DH5a, E, coli DE3 were transformed with the plasmid and colonies chosen, on the 
basis of restriction digests (data not shown), for further study. Professor Gordon 
Lindsay kindly canied out these initial stages.
3.6.2 Overexpression of BCOADC presequence-di-domain
construct.
Two colonies referred to here as B4 and C5 were chosen for the overexpression 
studies. Following IPTG induction, the cultures were left to grow at 37®C for 4h 
before the cells were harvested and samples resolved by 15% SDS-PAGE. 
Visualisation of the proteins was carried out on a light box, following staining with 
Coomassie Blue dye. Significant overexpression of a protein, larger than the native 
protein, was seen after this time (Figure 3.11).
3.7 The effect of the presence of presequence on the lipoylation
of the di-domain, as shown hy Western Blotting (ECL).
Having established the correct construction of the presequence-di-domain subgene, the 
next study involved investigating whether the di-domain segment was capable of 
undergoing lipoylation. To do this, B4 and C5 were induced in the presence and 
absence of exogenous lipoic acid, as was a BCOADC di-domain clone as a control and 
then the samples blotted with the monoclonal Ab (PDl) specific for the lipoylated 
domain (Figure 3.12). The immunoblot shows reactivity with the di-domain alone, 
which is enhanced by inducing in the presence of lipoic acid. It also shows that there is 
no reactivity with the presequence-di-domain clones, even when the cultures aie 
supplemented.
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Figure 3.11. Overexpression of BCOADC di-domain, alongside clones  
B4 and C5 which overexpress the di-domain plus pre-sequence 
construct. Lanes 1 and 2 show the BCOADC di-domain overexpressed without and 
in the presence of exogenous lipoic acid respectively. Lanes 3 and 4 show clones B4 
and C5 respectively overexpressing the pre-sequence di-domain constructs, in the 
presence of exogenous lipoic acid. Lane 5, un-induced extract. Lane M, molecular mass 
marker.
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Figure 3.12. Immunoblot showing the detection of the BCOADC d i­
domain and the BCOADC pre-sequence-di-domain constructs, using the 
monoclonal antibody, P D l, specific for the lipoylated form of the lip oyl 
domain. Lanes 1 and 2 respectively, BCOADC di-domain overexpressed in the 
absence and presence of exogenous lipoic acid. Lanes 3 and 4 respectively, clone B4, 
overexpressing the BCOADC pre-sequence-di-domain construct in the absence and 
presence of exogenous lipoic acid. Lanes 5 and 6 respectively, clone C5, 
overexpressing the BCOADC pre-sequence-di-domain construct in the absence and 
presence of exogenous lipoic acid.
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3 .8  D iscu ssion
These preliminary studies show that it is possible to attain the overexpression of the 
BCOADC di-domain with the mitochondrial pre-sequence also attached. The fact tliat 
the pre-sequence-di-domain constructs are appaiently unable to undergo lipoylation 
could be explained by the presence of the pre-sequence leading to or preventing the 
coiTect folding of the di-domain. This would result in the inability to undergo 
lipoylation, as only the correctly folded domain can be recognised by the lipoylating 
apparatus. Furthermore, the incorrect folding may increase the susceptibility of the 
construct to degradation. It has not yet been determined which part, indeed if all the pre­
sequence is required for targeting and maintaining the immature folded structure 
necessary for entiy into the mitochondrion. To this end, work is currently being 
undertaken in our laboratoiy using deletion mutants of the pre-sequence-di-domain 
construct. It is hoped to discover which residues or regions of the pre-sequence are 
essential for keeping the di-domain unfolded. The work should also show which 
regions are essential for targeting to the mitochondrion. These experiments aie yet 
another example of work which has now been made possible by developing a method 
for overexpressing sub genes of the vast 2-oxoacid dehydrogenase complexes.
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INVESTIGATION INTO THE LIPOYLATION OF THE APODOM AINS 
OF THE E2 AND PRO TEIN  X COMPONENTS OF HUMAN 
PYRUVATE DEHYDROGENASE COM PLEX.
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4.1 Introduction.
The oxidative decarboxylation of 2-oxoacids canied out by the complexes is mediated 
partially by the sulphur-containing prosthetic group, lipoic acid that is located on the E2 | |
or protein X components on these complexes. This prosthetic group is covalently 
bound via an amide linkage between the carboxyl group of lipoic acid and the e-amino
"J:group of a specific lysine residue. The lipoyl-lysine residue has a side chain 1.4nm
long, which acts as a “swinging arm”, carrying the substrate between three active sites;
_additional flexibility of the domain itself is provided by ala-pro rich sequences linking
the lipoyl domains to each other and to the C-terminal half of these polypeptides, S
'
allowing interaction with all 3 active sites. Although the role of lipoic acid in the
%catalytic cycle has been well studied, it is only recently that research on the enzymes
started to be examined in detail.
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responsible for the insertion of the lipoyl group and their recognition properties has
There are 2 types of systems responsible for lipoylation, both using lipoyl-AMP as an 
interaiediate:
(i) In E. coli, there is a single enzyme (lipoate-protein ligase), which activates and 
ligates the lipoyl groups to the apoenzyme.
(ii) In mammalian systems there are 2 separate enzymes; lipoyltransferase, responsible 'i 
for the transfer of lipoyl groups from the lipoyl-AMP intermediate to the apoenzyme
and lipoic acid activating enzyme, which initially activates the lipoic acid moiety.
.1
4.2 Initial lipoylation studies on the E2 component
In 1958, Reed et al. first described the lipoylation of PDC, using lipoic acid deficient S. 
faecalis cells. Following incubation with [^^S] lipoic acid, increases in both the amount 
of bound lipoic acid and in PDC activity were noted. Subsequent precipitation steps 
isolated the system responsible for protein lipoylation. This comprised 2 fractions, a 
heat-labile and a heat-stable fraction, both required for the activation of the apo-PDC.
:
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The heat-labile fraction catalysed the activation of the lipoic acid. Further work by the 
group showed that in order to activate apo-PDC, the intermediate lipoyl-AMP is 
required. This then suggested that the attachment of the lipoic acid to the E2 polypeptide 
occurred in two consecutive reactions;
(i) Lipoic Acid + ATP -> Lipoyl-AMP + PPi
(ii) Lipoyl-AMP -\- Apoprotein -> Lipoylated Holoenzyme + AMP
Wallis and Perham (1994) demonstrated that E. coli lipoate-protein ligase can lipoylate 
the correct lysine residue of foreign lipoyl domains. To confirm the necessity for the 
specific lysine residue, site-directed mutagenesis was cai'ried out on a sub-gene 
encoding the lipoyl domain of B. stearothermophilus PDC, expressed in E. colL Either 
the target lysine was moved or an extra one was introduced. In both cases, the ligase
95
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Until recently, little progress had been made in the study of lipoylation, owing to lack 
of a suitable substrate for the lipoylation reaction. Overexpression of subgenes using 
recombinant DNA techniques has allowed studies to progress in eukaryotes as well as
■bacteria. Overexpression of subgenes encoding single lipoyl domains from E. coli, B,
stearothermophilus and human sources provides both lipoylated and unlipoylated 
domains as the host cells are often unable to synthesise lipoate in sufficient amounts to 
meet the levels of overexpression.
4.3 The E. coli system of lipoylation
ÎIn E. co li, holo- and apolipoyl domains of PDC were overexpressed and purified (Ali 
and Guest, 1990). Two independent lipoate-protein ligase activities were then
determined (LPL-A and LPL-B) (Brookfield et al, 1991). Both have subunit Mr values ■
. 3
of approx. 45,000 and catalyse lipoylation of apo-domain in the presence of lipoic acid,
ATP and Mg^+. The main difference is in the inability of LPL-A to use octanoic acid as 1
a substrate.
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was unable to recognise any lysine other than that located in the original position (Lys 
42).
In 1994, Morris et a l using transposon mutagenesis to isolate mutants, which can only
grow under conditions that bypass any requirement for the lipoate-dependent enzymes, ■'if
isolated the gene encoding the E. coli lipoate-protein ligase. This Ipl-A gene was cloned
and sequenced and found to encode a 338 amino acid protein with an upstream |fiij
ribosome-binding site and a downstream Rho-independent transcriptional terminator. ï
Overexpression and purification of the Ipl-A gene product allowed studies which 
confirmed that the enzyme is ATP-dependent, catalysing both the activation of lipoic |
acid to lipoyl-AMP as well as the transfer of the activated species to apoprotein, with 
the concomitant release of AMP. Morris et a l (1994) also suggested that the two
■ '
lipoylation activities described by Brookfield et a l (1991) were isoforms of the Ipl-A 
gene product, as neither was detectable in Ipl-A null mutants. ■ 'i
In 1995, Morris et a l proposed a second pathway of lipoylation, not involving the Ipl- 
A gene product. They demonstrated, using null mutants, that lip-B (a gene previously 
thought to be involved in lipoic acid biosynthesis or metabolism) is responsible for lpl~ 
A-independent lipoylation, using lipoic acid generated endogenously. If free lipoic acid 
is available, the E. coli use Ipl-A to catalyse lipoyl-AMP formation. When there is no 
exogenous lipoic acid present, the fip-B-dependent ligase second pathway forms lipoyl 
groups by de novo synthesis. Both reactions appear to be catalysed by single enzymes 
in E. colt
4.4 Lipoylation of mammalian E2
With the advent of recombinant DNA technology, it has now been possible to generate 
lipoylated and unlipoylated forms of mammalian lipoyl domain. Quinn et a l  (1993) 
overexpressed a subgene encoding the fusion protein of the inner lipoyl domain of 
human E2-PDC with glutathione S-transferase in E. coll Both forms of the domain
96
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have been purified. Brookfield et al. (1991) incubated the unlipoylated fonu with 
pai'tially purified lipoate-ligase B from E. coli (Brookfield et a l, 1991) and the majority 
was converted to the lipoylated form, although at a considerably reduced rate. The 
presence of lipoylation activity in the mitochondrial matrix was demonstrated by Griffin 
et a l (1990). Recombinant mature bovine E2 (E2b) was overexpressed in E. coli and 
used as a substrate. Following incubation with [2~^H] lipoic acid, ATP and a soluble 
extract from the matrix of bovine liver mitochondria, incorporation of the radiolabelled 
lipoic acid into E2b was detected. It was also shown to be ATP-dependent. Having
"'3
established the presence in mitochondria of the lipoyltransferase enzyme, attempts were 
made to purify it from bovine liver mitochondria (Fujiwara et a l ,  1994). Partial 
purification on hydroxylapatite columns resolved 2 peaks of activity. Mr determinations 
of both forms showed proteins of subunit Mr 40,000.
Both lipoyltransferases I and II catalysed lipoylation of apo-protein, being absolutely 
dependent upon lipoyl-AMP and apo-protein (Fujiwara et a l,  1996). In contrast to E.
'I-coli lipoate-protein ligase, these enzymes could not use lipoic acid plus Mg-ATP as the 
lipoyl donor. The bovine lipoyltransferases, when incubated with lipoyl-AMP and 
various apolipoyl domains were able to recognise and lipoylate rat E2p and E2o.
This initially suggested that the enzyme recognises some features of the primary
structure. Fujiwara et a l (1991) carried out site-directed mutagenesis studies on H- 3
protein. This is one of 4 proteins making up the glycine cleavage system, which
?catalyses the reversible oxidation of glycine to yield carbon dioxide, ammonia, 5,10- 
methylenetetrahydrofolate and NADH. H-protein shows significant sequence homology !
with the corresponding region of E2 and also uses lipoic acid as a cofactor in its 
catalytic mechanism. They showed that conversion of a Glu residue, (3 residues f
upstream from the lipoyl lysine) to glutamine, alanine, or aspartic acid inhibited 
lipoylation by up to 60%. They also showed the positioning of a glycine residue 11 
residues downstream was involved in lipoylation. These results indicate that both 
charge and stmcture are both important for maximal lipoylation.
"9
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A subgene encoding the N-tenninal 85 amino acids (Ala-1 to Phe-85) of native E2 from 
B. stearothermophilus PDC has been overexpressed in E. coli and the structure 
determined by NMR spectroscopy (Dardel et a l, 1993). Similarly, the structure of E. 
coli lipoyl domain from the E2p chain has been determined by Green et a l  (1995).
The E l enzyme of the PDC complex requires the presence of the entire lipoyl domain in 
order to carry out efficient reductive acétylation of the lipoyl group. Various other 
substrates were substituted for the lipoyl domain (free lipoic acid, lipoamide, or a 
lipoylated decapeptide with the identical sequence to that around the lipoyl-lysine) and 
aU were shown to be extremely poor substrates for E l. In particular*, the lipoylated
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4.5 S tru c tu re  of lipoyl dom ains.
The domain is composed of two four-stranded p-sheets, forming a flattened P-barrel, 
with a core of well-defined hydrophobic residues. The polypeptide chain weaves back 
and forth between the sheets, with one exception; a type-I P-turn in one sheet that 
incorporates the lipoyl-lysine at its tip (Lys-42 in B. stearothermophilus and Lys-40 in 
E. coli). The N- and C-termini are close together in space, at the opposite ends of the |
molecule, in the other P-sheet. There are a further 6 to 8 amino acids at the C-terminus 
which form part of the linker region joining the lipoyl domain to the peripheral subunit 
binding domain. The p-barrel displays a 2-fold axis of quasisymmetry, reflecting a 
weak similarity between the N- and C-terminal halves of sequence noticed by Spencer 
et a l  (1984).
Lipoylation of the specific lysine residue causes no detectable change in conformation, 
as shown by NMR spectroscopy of the lipoylated and unlipoylated forms of the domain 
of the E2-PDC component from B. stearothermophilus (Dardel et al, 1990) and A. 
vinelandii (Berg e ta l, 1994).
19:!'
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More recently, work has been caixied out suggesting the importance of vaiious residues 
surrounding the lipoylation site for the functioning of lipoyltransferases (Fujiwara et 
ai, 1996).
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decapeptide was not recognised to any greater extent than free lipoamide. Evidence for 
specific El-lipoyl domain interaction was shown by Graham et a l (1989) whereby the 
El of E. coli OGDC was unable to recognise the lipoyl domain from E. coli PDC and 
vice versa.
The residues around the lipoyl-lysine are highly conserved in lipoyl domains from 
different sources. Many display the DKA motif that forms part of the exposed turn. The 
aspaitic acid and alanine residues can be changed by site-directed mutagenesis with no 
effect on the lipoylation of the domain from B. stearothermophilus in vivo in E. coll 
(Wallis and Perham, 1994).
In contrast, the recognition of the domain by El may be dependent on the side chains 
around the lipoyl lysine. Replacing the aspartic acid and alanine residues decreases the 
rate of reductive acétylation of B. stearothermophilus PDC domain by the cognate El 
(Wallis and Perham, 1994). The substitution of aspartic acid with large residues may 
obstruct access to other residues within the cleft-like stmcture of which aspartic acid is
located at the mouth. If the alanine is replaced by charged residues (lysine and
glutamate), a reduction in the rate of reductive acétylation is observed, suggesting a |
hydrophobic interaction between the alanine residue and the El enzyme (Wallis and
Perham, 1994).
■
However, this is still a largely under-investigated area, particularly in the mammalian
..9 .
system; thus a series of experiments were undertaken here to further determine the 
requirements within the lipoyl domain for lipoylation, specifically in conserved residues 
adjacent to the lipoylation site.
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4.6 Aims of this chapter
(i) Investigation into the reactivity of the iipoyl-containing polypeptides of bovine PDC 
and OGDC using the PDl monoclonal antibody.
(ii) Overexpression and subsequent purification of human lipoyl domain mutants.
(iii) Confirmation of lipoylation of mutant domains and recognition by PDl monoclonal 
antibody.
4.7 Materials and Methods
The monoclonal antibody PDl was obtained from Professor Freda Stevenson, 
University of Southampton, shown previously on native gel electrophoresis to cross- 
react with the lipoylated form of the human lipoyl domain. ECL was employed to detect 
reactivity.
Purified human lipoylated and unlipoylated lipoyl domain samples were obtained from 
Dr. J. Palmer, University of Newcastle.
A series of mutant human lipoyl domains, expressed as GST-fusion proteins were 
obtained from Dr. Janet Quinn in Newcastle. They encompassed the residues Serine 
181 to Lysine 282 of the E2-PDC gene.
4.8 R esults
4 . 8 . 1  Investigation into the reactivity of the lipoyl-bearing subunits o f  
bovine the PDC and OGDC and the lipoylation state of E2 
subgenes using the P D l monoclonal antibody.
The PDl monoclonal was used on purified PDC and OGDC isolated from bovine heart 
(see Materials and Methods). Prior to Western blotting, enzyme assays were carried out 
to determine the purity of the PDC and OGDC. It was established that the OGDC 
contained 2% PDC activity and that the PDC was cross-contaminated with OGDC 
activity to a significant extent (15-17%). Each sample (lOpg) was resolved by 10%
1 0 0
, j
Production of human anti-PDC-E2 monoclonal antibodies
The monoclonal antibody, PD l, was a kind donation from Professor Freda Stevenson, 
University of Southampton. It was generated by immortalising B lymphocytes from a 
patient with the autoimmune disease. Primary Biliary Cirrhosis (PBC). Venous blood 
was drawn and the B lymphocytes exposed to Epstein Barr Virus. Following 
incubation in suppIemented-RPMI, the cells were hybridised with mouse myeloma 
cells. Once of the hybridomas were visible, each clone was screened for reactivity with 
E2-PDC, which is the major autoantigen in PBC. Positive clones were selected and 
cloned until stable monoclonal populations were established.
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SDS-PAGE (Figure 4.1) and a corresponding gel run for Western blotting (Figure
4.2).
Western Blot analysis revealed that only the PDC-E2 and not the 0GDC-E2 reacted 
with monoclonal PD l. This result was somewhat surprising in view of the strong 
dependence of this monoclonal Ab on the presence of lipoic acid; however having 
already made subgenes, in the form of the di-domains, of human PDC, E. coli PDC, 
BCOADC and protein X, these were also blotted against the PDl antiserum (Figure
4.3). Immunoblot analysis demonstrated that the E2-PDC, protein X and branched 
chain di-domains reacted strongly, but not the E2 of the E, coli di-domain (data not 
shown for latter).
Following on from this obseiwation, sequence similarities around the attacliment site of 
the lipoic acid were investigated to determine whether variations in this sequence could 
be influencing reactivity with the antisera (see below).
4 . 8 . 2  Sequence comparison around the attachment site of the lipoic acid 
moiety of the E2 and protein X subunits:
PDC: A E V E T D K A T V
BCOADC: C E V Q S D K A S V
Protein X: C E I E T D K A S V
OGDC: D Q N V D K R T C
E. coli?DC: L I T V G D K A S M
1 0 1
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Figure 4.1 SDS-PAGE analysis of PDC and OGDC purified from bovine  
heart.
Purified PDC and OGDC (lOpg of each) aie resolved on a 10% SDS-polyaciylamide
gel and stained with Coomassie Blue as described in Methods section. Lane 1, PDC; 
lane 2, OGDC sample. Lane M, Mp marker.
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Figure 4.2 Western blot analysis of bovine PDC and OGDC, using a 
monoclonal antiserum specific for lipoylated form of E2-PDC.
:|
Lanes 1 to 3 contain 10, 5 and 2.5|Xg PDC respectively. Lanes 4 to 6 contain OGDC, 
loaded identically to the PDC samples. Mp standards were also mn on the gel, as 
indicated.
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Figure 4.3. Western blot analysis of the PDC, BCOADC and protein X 
di-domains, blotting with antisera specific to the holo-domains.
Extracts were prepared from E. coli DE3 cultures expressing the di-domains at Oh and 
3h after IPTG addition. Additional extracts were grown in the presence of lipoic acid at 
lOpg/ml. Lane 1, pre-induced human E2-PDC di-domain. Lane 2, 3 hour post­
induction sample and lane 3, the equivalent sample with the exception of it being 
induced in the presence of lipoic acid. Lanes 4 to 6 contain the equivalent samples, but 
for E2-BCOADC di-domain. Lanes 7 to 9, as for lanes 1 to 3, but of protein X di­
domain.
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From the result of this comparison, there was no obvious distinction between the 
sequences of those which provoked a positive response with the monoclonal antibody 
and those which did not, with the exceptions of the lack of a conserved valine 
downstream of the lipoyl-lysine (situated within the DKA motif) and a conserved 
glutamate upstream. It was decided to further investigate the influence of the 
surrounding sequence using point mutations of the PDC-E2, originally generated by 
Dr. Janet Quinn, University of Newcastle. It was hoped that residues could be 
identified which were required for both the lipoylation reaction and antisera recognition
4 . 8 . 3  Overexpression and subsequent purification of mutant human 
dom ains
For this series of experiments, a series of point mutations in the conserved sequence 
adjacent to the E2 lipoyl attachment site were obtained from Dr. Janet Quinn in 
Newcastle. The inner lipoyl domain from human E2-PDC (107 amino acids) had been 
cloned into the pGEX-2T plasmid (Pharmacia Biotech) (Figure 4.4), using EcoRI and 
Bam HI and propagated in E. coli, XL 1-Blue. The original lipoyl domain, referred to as 
pGLIP-2T, was subjected to one of five point mutations:
Mutant Name 
lA:
2A 
3A 
3B 
4A
Mutation
Alai74 to Ser 
Glul70 to Gin 
Lysl73 to Gin 
GlylSO to Asn 
Asp 172 to Asn
I
4Î
J
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MCS (multiple cloning site)
Glutathione S-Transferase
Amp'Tac promoter
pGEX
4,900bp.
L ad
pBR322 oh.
Figure 4.4 Features of pGEX Vectors.
Tac promoter for high-level expression, using IPTG.
Ampicillin resistance gene for selection.
Thrombin or Factor Xa protease recognition sites for cleavage of protein of 
interest from the fiision protein.
For these experiments, pGEX-2T was used, which contains a thrombin 
cleavage site within the multiple cloning site, shown below.
Thrombin cleavage site
CTG GTT CCG CGT GGA| TCC CCG^GGAATTj CAT CGT G \C TGA CTGACG
BamHl I I_ _ _
Smal EcoRI Stop Codons
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Having established that overexpression of the majority of the lipoyl domains had 
occurred, the next stage was a purification of the GST-fusion proteins from the bacterial 
lysates. Purification was achieved in a single step by affinity chromatography using a 
glutathione Sepharose 4B column (for overview see Figure 4.6 and Materials and 
Methods section).
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The aims were to investigate earlier claims of the importance of these residues in the
.lipoylation of the critical lysine residue (Lys 173) and to detennine if these amino acids 
are also important in antibody response to the holodomain. E. coli DE3pLysS were 
transformed with the plasmids containing the mutant or wild type domains and 
overexpression achieved using IPTG (Figure 4.5). The resultant protein products 
exhibited Mr values of approx. 40,000, since these are expressed as C-terminally
located GST-fusion proteins. As can be seen from the gel (lane 8), there was no 
overexpression of mutant 3B.
The fusion proteins were eluted over the first two to five fractions (Figure 4.7 
demonstrates this in the case of mutant 4A). The fractions were dialysed against |
distilled water, and then concentrated using Polyethylene Glycol-6000 (PEG-6000) to a i
final volume of approx. 1ml. The resultant product was run on a 15% SDS- f
polyacrylamide gel, along with the pre- and post-induction bacterial lysates (Figure 
4.8). As a control, the wild type domain (pGLIP-2T) was also treated in a similar 
manner. 7
.,1
4 .8 .4  Confirmation of lipoylation of mutant domains and recognition by ■I
P D l monoclonal antibody.
To determine whether the mutant lipoyl domains were recognised by the E. coli 
lipoylation system, two different teclmiques were employed:
(i) Western Blot analysis. |
(ii) Native Gel Electrophoresis.
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Figure 4 .5 Overexpression of mutant forms of the lipoyl domain from  
human PDC in E. coli DE3pLysS.
Cultures of E. coli DE3plysS (250ml) were induced with IPTG when their A^OO 
reached 0.5. A sample of the pre-induced and 3h post-induction sample were run in 
adjacent lanes of a 10% SDS-polyacrylamide gel. Proteins were visualised using 
Coomassie Blue stain. Lane M, molecular mass marker. Lanes 1 and 2, mutant 1 A. 
Lanes 3 and 4, mutant 2A. Lanes 5 and 6, mutant 3A. Lanes 7 and 8, mutant 3B. Lanes 
9 and 10, mutant 4A. There was no detectable overexpression of the 3B mutant.
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Figure 4.6 Overview of Glutathione Sepharose 4B column.
The structure of glutathione, the substrate for GST, permits high affinity binding of the 
fusion protein and specific, one-step purification by elution with free glutathione.
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Figure 4.7. Purification of a mutant lipoyl domain-GST-fusion protein 
by affinity chromatography on Glutathione Sepharose 4B
Purification was carried out on the mutant (see Materials and Methods), in this case 
mutant lA (Ala 174 to Ser 174) overexpressed without (lanes 1 to 8) and with (lanes 9 to 
16) exogenous lipoic acid in the growth medium. The gel shows the pre- and post­
induction samples, (lanes 1, 2; 9 &10), followed by the flow through from the column, 
(lanes 3 & 11) then 20pl aliquots of each 1ml fraction eluted from the column, in the 
presence of lOmM glutathione.
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Figure 4.8 Coomassie Blue-stained gel showing the final purified lipoyl 
domain mutant proteins.
The fractions containing the affinity purified fusion proteins were pooled and 
concentrated, then run beside the pre- and 3 hour post-induction samples on a 10% 
SDS-polyacrylamide gel. Mutant lA is shown in lanes 1 to 3, mutant 2A in lanes 4 to 
6, mutant 3A in lanes 7 to 9, mutant 4A in lanes 10 to 12 and the wild type domain in 
lanes 13 to 15. M, molecular mass marker.
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4 .8 .4 .1  Western Blot analysis o f lipoyl domain mutants.
Each purified lipoyl domain mutant, in the form of a GST-fusion protein was 
immunoblotted alongside the wild type domain and native GST (Figure 4.9). The lack 
of reactivity with GST alone (lane 10) confirmed the antigenicity resulted solely from 
the presence of the lipoyl domain. The blot shows that, when grown without 
exogenous lipoic acid, mutants lA (Alal74 to Ser) and 4A (Asp 172 to Asn) react 
strongly with the lipoylation-specific monoclonal (lanes 1, 2, 7 & 8). There was an 
extremely faint reaction with the 2A (Glul70 to Gin) mutant. When induced in the 
presence of the exogenous lipoic acid, lipoylation was enhanced in the cases of lA and 
2A, as evidenced by an enhanced recognition by the monoclonal antibody. There was 
no recognition of mutant 3A, the lipoyl lysine mutant. Little or no enhancement was 
observed in the case of mutant 4A suggesting that lipoylation may be complete without 
the addition of exogenous cofactor.
4.8.4.2 Native gel electrophoresis o f  lipoyl domain mutants.
Native gel electrophoresis was also employed to further establish the lipoylation state 
and confirm the altered primary sequence of the mutant domains. In this case, 
electrophoresis was carried out on native polyacrylamide 10% gels (Figure 4.11), Prior 
to running the samples on a native gel, they were subjected to thrombin cleavage to 
separate the GST from the lipoyl domain. SDS-PAGE analysis confirmed the 
completion of cleavage (Figure 4.10). The various mutations altered the overall charge 
of the domain, thus allowing separation on the basis of altered migration rates. In 
addition, this separation also allows resolution of the apo- and holo-domains with the 
lipoylated form migrating more rapidly owing to the removal of a positive charge on the 
amino group of the lysine side chain on insertion of the prosthetic group.
1 1 2
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Fig 4.9 Western Blot of the lipoyl domain mutants induced in the 
presence or absence of exogenous lipoic acid.
Lanes 1 and 2 show the result of the immunoblotting of mutant lA with monoclonal 
antibody PDl induced without and with exogenous lipoic acid, respectively. Lanes 3 
and 4, mutant 2A. Lanes 5 and 6, mutant 3A. Lanes 7 and 8, mutant 4A. Wild type 
domain (from pGLIP-2T) was resolved in lane 9 and purified GST in lane 10. The 
samples were run on a 15% SDS-polyacrylamide gel.
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Figure 4.10. Thrombin cleavage of GST-fusion proteins.
Each of the purified mutant fusion proteins was subjected to thrombin cleavage for 16h 
and the resultant products run on a 15% SDS-polyacrylamide gel. Lane 1, Mp marker.
Lanes 2 and 7, mutant 1A and wild type domains prior to cleavage respectively. Lanes 
3 to 6 show cleaved mutants lA, 2A, 3A, & 4A.
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Figure 4.11. Native gel electrophoresis of the purified lipoyl domain 
mutants following thrombin cleavage.
Lanes 1 and 2 of this 10% native gel, mutant lA unsupplemented and supplemented, 
respectively, with lipoic acid. Lanes 3 and 4, mutant 2A. Lanes 5 and 6, mutant 3A. 
Lanes 7 and 8, mutant 4A. The wild type domain, grown without exogenous lipoic acid 
is shown in lane 9. The arrows labelled ULip and Lip refer to the unlipoylated and 
lipoylated domains.
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4.9 Discussion and Conclusions
4,9.1 Lipoylation states o f  intact complexes and subgenes 
Lack of cross-reactivity of bovine OGDC and E. coli di-domains with monoclonal PDl 
was rather surprising in view of the absolute dependence of this antibody on the 
presence of the covalently-linked lipoate prosthetic group. These results suggest that the 
presence of the lipoate moiety is necessary but not sufficient to induce a positive 
immune reaction. Additional features such as a specific sequence motif or non­
contiguous conformational epitopes may be necessary. Furthermore, there is a lack of 
protein X reactivity on the blot. This could be a result of the lower levels of protein X in 
relation to E2-PDC, or the possibility that the monoclonal antibody displays a reduced 
reactivity as it was raised to the E2-PDC lipoyl domain. A reaction with protein X could 
perhaps be detected upon over-exposure.
Sequence compai'ison with bovine OGDC and E. coli E2-PDC shows 2 main 
differences; rat OGDC has a glutamic acid residue 3 residues upstream of the lipoyl 
lysine and it also has a valine residue 3 residues downstream. Neither of these residues 
is present in the bovine OGDC or E. coli sequences. This suggests that these residues 
are important for recognition by PDl in OGDC, regardless of the fact that the enzyme is 
lipoylated.
Figure 4.4 shows that the di-domains from human PDC, protein X and BCOADC aU 
cross-react strongly with the antibody. The E. coli PDC di-domain however failed to 
exhibit a similar reaction (data not shown). These results indicate that although PDl 
was generated against human lipoyl domain, its specificity is more broadly based. They 
also show that the presence of the lipoic acid cofactor is essential for molecular 
recognition by monoclonal PDl in all cases, but that additional factors are also required 
to achieve a positive response. It was in this context that a comparison of the amino acid
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sequences around the site of attachment of the lipoic acid was carried out. Unfortunately 
there were no obvious differences which could account for the differences observed in 
the recognition by PD l, with the exceptions that both bovine OGDC and E. coli PDC 
show more sequence variations compared to the human sequence. Both lack the 
conserved glutamate and valine residues located 5 residues upstream and 4 residues 
downstream respectively of the lipoyl lysine. Obtaining the human lipoyl domain point 
mutants meant the possibility of determining whether these residues and others around 
the lipoic acid attachment site were indeed important for promoting this reactivity.
4.9.2 Overexpression and purification o f human lipoyl domain 
m utants
As can be seen on Figure 4.8, the overexpression in E. coli DE3 pLysS and subsequent 
purification of the resultant GST-fusion proteins was successful for all mutants apart 
from mutant 3B (Glyl80-Asn), which failed to overexpress. This could possibly have 
been due to the mutation resulting in an incorrectly folded product that was rapidly 
degraded by the E. coli proteases. In 1996, Fujiwara et a l suggested that a small 
residue such as glycine or cysteine at this position is essential for correct folding and 
similar results have been obtained in Newcastle (J. Quinn, personal communication).
4.9.3 Lipoylation o f  mutant lipoyl domains.
The immunoblot (Figure 4.9) clearly shows the differences in the levels of reactivity 
between the various mutants and the PDl antibody. What is also obvious is that the 
presence of exogenous lipoic acid in the growth medium enhances the level of 
lipoylation as evidenced by the enhanced signals. This was tme for the 3 mutants that 
cross-reacted. As expected, mutant 3A failed to cross-react, since substitution of the 
lipoyl-lysine moiety removes the critical residue required for the attachment of the lipoic 
acid prosthetic group.
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The apparent lipoylation of mutant 2A contrasts with a report by Quinn et al, (1996), 
who showed that replacing the Glu by Gin caused the abolition of lipoylation as judged 
by growing the cultures in the presence of [^H] lipoate and measuring the incorporation 
of the radiolabelled prosthetic group into TCA-precipitated material. The low levels of 
cross-reaction observed here, which are enhanced to more detectable levels by 
exogenous lipoic acid, indicate that this mutant domain is an extremely poor substrate 
for the lipoylation reaction. Thus the sensitive detection method employed in this study 
could be the cause of this apparent disagreement.
These results are consistent with those of Wallis & Perham (1994), who showed that 
changing the equivalent residue (Aspl72 to Asn) in E. coli E2-PDC had no effect on 
the ability of the lipoyl lysine to be lipoylated. They also demonstr ated that this change 
caused a reduction in the rate of reductive acétylation by the El enzyme.
Moreover, our results in agreement with those obtained for in vitro assays on mutant 
forms of H-apoprotein by Fujiwara et al. (1996). The group showed that the glutamic 
acid residue, three residues upstream of the lipoyl lysine is important for lipoylation by 
the mammalian lipoyltransferases. Their suggestion was that the residue acts as a 
recognition signal for the enzyme. In fact, they demonstrated a 100-fold decrease in the 
rate of lipoylation when glutamic acid was replaced by glutamine.
Our evidence also suggests that the two residues flanking the lipoyl lysine are not 
critical for lipoylation, since both mutants 1A and 4A are lipoylated when induced in the 
presence or absence of exogenous lipoic acid. Furthermore, the immunoblot 
demonstrates the need for the lysine residue at position 173 (in the human domain) for 
lipoylation, since neither mutant 3A grown with or without exogenous lipoic acid 
appear to be lipoylated.
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Since the rate of migration of individual lipoyl domains on native polyaciylamide gels is 
primarily dependent on their net charge, mutations that remove a negatively charged 
amino acid will decrease the mobility. In contrast, neutral replacements should have 
little or no effect on mobility compared to the wild type domain. In addition, lipoylation 
itself results in the removal of a positively chaiged lysine side chain, resulting in 
increased migration. The nature of the mutations are such that mutants lA and 4A 
migrate similarly to the wild-type, 2A migrates more slowly than the wild type and 3A 
display a higher mobility.
In agreement with Western blot analysis, the lA mutant is predominantly in the 
unlipoylated state when grown without lipoic acid, but in the presence of it, there is a 
shift to the almost fully lipoylated form. This is shown by the presence of two bands on 
the gel. As already stated, the unlipoylated domain migrates slower on the native gel 
than the lipoylated foim owing to the difference in charge as the lipoic acid forms an 
amide linkage, increasing the overall net negative chaige. The gel also shows that the 
samples of mutant 2A grown +/-lipoic acid seem to run similarly. The Western blot of 
these two samples showed both to be lipoylated at extremely low levels. It is likely that 
these bands actually represent the unlipoylated forms, but there is a tiny percentage of 
lipoylated domain that is detected by the antisera. In the case of the lysine mutant (3 A), 
both the + and - lipoic acid samples run identically. Neither is lipoylated, as 
demonstrated by immunoblotting. Mutant 4A, grown without lipoic acid seems to only 
show one band, which must be assumed to be the lipoylated form. It is possible that the 
particular mutation makes the domain a better substrate for lipoylation.
119
120
Chapter 4
4.10 Concluding remarks
Taking the results obtained in this chapter together with those of other groups, it is 
possible to draw the following conclusions regarding the mammalian and E. coli 
lipoylation systems:
1
(i) Despite the conserved DKA sequence motif forming a 3-D P-turn, the aspartic acid 
and alanine residues are not the recognition signal for the enzyme selecting the lysine 
residue for lipoylation.
(ii) As fai' as the mammalian system is concerned, the conseiwed upstream glutamic acid 
is important, but conversion to Gin leads to greatly reduced but not to total abolition of 
lipoylation as reported previously.
(hi) The mode of recognition of the substrate by the lipoylating enzyme(s) are similar' in 
both mammalian and prokaryotic systems, with neither the amino acid sequence per se 
nor a structural cue being exclusive for the process of recognition by the lipoylation 
enzymes.
(iv) The basis of the positive response of individual lipoylated domains by monoclonal 
antibody PDl is still unclear'; however, it is apparent that conserved Asp and Ala 
residues forming the DKA motif at the site of lipoylation are not directly involved. 
Moreover, the conserved Glu also appears not to be essential for cross-reaction. The 
involvement of conserved Val located 3 residues downstream of the lipoate attachment 
site in positively-reacting domains was not investigated at this stage.
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OVEREXPRESSION AND PURIFICATION OF N-TERMINAL  
FRAGMENTS OF THE E l COMPONENT OF HUMAN OGDC: USE AS 
COMPETING INHIBITORY PEPTIDES IN OGDC RECONSTITUTION  
STU D IES.
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5.1 Introduction.
The structure and subunit organisation of the mammalian OGDC complex appears to 
differ markedly from the other members of the family of 2-oxoacid dehydrogenase 
complexes, namely PDC and BCOADC. The El enzyme of OGDC is a high Mr 
homodimer with a subunit of Mr 110,000, in contrast to the tetrameric structures 
of the analagous components of PDC and BCOADC. Sequence comparisons with 
protein X and E2-PDC from various sources show significant homology, particularly 
within the N-terminal region and includes a variation on the characteristic motif 
PALSP/GTM found in lipoyl domains, which in El-OGDC is PFLSGTS. Indeed, 
using specific proteolysis and N-terminal sequencing, it has been shown that there is a 
‘lipoyl-like’ region at the N-terminus of the E l component (Figure 5.1).
In this context, the cloning of the genes for human (Nakano et al., 1994) and rat heart 
(Nakano et al., 1991) E2-OGDC failed to detect the presence of an El or E3-binding 
domain, which is apparent in the E2-OGDC genes cloned from non-mammalian 
sources such as E. coli (Spencer et a l ,  1984) and indeed in all E2 core assemblies 
determined to date. Human E2-BC0ADC displays a high similarity to E2-0GDC, with 
the exception of the presence, in the former, of 1 exon encoding the E1/E3-binding 
domain (Lau et al., 1992). The loss of this exon and the surrounding introns appears to 
have occurred during the evolution of the complexes. In 1996, Usada et al. showed that 
the odhA gene from Corynebacterium glutanium that codes for El-OGDC, displayed an 
N-terminal extension with sequence homology to E2s from PDC and OGDC, albeit to 
their C-termini.
The E l component is the most proteolytically sensitive enzyme of OGDC (Rice et al., 
1992). The addition of protease aig C causes extensive degradation of E l, producing 
many smaller peptides. Trypsin in contrast, causes very selective degradation. A large 
stable fragment of subunit 100,000 M^ is produced, termed E l' and a smaller N-
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JOkDa
Lipoyl-like
sequence
Putative
E 3 /E 2
binding
domain
El' lOOkDa
Active C-terminal domain
Figure 5.1 Schematic representation of the E l component of OGDC.
At present, the domain organisation of El-OGDC is poorly understood. What is 
known is that there is a highly-sensitive tryptic cleavage site which results in the 
production of a 1 OkDa fragment plus a lOOkDaEl' fragment (as shown). Within the 
putative E2/E3 binding domain, sequence similarity has been detected to the subunit 
binding domain of protein X; hence the suggestion that the El-OGDC binds the E3 
as well as the E2 enzyme.
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terminal 10,000 Mp peptide is also generated. This pattern of degradation is similar to 
that obtained by the cleavage of E2-PDC. It generates lipoy 1-bearing peptides and C- 
terminal intersubunit binding domains. The small El fragment displays another 
characteristic of a lipoyl domain in that it is highly immunogenic. The response is 
greater than that elicited by the large E l' fragment, which retains full catalytic activity. 
Sequencing of the E l' fragment has confirmed that the small peptide has been cleaved 
from the N-terminus of E l, a positional similarity to the lipoyl domain.
To date, the precise functional properties and domain boundaries of El-OGDC been 
little studied. The main problem is the high affinity which El displays for the E2 core. 
However, a method has been recently developed to release catalytically active El from 
the core using IM MgCl2 (McCartney et a l ,  1998), although the free enzyme is
extremely unstable under these conditions. Current evidence indicates that the El 
enzyme of OGDC, in particular' the N-terminal region, is important for maintaining 
overall complex integrity in that it seems to be involved in binding both the E2 and E3 
components. Thus a single tryptic cleavage within this region causes total inactivation 
of the complex by releasing both the E l' and E3 components, which are fully active.
This chapter details the overexpression of various different sized fragments of the N- 
terminal region of human OGDC. The rationale behind this series of experiments was 
to map more precisely the boundaries of the putative regions involved in E2 and E3 
binding. To do this, it was decided to generate, by PCR, a series of N-terminal 
fragments of the El component and subsequently overexpress them as GST-fusion 
proteins in E. coli for use in competition studies. Investigations would centre on 
whether these fragments displayed the ability to bind to E2 and/or E3 and could thus 
compete for binding when E3 and/or El and E3 were added back to the E2-OGDC 
core.
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5.2 Materials
The PCR amplification was caiTied out using human fetal liver cDNA (Clonetech) as 
the template. The primers were designed to the known El sequence and are detailed in 
section 5.5. The expression vector pGEX-2T was used for insertion into E. coli 
DH5a. The recombinant plasmids were subsequently used to transform E. coli DE3 
pLysS. Glutathione Sepharose 4B (Pharmacia) was employed to purify the GST fusion 
proteins.
5.3 Methods
Initial investigations involved PCR amplification of DNA fragments from human fetal 
heart cDNA, corresponding to the first 80, 100 and 120 N-terminal amino acids of El- 
OGDC. Primers were designed on the basis of the sequence published by Koike et al,
(1992) (see section 5.4). The products were inserted into a pE T lld  expression vector 
and the protein overexpressed in E. coli DE3 pLysS. This method was subsequently
%adapted to that detailed below as it was deemed easier to purify the overexpressed 
proteins when generated as GST-fusion proteins.
This adapted method again involved the PCR amplification of three different sized 
fragments of the N-terminal of E l, (60, 110 and 160 amino acids) but differed from the 
first method in that the primers were designed to allow the insertion of the PCR 
products into a pGEX-2T vector to form a GST fusion protein, by engineering Bam HI 
restriction sites onto each end of the PCR products (see section 5.4). A further notable 
difference was that high fidelity Pfu DNA polymerase was used for the PCR 
amplification to minimise mis-incoiporation.
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5.4 Aims of this chapter
1. PCR amplification and subsequent cloning of 3 N-teiminal fragments of the El 
enzyme of OGDC.
2. Competition studies for El and E3-binding between the N-terminal fragments and 
the OGDC core.
3. Draw conclusions regarding the regions of the El enzyme of OGDC involved in 
binding E2 and E3.
5.5 Polym erase C hain Reaction (PCR) of the OGDC E l N -term inus
]Four oligonucleotides were designed to allow the insertion of the PCR product into : ;
0pGEX-2T for expression as a GST fusion protein. The underlined sequences in the 5 ' 
primer (OGDC-UP) and the 3’ primers (OGDC-60, OGDC-110 and OGDC-160)
;
denote the Bam HI restriction sites.
OGDC-UP CAGATTCGGGGATCCTCTGCACCTGTTGCTGCTG
OGDC-60 CACAGCAGCGGATCCAGTTCGGCTCAGGGAAGG
OGDC-110 CAGATCAGCGGATCCAGTCCCCAGGGGGTCCAG
OGDC-160 GATCTCCCGGGATCCAGTTGCTGATTCCTGTCC
S'
In combination with OGDC-UP, OGDC-60 was used to amplify the first 60 amino 
acids, OGDC-110 the first 110 and OGDC-160 the first 160. High fidelity Pfu DNA 
polymerase was used for the PCR to minimise misincorporation. The cycling 
conditions of the PCR differed to those previously employed, when Taq DNA 
polymerase was used for the amplification. Pfu polymerase catalyses base- 
incoiporation more slowly than Taq, as a result of its increased proofreading 
exonuclease activity and thus requires a far greater extension time. The programme 4
consisted of an initial dénaturation of 95°C for 45 sec, then 35 cycles of the following 
(95°C for 45 sec, 65®C for 30 sec, 72^C for lOmin), followed by a final extension 
time of 15 min.
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5.6 R esu lts
5.6.1 PCR amplification of N-terminal fragments of El-OGDC
The human fetal liver cDNA template was subjected to PCR using the OGDC-UP and 
OGDC-160 primers. This generated the lai'gest PCR fragment (OGDC-160). 
Restriction digest of the PCR product, with Bam HI, was carried out as detailed in the 
Materials and Methods section and the product subsequently ligated into pGEX-2T. 
Recombinant plasmid was amplified in E. coli DH5a. The plasmid was then used as 
template for the remaining two PCR reactions. All three products were visualised on a 
2% TAE-agarose gel, under UV transillumination (Figure 5.2).
5.6.2 Construction of recombinant plasmid
Each PCR product was purified using a Qiagen gel extraction Idt, then digested with 
Bam HI. Following further gel purification, the PCR products were ligated overnight 
into pGEX-2T. Ligations were carried out over a range of vector to insert ratios and a 
1:1 ratio deemed optimal. Positive clones were detected by successful release of the 
appropriate-sized fragment from the recombinant vector. Initially only 2 positive 
colonies were isolated. Their failure to overexpress when transfomried into E. coli DE3 
pLysS suggested that the cloned fragment had ligated into the vector in the inverse 
orientation. To overcome this, the insert was re-digested from the vector, re-purified 
and subsequently re-ligated back into the digested vector. This increased the frequency 
of positive colonies and pemiitted isolation of plasmid with the PCR product inserted in 
the correct orientation.
5 . 6 . 3  Overexpression of the 3 N-terminal fragments of El-OGDC
Overexpression of each of the 3 N-terminal fragments was observed following the 
transformation of E. coli DE3 pLysS cells (Materials and Methods section 2.15) using 
IPTG induction (Materials and Methods section 2.16). Visualisation of the GST-fusion 
proteins was carried out by resolution on a 12% SDS-polyacrylamide gel (Materials and
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Figure 5.2. Agarose gel of the PCR amplification of the three N-terminal 
fragments of El-OGDC.
Lane 1, OGDC-60. Lane 2, OGDC-110. Lane 3, OGDC-160. Lane M, lOObp size 
ladder. The gel was visualised under UV illumination following staining with ethidium 
bromide.
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Methods section 2.2.16) and staining with Coomassie Brilliant Blue. A substantial 
overexpression was observed within an hour of induction in all cases (Figure 5.3).
5 . 6 . 4  Purification of the 3 N-terminal fragments of El-OGDC
On achieving successful overexpression of the fragments; the next stage was 
purification of the GST-fusion proteins from the bacterial lysates. This was achieved in 
a single step by affinity chromatography using a bench-top glutathione Sepharose 4B 
column, as detailed in the Materials and Methods section. The fusion proteins were 
eluted over the first one to five 1ml fractions. Figure 5.4 demonstrates the purification 
profile of OGDC-60. The fractions were dialysed against distilled water then 
concentrated using polyethylene glycol-60(X) (PEG-6000) to a final volume of approx. 
1ml.
Part 2
5.7 Competition studies using the N-terminal fragments as inhibitors 
of OGDC reconstitution
5 . 7 . 1  Dissociation of native OGDC using IM NaCl
After successful purification of the 3 N-terminal fragments of El-OGDC, the next stage 
was to discover whether they were capable of inhibiting reconstitution of OGDC. Thus 
the ability of the N-terminal fragments to inhibit the reconstitution of dissociated OGDC 
was tested by competing for E3 binding. The E3 enzyme of the 2-oxoacid 
dehydrogenase complexes can be selectively released by incubating the complex in IM 
NaCl at 4°C for 20min (Sanderson et al, 1996).
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Figure 5.3. SDS-PAGE analysis of the overexpression of the N-terminal 
fragments of El-OGDC in E. coli DE3 pLysS.
Lane 1, pre-induced whole cell extract. Lane 2, overexpressing OGDC-60. Lane 3, 
overexpressing OGDC-110. Lane 4, overexpressing OGDC-160. M, molecular mass 
marker.
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Figure 5.4. Purification profile of OGDC-60, purified as a G ST -fusion  
protein on a glutathione Sepharose 4B column.
Lane 1, flow through following loading of the sample onto the column. Lanes 2 to 6 
show samples (lOpl) from successive 1ml fractions collected following addition of the 
elution buffer to the column.
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To assess the extent, if any, of E3 binding by the fragments (detected by the inhibition 
of OGDC recovery) it was first necessaiy to determine the efficiencies of reassociation 
of OGDC after salt treatment. OGDC (lOjJig) was reconstituted at 20°C for 20 min. in 
670(il solution A and 14|Lii of solution B (Materials and Methods section 2.2.23.1) 
following the dissociation in IM NaCl. In order to initiate NADH production, 14pl of 
lOOmM 2-oxoglutarate was added to the assay components. The activity measured, 
expressed as a percentage of initial OGDC activity, prior to salt treatment was 47.7% 
(+/- 2.5%) (Figure 5.5).
Subsequently, this experiment was repeated in the presence, in the assay buffer, of a 
10-fold stoichiometric excess of each of the El-OGDC N-terminal fragments. On the 
addition of the substrate 2-oxoglutarate, the activity of the OGDC complex was 
measured and again expressed as a percentage of reconstituted complex. Figure 5.5 
demonstrates that despite the large excess of El-GST, there is no significant inliibition 
of reconstitution of the OGDC complex, with values in the presence of OGDC-60, 
OGDC-110 and OGDC-160 of 92.2% (+/-2.6%), 88.9% (+/-4.8%) and 95.6% (+/- 
4.9%) respectively. Furthermore, to confirm that the GST was not hindering access to 
the E3 components, the fusion proteins were subjected to cleavage by thrombin, to 
release the GST component. El-GST fusion protein (lOpg) was incubated overnight at 
16°C with 20 units thi'ombin and the resultant cleaved fragments added to the OGDC 
reassociation mix. The results obtained were indistinguishable to those for the intact 
GST-fusion proteins, indicating that the GST does not interfere with any potential intra­
complex interactions.
5.7.2 D issociation using IM  M gCl2 .
In contrast to the E3 component of OGDC, the El enzyme is very tightly bound to the 
E2 core. Previous studies have shown however that high concenti’ations of divalent 
cations, especially Mg "^^ , aie capable of dismpting the strong interaction, whilst also 
causing the release of the E3 enzyme (McCai tney et al, 1998).
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Figure 5.5 Reconstitution of native OGDC in the absence and presence 
of the El-OGDC N-terminal fragments.
Following the dissociation of the OGDC complex in IM NaCl, samples (10|lg) were 
removed and incubated for 20 min. In reassociation buffer, prior to being assayed for 
OGDC activity. The activity recovered was expressed as a percentage of the original 
activity prior to dissociation. Assay values were the result of duplications which 
differed by no more than +1-5%. In the presence of each of the N-terminal fragments, 
there is no significant inhibition of reconstitution.
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This technique was employed here to determine whether the El-OGDC N-teiminal 
fragments had any effect upon the subsequent reconstitution of the complex following 
its dissociation in the MgCl2 . An inhibition of assembly would indicate interference of
the reassociation of the El component to the E2 core.
In order to determine the effect on reconstitution of the N-terminal fragments; OGDC- 
60, OGDC-110 and OGDC-160, each fragment was added to the reassociation mix in a 
10-fold stoichiometric excess. Dissociated OGDC (lOjig) was incubated for 20min at 
20°C, then assayed to determine the extent of reconstitution (Figures 5.6a, b and c). 
When each fragment was added to the reassociation buffer, there was a significant 
decrease in the amount of activity that was regained relative to the values for 
reconstitution in the absence of inhibitor. With OGDC-60 61.3% (+/-4.2%) returned, 
with OGDC-110 68.1% (+/-3.6%) returned and with OGDC-160 70.2% (+/-2.1%) 
returned.
As already mentioned, these N-terminal fragments had been engineered as GST fusion 
proteins, giving rise to the question of whether the GST was in any way interfering 
with their mode of action. Thus, they were subjected to thrombin cleavage (lOfig of 
fragment was incubated overnight at 16°C with 20 units thrombin) and the resultant 
cleaved fragments added to the OGDC reassociation mix. Again the OGDC assays were 
performed and the results are shown in Figures 5.6a to c, alongside those of the 
uncleaved and the pre-dissociation samples. What is clear is that the removal of the 
GST from the fragments causes a small but significant enhancement in the inhibition of 
complex reassociation, with 50.3%, (+/-3.5%) 58.8% (+/-2.9%) and 61.2% (+/-1.8%) 
of activity returning in the presence of OGDC-60, OGDC-110 and OGDC-160 
respectively.
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Figure 5.6a Reconstitution of OGDC, in the presence of OGDC-60,  
following dissociation of the complex in IM MgCl^.
Samples (lOfXg) were removed from the dissociation buffer and incubated for 20mins 
in reassociation buffer (Materials and Methods section 2.2.23.1). The sample was then 
assayed for OGDC activity and expressed as a percentage of the activity recovered 
following salt treatment in the absence of inhibitor. Column 1 shows the activity 
returned in the presence of a 10-fold stoichiometric excess of OGDC-60. Column 2 
shows the activity returned in the presence of thrombin protease-treated OGDC-60.
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Figure 5.6b Reconstitution of OGDC, in the presence of OGDC-110, 
following dissociation of the complex in IM MgClz.
Samples (lOpg) were removed from the dissociation buffer and incubated for 20mins 
in reassociation buffer (Materials and Methods section 2.2.23.1). The sample was then 
assayed for OGDC activity and expressed as a percentage of the activity recovered 
following salt treatment in the absence of inhibitor. Column 1 shows the activity 
returned in the presence of a 10-fold stoichiometric excess of OGDC-110. Column 2 
shows the activity returned in the presence of thrombin protease-treated OGDC-110.
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Figure 5.6c Reconstitution of OGDC, in the of OGDC-160, fol lowing  
dissociation of the complex in IM MgCli-
Samples (lOpg) were removed from the dissociation buffer and incubated for 20mins 
in reassociation buffer (Materials and Methods section 2.2.23.1). The sample was then 
assayed for OGDC activity and expressed as a percentage of the activity recovered 
following salt treatment in the absence of inhibitor. Column 1 shows the activity 
returned in the presence of a 10-fold stoichiometric excess of OGDC-160. Column 2 
shows the activity returned in the presence of thrombin protease-treated OGDC-160.
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5.8.1 Overexpression and purification of N-terminai fragments
The first section of this chapter detailed the successful overexpression and subsequent 
purification of three N-teiminal fragments of El-OGDC. The constmction of E, coli 
strains capable of overexpressing a gene, or subgene of interest allows production of 
large quantities of protein in a relatively short time. In the case of the N-terminal 
fragments, these were generated as GST-fusion proteins by ligating into pGEX-2T.
The rationale behind the use of this particular vector was the subsequent single-step 
purification procedure by affinity chromatography, using glutathione Sepharose 4B.
The protein is recovered from the matrix under mild elution conditions which normally 
preserves its antigenicity and functionality. Cleavage of the GST is possible using a 
site-specific protease, whose recognition sequence is located immediately upstream 
from the multiple cloning site on pGEX plasmids. Previous cloning work had 
employed the pET 11 series of vectors which proved problematic when attempts at 
purification were carried out. Thus the generation of three N-terminal fragments of El- 
OGDC in high yield has allowed investigations into this critical region of the enzyme.
Their ability to compete with the native components of the complex following 
dissociation is studied here in detail.
•■I
5 . 8 . 2  Dissociation of native OGDC
The mammalian 2-oxoglutarate complex seems to have evolved with stmctural and 
organisational differences far diverged from the other two 2-oxoacid dehydrogenase |
complexes. The cloning of the gene for mammalian E2-0GDC failed to show the I
presence of a peripheral subunit-binding motif, which is apparent in the E2 genes of 
PDC. There are sequence similarities between El-OGDC protein X of PDC, suggesting 
that the E l enzyme has evolved a degree of bi-functionality by carrying out the E3- 
binding functions along with its well-documented catalytic role. In this regard, a direct
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interaction between El-OGDC and E3 has been reported recently by McCartney et a l 
(1998).
It was hoped that the competition studies in part two of this chapter would go some 
way to defining the boundaiies of the E3-binding domain on the El enzyme and also 
the region involved in E2 binding. Three different sized N-terminal fragments were 
generated, encoding the first 60, 110 and 160 amino acids, then used to inhibit the 
reconstitution of native OGDC, following its dissociation by either NaCl or MgCl2 
treatment. These fragments span the proteolytic cleavage site which results in the 
release of both an active E l’ species and E3, causing inhibition of overall complex 
activity. Hence this region is thought to be important in the binding of both El and E3 
to the E2 core.
Partial dissociation of native OGDC can be successfully carried out using IM NaCl. 
This causes specific release of the E3 enzyme, whereas the E1/E2 subcomplex remains 
intact under these conditions. In order to fully disassemble the complex into its three 
constituent enzymes, high concentrations of MgCl2 are required (McCartney et a l, 
1998). Complete dissociation could only be deemed successful if each of the 
components were functionally active following the high salt treatment. This was 
confirmed by the reconstitution studies. The levels of reconstitution obtained following 
IM NaCl and IM MgCl2 treatments were between 45% and 54%, indicating that the 
individual enzymes did indeed remain functionally active and that significant levels of 
complex reconstitution could be achieved. These levels are lower than the 60% to 80% 
reconstitution levels obtained for PDC previously in our laboratory (Sanderson et al., 
1996). This is likely to be a reflection of the haisher conditions required for the 
dissociation. Dissociation of PDC in high salt results in the release of the El and E3 
components while the E2/X core remains intact, enabling easier reassociation. This 
further highlights the possible functional comparison between El-OGDC and protein X 
of PDC with both enzymes being tightly bound to their respective E2 cores. To date,
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Structural analysis of the OGDC core has yet to determine whether the E l enzyme binds 
with the same orientation as protein X does to the PDC E2 core, Le. that it is associated 
with each of the individual faces. Further work is also required to determine the 
optimum length of incubation time in reassociation conditions to obtain maximum 
OGDC activity. Owing to the instability of dissociated E l, extended incubation will 
possibly result in reduced recovery of activity. The pH of the dissociation reactions 
would appear, from previous studies, to be an important contributing factor in the level 
of reconstitution. McCartney et a t (1998) demonstrated that dissociation under acidic 
conditions results in a slow loss of activity and high levels of recovery. In contrast, 
they showed that under alkaline conditions, there is a far more rapid loss of activity and 
lower levels of recovery. This is possibly due to an incomplete dissociation of El from 
the E2 core at more acidic or neutral pH.
The experiments in this chapter were all conducted at pH 7.6, which are too alkaline to 
allow maximal recovery of OGDC activity following dissociation but are required to 
promote complete release of the E l component (McCartney et ai, 1998).
5.8.3 Reconstitution of native OGDC
(1) Effect of N-terminal fragments on E3-binding
Reconstitution analysis showed that the individual components of OGDC were capable 
of reforming active complex following dissociation. The N-terminal fragments; OGDC- 
60, OGDC-110 and OGDC-160 had been designed with the view that they may be able 
to bind the E3 enzyme. This ability would present itself in the form of an inhibition of 
OGDC reconstitution, as the fragments would compete with the native E2/E1 
subcomplex for E3 binding.
The results, however, did not suggest that any of the fragments had the ability to inhibit 
E3-binding. This is highlighted in Figure 5.5, where it can be clearly seen that the 
presence of each of the individual fragments in a 10-fold excess has no effect on the
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level of complex reconstitution. As a further confirmation of this result, each fragment 
(10p.g) was incubated with purified E3, then the sample analysed by non-denaturing 
PAGE (data not shown). The gel showed the presence of two bands corresponding to 
E3 and the N-terminal fragment, but no discrete band representing an E3-N-temiinal 
fragment complex. Adding overexpressed parent GST to the reassociation assay 
provided information that the GST was not interfering directly with reassociation.
As a control to mle out the possibility of the GST part of the fusion protein interfering 
with any E3 interaction, it was cleaved away from the N-terminal fragment using 
thrombin. The reconstitution analysis was then repeated, in the presence of the 
thrombin-treated fragments. The results were as before, with no inhibition of 
reconstitution occurring. Interpretation of the data should be carefully considered. As of 
yet there is no real knowledge of the domain organisation of El or whether the N- 
terminal fragments are capable of correct folding. It is possible that the fragments 
generated aie too small to form stable domains. Furthermore a dimeric stmcture could 
be required for binding and finally, the binding site may be composed of other regions 
outwith the boundaries of the N-tenninal fragments. Obviously further work with lai'ge 
excesses of the N-terminal fragments may generate further inhibition of OGDC activity 
if they are able to compete more strongly with native El. The experimental series 
reported here was limited by the amounts of El-GST fragments generated. To this end, 
lack of positive effects on OGDC reconstitution must be treated with caution at this 
stage.
(2) Effect of N-terminal fragments on E l and E3 binding
The second series of reconstitution studies were performed following dissociation with 
IM MgCl2 which releases both the El and E3 components. The reassociation and 
subsequent OGDC assay was carried out in the presence of a 10-fold excess of each N- 
terminal fragment. The results demonstrated a significant inhibition of OGDC 
reconstitution in the presence of each fragment. In fact there was a decrease in complex
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activity of approx. 50% when compared to reconstitution in the absence of any of the 
N-terminal fragments. As with the previous set of reconstitution experiments, they 
were repeated following the removal of the GST from the fragment with thrombin. The 
results here showed an enhanced level of inhibition of complex formation. These 
results show that in this case, the GST is interfering to some extent with the mode of 
action of the N-terminal fragments. These results implicate the importance of this region 
of the El component in interacting with the E2 core as evidenced by the ability of the 
fragments to reassociate with E2 and E3 into the native complex. There is no significant 
difference between each fragment, but they all show the same degree of inhibition. It 
appears therefore that each fragment, despite having no functional ability to bind E3, 
can interact with the El binding sites on the E2 core, thus inhibiting the levels of 
reconstitution in this manner.
In summary, these studies have been unable to define regions of El-OGDC involved in 
E3-binding. It is possible that the N-terminal fragments that were generated cannot
'form a stable domain structure to retain this function; however, they have shown the 
ability promote partial inhibition of El binding when present in a 10-fold excess which 
argues against this hypothesis. Previous studies have shown that the native El and E3 
interact directly, whereas this is not the case for the stable E l’ species produced by 
tryptic cleavage. Perhaps there are also sequences further downstream whose presence 
is required to allow the binding of E3. It may still be possible to define the E3-binding 
region, by generating larger fragments. However, all that can be concluded at present is 
that the N-terminal region of E l appears to be involved in promoting its interaction with 
the E2 core. Current work is concentrating on extending the series of tmncated forms 
of El to span the complete open reading fiame of this polypeptide. Future analysis 
should elucidate the domain organisation of the El-OGDC enzyme as well as leading to 
more conclusive evidence regarding the diverse properties of this component.
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CHAPTER 6
BIACORE STUD IES OF BIND ING INTERACTIONS BETW EEN TH E 
D I-DOM AINS OF PRO TEIN  X AND E2-PDC AND E3 ENZYM ES 
FRO M  VARIOUS SOURCES.
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For these binding and kinetic experiments a CM5 sensor chip was used. It has a surface 
matrix consisting of non-crosslinked cai'boxy-methylated dextran with approximately
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6.1 Introduction
Having demonstrated earlier in this thesis, the ability to generate significant quantities of 
lipoyl domain plus peripheral subunit binding domain, termed the di-domain from 
various sources, the possibility of studying the kinetics and affinities of binding 
between specific di-domains and the E3 enzyme becomes available. Very few such 
investigations have been feasible until recently owing to the constraints of technology. 
However, with the development of surface plasmon resonance (SPR) in particular', 
such studies have now been made possible. One such system is BIAcore, which was 
employed here. BIAcore is an analytical system allowing real-time biomolecular' 
interactions to be monitored where the binding of analytes to surface immobilised 
ligands can be directly observed.
The detection principle relies on SPR, which is an optical phenomenon arising when 
light illuminates a film of conducting material under specific conditions. In summary, 
polarised light which is reflected at an interface between media of 2 refractive indices 
separated by a thin film of conducting material will resonate at a specific angle and 
result in a reduction in intensity of the reflected light at that angle. An electromagnetic 
evanescent wave then propagates away from the interface into the lower refractive index 
medium. The wave decays exponentially with distance from the interface so can only 
travel a distance of about 300nm. Thus SPR only detects changes in refractive index 
very close to the chip surface. Biomolecular interactions occurring at the sensor surface 
alter the solute concentration and the change in mass causes a depletion in the quantity 
of reflected light, thus altering the refractive index. SPR can therefore be used to 
monitor these interactions. One important advantage in using SPR is that there is no 
requirement for the labelling of the components being studied to permit their detection.
Chapter 6
one carboxyl group per glucose residue. Each chip displays four separate channels on 
its surface, called flow cells. These can be independently modified, to study the 
interactions of one analyte with different ligands at any one time. The carboxyl groups 
aie used for covalent immobilisation of the ligand (in this case the E3 enzyme of the 2- 
oxoacid dehydrogenase complexes) via amine, thiol and aldehyde or carboxyl groups. 
The matrix is hydrophilic and gives little non-specific binding, allowing veiy selective 
analysis when the analyte is in cmde samples such as cell extracts. Due to the covalent 
nature of the bound ligand, the chip surface can be regenerated following the passage of 
analyte over its surface for repetitive measurements of binding. The output signal of a 
BIAcore is measured in resonance units (RU), with 1000 RU equal to Ing of mass per 
mm^. Inclusive software packages are available allowing calculations of association rate 
constants (kon), dissociation rate constants ( k o f f )  and affinity (K a )  or dissociation 
constants (Kd).
A recent series of experiments was carried out by Lessard et a l (1996), with a degree
of relevance to the work of this chapter. The group employed the biosensor system to
study interactions between B, stearothermophilus E2-PDC with both the El and E3
enzymes of the complex. It has been demonstrated that one subunit binding domain of
B. stearothermophilus is capable of binding either one E l tetramer or one E3 dimer, but
not both simultaneously (Lessard and Perham, 1995). The use of the biosensor allowed
the determination of accurate measurements of the kinetics of the interactions. For the
experimental series, the di-domain from B. stearothermophilus was attached to the
surface of a CM5 chip, through the lipoyl group on the lipoyl domain. The oxidised
form of the lipoyl group was used to generate a disulphide bridge with the thiol groups
introduced to the chip surface. Samples of E l and E3 were then passed over the 
immobilised di-domain and kinetic constants obtained. Values for k^^ were calculated
to be identical for the El-di-domain and E3-di-domain complexes (3.26 x 10^ M~1 sec" 
: ^). The rates of dissociation in contrast were vastly different: 1.06 x 10"^ sec"^ and
I 1.87 X 10^ sec"l respectively. Thus the experiments confirmed that the affinity of the
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di-domain for E l is greater than for E3 due entirely to the kinetics of dissociation. 
Further experiments were canied out by the group to define precisely the interactions 
between E l and the binding domain. They were able to confirm that binding occurs 
solely through the E lp  subunit, with no detectable binding between the E la  subunit 
and the binding domain on E2.
As has been mentioned earlier, it appears that with regard to PDC, a separate gene 
product, namely protein X, has evolved with the ability to bind the E3 enzyme. Indeed, 
the removal of protein X from the PDC core results in a lai'ge decrease in whole 
complex activity. However, approx. 20% of this loss of activity can be regained by the 
addition of 100 fold excess amounts of E3.
It was with this in mind that the following BIAcore studies were performed. Having 
successfully overexpressed the di-domains of both E2-PDC and protein X, their ability 
to bind the E3 enzyme was investigated to determine whether indeed binding to protein 
X is stronger and to calculate the amount of residual binding to E2-PDC. Three sources 
of the E3 enzyme; human, porcine and yeast, were tested to determine whether protein 
X has indeed evolved with an increased ability to bind E3, over E2-PDC. 
Reconstitution studies in our laboratory (McCartney et al., 1998) have shown that for 
maximal PDC activity to be recovered it is necessary to add back the parent E3, 
therefore it was investigated whether this result could be confirmed more precisely 
using the BIAcore instrument. Further studies in Glasgow had also demonstrated that 
the addition of yeast E3 causes a pronounced inhibition of recoveiy of mammalian PDC 
activity. In the following studies, yeast E3 was used as a substrate in an attempt to 
deduce whether its mode of inhibition involves high affinity binding to protein X, or if 
its mode of inhibition is by another means.
146
Chapter 6
6.2 Aims of chapter.
1. Coupling of the E3 enzyme from porcine, human and yeast sources to a CM5 sensor 
chip.
2. Optimisation of the conditions required to study the interaction of the above- 
mentioned E3 enzymes with the overexpressed di-domains of protein X and E2-PDC, 
generated in an earlier chapter.
3. Obtaining kinetic and affinity data relating to the binding interactions.
6.3 R esults
6.3.1 Immobilisation of various E3 enzymes onto the surface o f a CM5 
sensor chip.
Commercial porcine and yeast E3s (Sigma) were used for immobilisation along with E3 
isolated from partially purified human OGDC (Materials and Methods, section 2.2.22). 
The final stage in the purification of the human E3 involved the use of a Poros 20PSi 
column on the BioCAD Sprint Perfusion Chromatography System (PerSeptive 
Biosystems, Inc). The flow rate was set to lOml/min, and the column equilibrated in a 
25mM Bis/Tris propane buffer (pH 7.5), prior to loading the sample (1ml). A NaCl 
gradient was programmed to run from 4(X)mM to 8(X)mM over 15 column volumes. 
Fractions (1ml) were collected during this time. A final 10 column wash of 2M NaCl 
was carried out to remove any remaining material bound to the column. The final E3 
sample was mn in parallel with the same sample prior to purification. Figure 6.1, 
obtained following a 1ml injection of salt and heat-tieated complex, shows 4 main 
peaks at 280nm. A sample (lOpl) of each 1ml fraction corresponding to these peaks 
was resolved by SDS-PAGE analysis, to determine where the E3 had eluted. Having 
determined that the second peak was the one of relevance, fractions 4 to 7 were pooled 
together and concentrated using PEG-6000. Figure 6.2 shows a sample (lOp.1) of this 
purified B3 resolved by SDS-PAGE analysis, run in parallel with an equal volume of 
sample, prior to the column purification step.
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Footnote for Figure 6.1
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Figure 6.1 Elution profile obtained for the purification of the E3 enzym e 
from human OGDC complex using the BioCAD Sprint Perfusion  
Chromatography System.
Following heat treatment at 65^C in the presence of high salt (see Materials and 
Methods), a 1ml sample of crude complex preparation was injected onto a Poros 20PSi 
column. Four major peaks of absorbance were observed at 280nm. A sample (lOpl) of 
each corresponding 1ml fraction was analysed by SDS-PAGE to identify peak 2 as 
being the purified E3 enzyme.
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Figure 6.2 Coomassie Blue-stained SDS-PAGE demonstrating the final 
step in the purification of the E3 enzyme from human OGDC.
Lane 1 shows the OGDC sample (lOpl) following a 65®C heat treatment. Lane 2 shows 
sample (lOpl) following ion-exchange on a BioCAD Sprint Perfusion Chromatography 
system. M, molecular mass marker.
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Each E3 was at a final concentration of 50|ag/inl in lOmM sodium acetate buffer (pH 
4.5) when injected over the surface of a CM-5 sensor chip. The immobilisation used 
NHS [N-hydroxysuccinimide] and EDC [N-ethyl~N’~ (3-dimethylaminopropyl) 
carbodiimide hydrochloride] in accordance with the manufacturers’ protocol for amine 
coupling. In each case, the flow rate was set to 5jil/min and sample was manually 
injected so that binding of ligand reached levels of between 1000 and 2000 RU. This 
level was deemed optimal for kinetic analysis studies. The true rates of association and 
dissociation can be limited by mass transport of the analyte (in these studies, the di­
domains) to and from the binding surface. Relatively low levels of immobilised ligand 
help to keep intrinsic binding rates low so that mass transport effects are reduced to a 
minimum. Mass transport is influenced by the diffusion coefficient, which itself is 
dependent on moleculai' mass. An indication of mass transport limitations is if the value 
for the association constant increases as the concentration of analyte increases. 
Regeneration of the chip surface between analyte passages was achieved using IM 
NaCl.
Figure 6.3 shows a theoretical sensorgram for an immobilisation sequence. The 
numbered points refer to the following stages in the process.
(i) Baseline response for the pre-modified sensor chip surface, with a continuous
flow of buffer across its surface.
(1) Activation of the surface with NHS/EDC causes an initial increase in signal 
caused by the change in refractive index.
(2) The base-line following activation is increased by approx. 250 RU due to the 
activation of NHS-esters.
(3) Injection of ligand causes coupling to the chip surface. The ligand solution is 
still in contact with the sensor chip, so the response includes both the 
immobilised and non-covalently bound ligand. The sharp fall back to base line 
occurs when the solution has fully passed over the surface, taking with it any 
non-bound ligand.
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Response Units (RUs)
Time (min)
Figure 6.3 Theoretical sensorgram showing flie trace expected when coupling 
ligand to the flow-cells of the chip.
1. Surface activation with NHS/EDC.
2. Injection of ligand.
3. Coupling to the chip surface.
4. Blocking non-specific binding with ethanolamine.
The difference between (i) and (ii) represents the amount of ligand bound to the chip 
surface, in terms of response units, with 1,000RU being equivalent to Ing protein per 
squaie mm.
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(4) Deactivation of unreacted NHS-esters by the addition of ethanolamine
hydrochloride. Any ligand bound electrostatically is also removed.
(ii) The amount of immobilised ligand after deactivation.
The immobilisation profiles of the E3 enzymes are shown by Figures 6.4a, b and c 
(sensorgrams A, B and C), corresponding to porcine, human and yeast sources. From 
the sensorgrams, the injection of each E3 enzyme gave the following results:
Porcine E3 1865 RU of binding
Human E3 1667 RU of binding
Yeast E3 1048 RU of binding
6.3.2 Interactions between the protein X and E2-PDC di-domains with  
the immobilised E3 samples.
In order to study binding interactions between the previously generated di-domains and 
the E3 samples, 50ml cultures were IPTG-induced to overexpress the relevant di­
domain and the pellets resuspended in HBS buffer (lOmM HEPES (pH 7.4), 15mM 
NaCl, 3.4mM EDTA, 0.005% surfactant P20) to a final concentration of 1 mg/ml. It 
was estimated from the SDS-PAGE analysis that the di-domain represented approx. 
10% of the total protein in the cell extract, hence was at a concentration of approx. 
0.1 mg/ml, which corresponds to a 50jxM solution. Each (60jil) extract was passed over 
the chip surface at a rate of 30|il/min, followed by lOpl IM NaCl to regenerate the chip 
surface between analyte samples. Separate runs were caixied out over a range of 
concentrations, from 50jxM to 250nM. Reproducibility was confirmed using fresh cell 
extr acts. Control injections were carried out by having a flow cell on the chip that had
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Figure 6.4a Sensorgram A, showing immobilisation of porcine E3 to a 
CMS chip.
Immobilisation was carried out using standard amine chemistry. E3 was passed over 
the chip surface at a final concentration of 50pg/ml and at a flow rate of 5pl/min until 
binding reached the level of 1865 RU. Any unbound E3 was washed away from the 
chip surface using IM ethanolamine hydrochloride. The first X on the trace represents 
the point of injection of the E3. The second X represents the end of the manual 
injection. The third X represents the end of the second manual injection. The difference 
in RU between the first and third points shows the level of immobilisation.
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Figure 6,4b Sensorgram B, showing immobilisation of human E3 to a 
CMS chip.
Immobilisation of porcine E3 was carried out using standai'd amine chemistry. E3 was 
passed over the chip surface at a final concentration of 50|ig/ml and at a flow rate of 
Spl/min until binding reached the level of 1667 RU. Any unbound E3 was washed 
away from the chip surface using IM ethanolamine hydrochloride. The three spikes in 
the initial activation phase aie an artefact caused by a reaction between NHS and EDC. 
This causes air bubbles to be produced, which are subsequently inti'oduced during the 
injection phase. The three sites designated X aie explained in the footnote for 
sensorgram A.
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Figure 6.4c Sensorgram C, showing immobilisation of yeast E3 to a 
CM5 chip.
Immobilisation of yeast E3 was carried out using standard amine chemistry. E3 was 
passed over the chip surface at a final concentration of 50jxg/ml and at a flow rate of 
5p,l/min until binding reached the level of 1048 RU. Any unbound E3 was washed 
away from the chip surface using IM ethanolamine hydrochloride. As with the previous 
2 sensorgrams, 2 manual injections were carried out to obtain the level of 
immobilisation of E3 required for these studies. The 3 sites designated X are explained I
in the footnote for sensorgram A.
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been treated by the same immobilisation protocol as for the E3 enzymes, with the 
exception of having no E3 in the sample. This allowed any background interactions 
with the chip surface to be detected and thus correcting the base-line binding levels. As 
a further control, an extract of E. coli DE3 pLsyS was passed over the chip surface. It 
was noted that no significant binding occurred. Table 6.1 shows the rate and affinity 
constants obtained between the various E3 enzymes and protein X (A) and E2-PDC (B) 
di-domains.
Table 6.1A Rate and affinity constants for the protein X di domain 
interacting with the immobilised E3 enzymes.
E3 source Ka Kd
M'^s' 1 s'^ M"' M-‘
Human E3 6.98 X 10® 3.71 X 10^ 1.88 X 10^ 5.31 X 1 0 ’
Porcine E3 1.14 X 10® 5.21 X 10^ 2.18 X 10^ 4.58 X 1 0 ®
Yeast E3 1.02 X lO** 1.16 X 10-2 8.79 X 10^ 1.14 X 10“
Table 6 .IB . Rate and affinity constants for the E2-PDC di-dom ain  
interacting with the immobilised E3 enzymes.
E3 source ^off Ka Kd
s'^ m ‘ M"'
Human E3 8.32 X  10^ 3.27 X 10 ® 2.52 X  10® 3.93 X 10 ’
Porcine E3 1.47 X  10^ 4.01 X 10® 3.67 X 10® 2.72 X 10 ’
Yeast E3 2 .1 5 1.12 X 10® 1.91 X 10® 5.23 X 10 ®
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6.3.3 Interactions between fuii-iength protein X and fulï-îength E2-PDC  
and the immobilised E3 samples.
As a compai’ison to the kinetic data obtained for the protein X and E2-PDC di-domain 
interactions with E3, the full-length mature protein X and E2-PDC genes were 
overexpressed in E. coli DE3 pLysS and the whole cell extracts passed over the surface
successful overexpression. The protein X gene generated a protein of Mj. approx. 
50,000 and the E2-PDC gene generated a protein of Mj. approx. 70,000. (These initial 
stages were kindly carried out by Miss Audrey Brown in the laboratory). Tables 6.2A 
and 6.2B below show the rate and affinity constants obtained between the protein X 
and E2-PDC and the various E3 enzymes.
of the CM5 chip, as before with the extracts of the overexpressed di-domains. Primers %
%were designed to the published E2-PDC and protein X sequences, to allow PCR 
amplification. The PCR products were ligated into pET14b, which resulted in the 
generation of a His-Tag protein. The recombinant plasmids were amplified in E, coli 
XL-10 Gold. Following transformation into DE3 pLysS, the genes of interest were 
induced with IPTG and the whole cell extracts analysed by SDS-PAGE to confirm
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Table 6.2A Rate and affinity constants for full-length protein X 
interacting with the immobilised E3 enzymes.
E3 source K», K»// Ka Kd
s-‘ M‘‘ M''
Human E3 5.11 X  10® 4.81 X  10® 1.06 X  10* 9.42 X  10 ’
Porcine E3 4.58 X  10® 9.03 X  10 ® 5.06 X  10® 1.97 X  10 *
Yeast E3 1.04 X  10“ 1.07 X  10 ® 9.66 X  10® 1.04 X  10 ®
Table 6.2B Rate and affinity constants for full-length E2-PDC  
interacting with the immobilised E3 enzymes.
E3 source K„„ K»// Ka Kd
M-‘s ' s'^ m ‘ M-‘
Human E3 1.6 X  1 0 ® 1.91 X  10® 8.38 X 10® 1.19 X 1 0 ^
Porcine E3 1.42 X  10“ 3.84 X  10® 2.57 X 10® 2.70 X 1 0 ^
Yeast E3 2 . 9 9 1 . 0  X 1 0 ® 2.99 X 10® 3.36 X 1 0 ®
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6.4 D iscussion.
The advent of surface plasmon resonance (SPR) detection has now opened the way for 
in-depth investigations of the precise kinetics of interactions between proteins, which 
has particular relevance to the 2-oxoacid dehydrogenase complexes. The mobility of the 
individual domains hampers crystallisation studies and thus also the study of how the 
various components interact. SPR measurements are at the forefront of advancing this 
area of study.
The peripheral subunit-binding domain of B. stearothermophilus E2-PDC is known to |
interact strongly with both the El enzyme and the E3 component of the complex.
Furthermore actual affinity constants have been determined, showing that vast
.1
differences in dissociation rates are primarily responsible for the differences in the 
observed binding affinities. Thus interactions between El and E3 and the binding ^
domain occur in a non-simultaneous manner. In mammals, protein X has evolved as a 
separate gene product which is capable of binding the E3 enzyme, with high affinity.
Surface plasmon resonance has been employed here as a way of studying the binding
interactions between the peripheral subunit binding domains of E2-PDC and the i
equivalent putative binding domain of protein X with E3.
Prior to analysis of E2-E3 and protein X-E3 interactions on the BIAcore 2000
■apparatus, a preliminary investigation had to be undertaken to confirm the stability of 
the E3 enzyme in the acidic conditions required during the immobilisation process. E3 
assays were carried out at 4.5, following overnight incubation, to see what effect, if 
any the low pH would have on the enzyme. The activity of the enzyme was seen to 
reduce by 25%, when compared to E3 incubated at the noimal assay pH of 7.6 (data 
not shown). The incubation time was far greater than that required for the 
immobilisation process, so it was decided that this decrease was not large enough to 
affect the experimental series. E3 is known to be a very robust enzyme, extremely 
resistant to proteolysis and capable of resisting degradation on heating to 65®C for
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prolonged periods of time. Optimal immobilisation to the sensor chip surface requires 
low pH to keep the ligand protonated to interact with the negatively charged chip 
surface. Indeed, the pH was maintained at 1 pH unit below the pi of the enzyme. 
Furthermore, the actual buffer itself required to have no free amine groups, as this too 
would hinder the immobilisation process.
Before reliable rate constants and subsequently the dissociation constant (K^ )^ can be
determined for the interactions between the di-domains and the E3 enzymes, it is 
necessary to cany out a systematic series of experiments. The on rate constant (korù
can only be measured under non-equilibrium conditions i.e. where the rate of di- 
domain-E3 complex formation does not equal the rate of dissociation of the 2 
components. A series of dilutions of the analyte solution (the di-domain) are therefore 
passed over the chip surface. These ranged from 250nM to 50pM. At the higher |
concentrations it was observed that equilibrium was reached too rapidly for the f
measurement of kon.
Analysis of the dissociation constants (K^) for the variuos E3 interactions with E2 and 
protein X shows values in the jaM to nM range. The lowest value of 5.31 x 10"^ M“  ^
was obtained for the interaction between the protein X di-domain and human E3.
Furthermore a similar' value was obtained for the interaction between the full-length 
protein X and human E3 (9.42 x 10"^ M"l). These results would seem to substantiate
the hypothesis that protein X has originated from E2 by gene duplication and has 
subsequently evolved a specific role in binding E3. Similar values are observed for
the interaction between a heterologous mammalian E3 (porcine) and the protein X di­
domain (4.58 X 10"^ M"l) and also full length protein X (1.97 x 10~  ^ M“l). As 
reported previously, reconstitution is optimal when the E3 and subunit binding domains 
are from the same, i.e. parental source. The affinities of the interactions involving 
human E3 with the E2-PDC di-domain and full length E2 are lower than those 
involving protein X, although E2 displays a residual ability to bind E3 as expected from
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previous biochemical studies. As is the case with protein X, the highest affinities are 
seen when the E3 is from the parental source. There is an obvious discrepancy between 
the values for the on and off constants obtained for full length E2 and the E2 di-domain 
which may be a result of full length E2 forming 60meric structures. In contrast, no such 
difference is observed between full length protein X and the di-domain, the former 
exhibiting a monomeric structure.
Analysis of the full length E2-PDC and the di-domain interactions with the human and 
porcine E3 enzymes shows that there is a decrease in the affinity of binding compared 
to the full-length protein X and the protein X di-domain. This again substantiates recent 
work demonstrating the necessity for the parental enzyme for restoring maximal 
affinities on reconstitution.
With regard to the interactions involving yeast E3, the dissociation constants are much 
greater than for the other two E3 enzymes from mammalian sources; 1.14 x 10'  ^M'  ^ for 
protein X di-domain, 1.04 x 10'  ^M'  ^ for full-length protein X, 3.36 x 10 ’^ M ' for full 
length E2-PDC and 5.23 x 10  ^M"‘ for the E2-PDC di-domain. This again shows the 
necessity for parental source interactions for high affinity interaction. As mentioned 
earlier, yeast E3 has been shown, in experiments carried out in our laboratoiy, to inhibit 
the reconstitution of mammahan PDC, when added in excess to the reconstituting 
enzyme components. The results obtained here from the BIAcore instrument show that 
the yeast E3 does not discriminate between E2 and protein X as the affinity constants 
are relatively similar. Taking this evidence together, would suggest that it is the binding 
to and interaction with the protein X or E2-E3-binding domain that causes the inhibition 
of the PDC complex reconstitution. Once bound to the main E3 binding site, the yeast 
E3 prevents interaction with the parental E3 enzyme.
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The use of the full-length protein X and E2-PDC genes in the latter part of this chapter
has provided further confirmation that the di-domains aie fully functional subgenes of 
the mature E2-PDC and protein X genes. The BIAcore software does have some 
limitations because it assumes a 1:1 binding of analyte to ligand. Therefore the data 
obtained for full-length E2 should be interpreted with caution as it is likely that the 
recombinantly-expressed E2 which is fully active will be present as a bOmeric 
assembly.
The experiments reported here involve, in effect, a simple immobilised ligand plus 
analyte format. Future investigations could employ a capture system employing the 
previously described monoclonal antibody PDl. As it recognises the lipoyl domain of 
the di-domain, a practical scenario would be to immobilise the antibody onto the chip 
surface. This process involves the Fc region, leaving the antigen recognition sites free 
for binding. Next, the cell extracts containing the overexpressed di-domains or full- 
length proteins would be passed over and allowed to interact with the antibody. Finally 
the various E3 enzymes would be passed over the Ab-E2 or Ab-protein X complexes >
allowing on and off rates and dissociation constants to be determined. This may 
potentially be a better system than that employed in this chapter because in addition to 
supplying data about two sets of binding constants (the antibody-di-domain interaction 
could be measured too), would reduce the chance of any non-specific reaction. The 
presence of the lipoyl domain attached to the subunit binding domain provides an ideal 
route for the attachment of the binding domain to the chip, whilst not interfering with
.is
subunit binding domain interactions. sf
i:
s"Future studies could be conducted to confirm the accuracy of the binding data. Crude 
extracts may not represent the ideal source of di-domain or full-length protein and 
attempts are currently being made in the laboratory to generate them as GST-fusion 
proteins, which would make their purification easier. Research is also being carried out 
to generate the subunit binding domains of human E2 and protein X individually as
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GST-fusion proteins. In addition, a purification strategy has been devised devised so 
that pure E2-PDC and protein X can be generated, following their constmction as His- 
Tagged proteins.
These initial binding experiments have certainly proved that the BIAcore 2000 
instrumentation is a powerful tool, capable of generating much needed quantification of 
the interactions of the individual components of the 2-oxoacid dehydrogenase 
complexes. The evidence obtained to date supports biochemical evidence that protein X 
has evolved a specific role in high affinity E3-binding; however, as suggested from 
biochemical studies on protein X-deficient complexes, the E2 subunit binding domain 
retains an appreciable affinity for the E3 components and is able to sustain partial PDC 
function in the presence of an excess of this enzyme. Future work will hopefully give 
an insight into the OGDC complex in particular, as htüe is currently known about 
subunit interactions involved in maintaining complex integrity. Along with 
crystallography studies, studies of the dynamics of protein-protein interactions by 
evolving technologies such as SPR will lead to a rapid increase in our understanding of 
stmcture-function relationships in multisubunit systems.
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1GENERAL DISCUSSION
The family of mitochondrial 2-oxoacid dehydrogenase complexes represent the largest 
multienzyme systems studied to date and serve as paradigms for molecular- 
enzymologists in then analysis of the enhancement of catalytical efficiency and 
regulatory control conferred by organisation into multisubunit structures. In addition, 
these complexes have several other unique properties: (a) as their subunits are nuclear 
encoded, these massive arrays must be assembled in situ within the mitochondrial 
matrix inner membrane compartment following import of their individual component 
polypeptides as larger precursors from the cytoplasm; (b) the activity states of PDC and 
BCOADC, uniquely amongst mitochondrial enzymes, are regulated by a 
phosphorylation/dephosphorylation cycle involving tightly-associated kinases and 
loosely-bound phosphatases, indicative of then key roles in carbohydrate and amino 
acid metabolism respectively; (c) defects in the catalytic function, import and biogenesis 
of the complexes are implicated in a wide range of biochemical and genetic disorders 
including various types of metabolic lactic acidosis (Robinson et al., 1990), Alzheimers 
disease (Sheu et al., 1994) and autoimmune conditions such as primary biliary cirrhosis 
(Sherlock & Dooley, 1993). The multifaceted nature of research into these complexes 
has meant that they have been subjected to extensive investigation from a number of '5'
directions in recent years. Despite this increased attention however, much remains to be 3
learned about their stmcture-function relationships and involvement in a variety of s
pathological processes. 3
3.
Until recently, models for their organisation have been based on our knowledge of 
bacterial PDCs, which have been subjected to intensive scrutiny. In the bacterial 
complexes, the oligomeric E2 assembly provides the stmctural and mechanistic 
framework for the complexes with the E l and E3 components, non-covalently bound to
ir
a common or partially overlapping subunit binding domain, located in the N-terminal
region immediately ac^acent to the lipoyl domains. As has been observed in this thesis, si
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:the E2 polypeptide possesses a multidomain organisation. This modular design permits 
the generation and subsequent overexpression of subgenes and individual domains as 
functional entities. An extra component of human PDC, termed protein X has a similar 
domain structure and has evolved from E2-PDC as a separate gene product, displaying 
a binding affinity for E3. Protein X has not been found in any bacterial sources.
In chapter three, we have overexpressed a subgene of the E2-PDC component from 
various sources and human protein X, which we have termed the di-domain. With the 
exception of Quinn et al, (1997), who successfully overexpressed the human lipoyl 3: .3 Tdomain, this is the first reported overexpression of human and bovine subgenes in E.
?coli. Subsequently we have confirmed that these subgenes are correctly folded by two 
independent methods: (a) the mammalian domains are able to cross-react with a 
monoclonal antibody (PDl) raised specifically to the lipoylated form of the human 
lipoyl domain. Any incorrect folding would result in an inability to be recognised by the i
E. coli lipoyl ligase enzyme, responsible for the attachment of the prosthetic group; (b) 
surface plasmon resonance studies have also confirmed that the subunit binding
■i!
domains of these subgenes are correctly folded by measuring the kinetics of binding 
interactions between the di-domains and various E3 enzymes.
i
A number of factors must be involved in the recognition by the lipoylating enzymes, in
order that only the specific Lys residue within the lipoyl domain is lipoylated. The 3
positioning of this residue is such that it extends outwards from the folded domain at
the tip of a p-turn structure. In conjunction with the spacial positioning of the lipoyl-
lysine, it is postulated that amino acid residues in the vicinity are also important in the
recognition processes. In chapter four we have obtained the human lipoyl domain plus a
series of point mutations of the domain in order to investigate the role of several
■
residues in affecting the efficiency of lipoylation. We have shown that the residues 
immediately flanking the lipoyl-lysine are not necessary for lipoylation. Furthermore, 
we have shown, in agreement with Fujiwara et al, (1996) that the conserved upstream
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Glu is important, as conversion to Gin leads to greatly reduced although not to total 
abolition of lipoylation. The possibility of a downstream conserved residue being of 
importance has still to be investigated.
As already mentioned, the individual components of the multienzyme complexes show 
a modular- design, with each enzyme displaying several domains within its structure. 
The organisation of the 2-oxoglutarate complex (OGDC) is quite distinct to that of 
PDC, with regard to the ability of each of the components to interact with one another. 
As with PDC, the E2 polypeptides form an organisational framework, which provide 
binding sites for the other components; El and E3. Unlike PDC, E3 does not appear to 
bind directly to the E2 core. Instead, it does so via the El enzyme, in an association 
within its N-terminal region. Previous studies have been limited due the tight binding of 
E l to the E2 core and also the instability of El on its release, thus the domain 
boundaries remain as yet ill-defined, so in chapter five we devised an experimental 
series to map more precisely the boundai-y of the E3-binding site on E l in mammalian 
OGDC (a bovine heart source). Several N-terminal subgenes of El were generated as 
GST-fusion proteins and overexpressed then their ability to bind E3 was investigated. 
A direct interaction between El-OGDC and E3 has been reported recently by 
McCartney et al, (1998). However, the N-terminal fragments failed to exhibit any 
ability to interact with E3 as detected by their failure to act as competing inhibitory 
peptides. We were unable to confirm, at this stage whether these El-GST fragments 
had folded correctly. It is possible that incoiTect folding would prevent interaction with 
E3, however, they did paitially inhibit reassociation following the release of both El 
and E3 from the E2 core.
The vast airay of moleculai- bioliogical techniques now available have opened many 
new avenues for research. One such field is that of surface plasmon resonance, using a 
BIAcore 2000 machine. In chapter six we have shown its usage in obtaining precise 
binding constants for interactions between human protein X and PDC-E2 with E3. This
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technique is likely to recreate an environment similar to that in vivo, where binding is a 
continuous process, which reaches a state of equilibrium. It was possible to substantiate 
the hypothesis that protein X evolved a specific role in binding E3. The data 
demonstrated that the affinity of interaction between protein X and human E3 is greater 
that that for the interaction between human E2-PDC and human E3. It was shown that 
E2-PDC has retained an ability to bind E3, despite protein X being the main E3-binding 
protein. This is in agieement with clinical studies where patients lacking an 
immunologicaUy detectable protein X, still retain a residual level of PDC activity. By 
using heterologous sources of E3, previous work has been further substantiated which 
showed the need for the parental E3 to gain optimal reconstitution. The binding 
affinities for the interaction between the porcine E3 and both protein X and E2-PDC 
were significantly lower than those involving human E3. This technique should, in 
future studies be able to provide a large amount of data regarding the numerous 
interactions that occur within the multienzyme complexes.
What should be recognised from this thesis and other studies recently being undertaken, 
is the speed at which our knowledge about these large 2-oxoacid dehydrogenase 
complexes is expanding. With the ability to generate vast quantities of material using a 
variety of expression systems and purification techniques now available, straicture- 
function relationships and the molecular basis for many disease states associated with 
these 2-oxoacid dehydrogenase mulitenzyme complexes can now be investigated.
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